- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterConferences
Coverage from professional conferences related to lung cancer.
Non-small Cell Lung Cancer
| A Prospective Randomized Study of Adjuvant Chemotherapy with Navelbine + Cisplatin in Completely Resected Non-Small Cell Lung (the ANITA trial) Presenter: J.Y. DouillardPresenter's Affiliation: Adjuvant Navelbine International Trialist AssociationType of Session: ScientificBackground Recent randomized trials have shown an overall survival (OS) benefit to adjuvant chemotherapy added to definitive surgery for stage I-III NSCLC. However, there is still question regarding the exact stages |
| Exclusive High-Dose Rate Brachytherapy (HDR-BT) for Limited Non-small Cell Lung Carcinoma: Results of a French Study in 199 Patients Presenter: M.A. MahePresenter's Affiliation: Radiotherapy, Centre Oscar Lambret, Lille, FranceType of Session: ScientificBackground The standard of care for treatment of early stage lung cancer is surgery with or without chemotherapy. HDR-BT is an alternative option for patients with contraindications to surgery. This study was undertaken to |
| Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma Presenter: U. GatzemeierPresenter's Affiliation: Hospital Grosshansdorf, Grosshansdorf/Hamburg, GermanyType of Session: ScientificBackground The Raf/MEK/ERK pathway is an attractive target in NSCLC 20% Ras mutations which are upstream of Raf EGFR is upstream of Raf, and inhibitors have shown activity in |
| Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Presenter: S. RamalingamPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: PosterBackground Benefit from combination chemotherapy extends to all age patients with advanced NSCLC Elderly patients with good performance status have comparable efficacy with 'standard' platinum-based doublets. There is concern of |
| Induction chemotherapy followed by concominant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell cancer: Initial analysis of a randomized phase III trial Presenter: Everett V. VokesPresenter's Affiliation: Cancer and Leukemia Group BType of Session: ScientificBackground Induction chemotherapy has been shown to improve survival in patients with stage IIIB non-small cell lung cancer (NSCLC) compared to radiation (RT) alone Concurrent chemoradiotherapy (CT/XRT) has also been shown to be superior to |
| Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer Presenter: Keunchil Park, MD, PhD Presenter's Affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea Background About 20% of all lung cancers are small cell lung cancer (SCLC) and about 1/3 of SCLC patients present with limited stage disease that is confined to the thorax |
| Long-Term Survival Following Immunization with BEC2 Plus BCG after Initial Therapy for Small Cell Lung Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in advanced renal cell carcinoma (RCC). According to Dr. Négrier, despite the large number of |
| Increased Frequency of Radiation Therapy Treatment for Small-Cell Lung Cancer Improves Survival Rates Lung cancer is the leading cancer killer, with more than 160,000 deaths annually. Radiation therapy is a standard treatment approach for people with lung cancer, and can be used alone or in combination with surgery or chemotherapy. In this study of radiation treatment schedules for patients with small-cell lung cancer, after five years of |
| PET Scanning in Radical Radiation Therapy Candidates with Non-Small Cell Lung Cancer: High Impact on Staging and Management and Delineation of a Subgroup with Poor Survival Presenter: Mac Manus MP Affiliation: Peter MacCallum Cancer Institute Summary:The standard work-up for a patient with non-small cell lung cancer (NSCLC) includes surgical staging as well as imaging by CT, bone scan, and possibly MRI. Even in the most experienced hands, however, these modalities do not always accurately reflect the true extent |
| A Multicenter Randomized Phase III Study Comparing Paclitaxel-Cisplatin-Etoposide (TEP) Versus Cisplatin-Etoposide (EP) as Front - Line Treatment in Patients with Small Cell Lung Cancer (SCLC) Presenter: Dimitrios Mavroudis Affiliation: The Greek Lung Cancer Cooperative Group Background: The combination of etoposide (E) and cisplatin (P) is standard first line treatment for small cell lung cancer (SLSC). A complete response (CR) rate of 30-40% is seen in limited stage (LS) and 10-20% in extensive stage (ES). Paclitaxel |
| Topotecan (T) vs. Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): A Phase III Trial of the Eastern Cooperative Oncology Group (ECOG) Presenter: D. H. Johnson Affiliation: Vanderbilt University Background: Topotecan, a topoisomerase I inhibitor, has a 40% response rate as a first line agent in SCLC and moderate activity in chemoresistant SCLC. This Phase III trial was designed to determine Topotecan?s efficacy in combination with standard chemotherapy. |
| Randomized Study of Single Versus Fractionated Radiotherapy (RT) in the Palliation of Non-Small Cell Lung Cancer; NCIC CTG SC.15 Presenter: A. Bezjak Affiliation: Dept of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada Background In comparison to definitive radiation therapy, the optimal doses and fraction schedules for palliative treatments are less well defined. Theoretically, administration of larger daily fractions over fewer days offers |
| Multicenter Phase II Trial Of Paclitaxel (P), Ifosfamide (I), And Carboplatin (C) In Previously Untreated Extensive Stage Small Cell Lung Cancer (ES?SCLC) Presenter: Marcus A NeubauerPresenter's Affiliation: US Oncology Inc, Houston, TXType of Session: PosterBackground ES-SCLC accounts for 60-70% of the 30-35,000 new cases of SCLC diagnosed each year in the US The median survival for ES-SCLC reported in phase III trials is 9-12 months Overall survival at 2 years is Platinum + etoposide are |
| Phase II Study Of STI571 (GleevecTM) For Patients With Small Cell Lung Cancer Presenter: Bruce E JohnsonPresenter's Affiliation: Dana-Farber Cancer Inst, Boston, MAType of Session: ScientificBackground STI571 is a small molecule that inhibits the tyrosine kinase activity of the BCR-Abl and Kit receptors The oral preparation of STI571 has been proven safe and very efficacious against CML (BCR-ABL positive) and GIST (Kit |
| SWOG 0004 - Pilot Study Of Tirapazamine (TPZ) Plus Cisplatin/Etoposide (PE) And Concurrent Thoracic Radiotherapy (RT) In Limited Small Cell Lung Cancer (LSCLC) Presenter: Quynh-Thu LePresenter's Affiliation: SWOGType of Session: ScientificBackground Tirapazamine (TPZ)is a novel hypoxic cytotoxin that has been proven to increase cell killing in hypoxic cells. TPZ has also demonstrated synergistic increases in the effectiveness of chemotherapy and radiation therapy (RT) in both preclinical and clinical |
| Cisplatin And Etoposide Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (TRT) Followed By Three Cycles Of Irinotecan And Cisplatin For The Treatment Of Limited-Stage Small-Cell Lung Cancer (SCLC); Updated Results: JCOG 9903-DI Presenter: Kiyoshi MoriPresenter's Affiliation: National Cancer Center Hospital, Tokyo, Japan.Type of Session: ScientificBackground Noda K. et al have demonstrated that Irinotecan and cisplatin (IP) significantly improves survival compared with cisplatin and etoposide (EP) in patients with extensive stage SCLC (Pro ASCO, 483a, 2000). The use of |
| Current Role of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Dates: December 4, 2004 Conference Location: Chicago, IL Sponsoring Group: Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who |
| 70 Gy Thoracic Radiotherapy (TRT) is Feasible Concurrent with Chemotherapy for Limited Stage Small Cell Lung Cancer (L-SCLC): Preliminary Analysis of a CALGB Phase II Trial
Presenter: J.A. BogartPresenter's Affiliation: Upstate Medical University, Syracuse, NY, USAType of Session: ScientificBackground This study was designed to further investigate the optimal treatment regimen for L-SCLC. A previous randomized intergroup trial showed a survival benefit for twice-daily TRT (total 45 Gy) with chemotherapy, versus |
| Age-Specific Sub-Analysis of ECOG 1594: Fit Elderly Patients (70-80 yrs) with Non-Small Cell Lung Cancer Do As Well As Younger Patients (<70 yrs) Presenter: CJ LangerPresenter's Affiliation: Fox Chase Cancer CenterType of Session: PosterBackground Exclusion of elderly patients from studies of advanced non-small cell lung cancer (NSCLC) has been common due to fear of increased toxicity of platinum-based regimens in these patients. Previous retrospective studies have been mixed regarding the |
| Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) Presenter: P LoriganPresenter's Affiliation: Manchester Lung Cancer GroupType of Session: ScientificBackground Although SCLC is chemosensitive, it is associated with low rates of cure. Several previous phase II and III trials have attempted to increase dose intensity in an attempt to improve the outcome of these patients. Recently the EORTC has |
| Traditional versus up-front 18-FDG PET staging of non-small cell lung cancer (NSCLC): A Dutch Co-operative randomized study Presenter: G.J. HerderPresenter's Affiliation: POORT Study Group, NetherlandsType of Session: ScientificBackground The use of FDG-PET scan as an add-on study in non-small-cell-lung-cancer (NSCLC) patients scheduled to undergo surgery has been shown to be a cost-effective and useful tool in guiding patient management. When employed after |
| Clinical Application of Positron Emission Tomography (PET) in Designing Radiation Fields in Non-Small Cell Lung Cancer (NSCLC) Patients Presenter: Charles G. Wood, MDPresenter's Affiliation: University of Pennsylvania, Dept. of Radiation Oncology, Philadelphia, PAType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans have become commonplace in the staging of non small cell lung |
| Impact of Computed Tomography and 18F-Deoxyglucose-Hybrid Positron Emission Tomography Image Fusion on Conformal Radiotherapy in Non-Small Cell Lung Cancer Presenter: E. Deniaud-Alexandre.Presenter's Affiliation: Tenon Hospital, Paris, FranceType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans have become commonplace in the staging of non small cell lung cancer (NSCLC) Recently, computer |
| Pemetrexed in Extensive Stage Small Cell Lung Cancer Small cell lung cancer (SCLC) represents about 20% of all lung cancers diagnosed in the US, with about 25,000 to 30,000 new cases each year. Of these cases, about two-thirds are considered "extensive stage" (ES), and combination chemotherapy is considered the standard of care. Specifically, the standard chemotherapy regimen is cisplatin |
| Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Presenter: Minesh P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. It can induce redox stress and is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is |
| Patient Summary: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 There have been several studies showing the benefit of chemotherapy in surgically resected non small cell lung cancer (NSCLC). Unfortunately, most studies have limited numbers of elderly patients enrolled in |
| Motexafin Gadolinium (MGd) Combined With Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases: Results of a Randomized Phase 3 Trial Presenter: M.P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor |
| Impact of Radiation on Survival After Complete Resection of Non-Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 Impact of Radiation on Survival After Complete Resection of Non-Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 This analysis was done on a study designed to look at the benefit of chemotherapy for early stage lung cancers. The researchers have analyzed the use of radiation therapy in the |
| Elective Nodal Irradiation in the Treatment of Non-Small Cell Lung Cancer Presenter: K.E. RosenzweigPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground It is difficult to know which nodal regions need irradiation when treating lung cancer with radiotherapy. At the Memorial Sloan Kettering Cancer Center, physicians decided to omit treating clinically |
| Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials Presenter: William ShapiroPresenter's Affiliation: Barrow Neurological Institute, Phoenix AZType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor |
| A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993) Scientific Session: A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993) At diagnosis, patients with small cell lung cancer (SCLC) have a high rate of brain metastasis (around 20%), and this number rises to >50% at 2 years. |
| Prophylactic Cranial Irradiation (PCI) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EORTC 22993-08993) Presenter: Bernard J. Slotman, MD, PhDPresenter's Affiliation: VU University Medical Center, EORTC Radiation Oncology and Lung Cancer GroupsType of Session: ScientificBackground At the time of diagnosis, approximately 20% of patients with small cell lung cancer (SCLC) have brain metastases, and at least 50% will develop brain metastases at |
| Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Non-small cell lung cancer (NSCLC) remains the number one cause of cancer death in both men and women in the United States. The greatly increased risk of NSCLC development |
| Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) Presenter: Le Pechoux C.Presenter's Affiliation: Institute Gustav Roussy, Villejuif, FranceType of Session: ScientificBackground The use of prophylactic cranial irradiation (PCI) in patients with limited stage small cell lung cancer (SCLC) has been shown to provide an overall survival benefit (3-year overall survival of 20.7% with PCI versus |
| Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) The use of prophylactic cranial irradiation (PCI) in patients with limited stage small cell lung cancer (SCLC) has been |
| SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC) SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC) The combination of etoposide and cisplatin (EP) is the most widely used chemotherapy regimen for small cell lung cancer. Two large studies looked at using |
| Acute Esophageal Reactions from Proton Beam Therapy and Concurrent Chemotherapy for Non-Small Cell Lung Cancer: Reduction in Incidence and Severity Despite Higher Doses Presenter: R. KomakiPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground In the United States, concurrent chemotherapy and radiation therapy is standard for unresectable NSCLC. However, there is significantly increased toxicity with concurrent radiochemotherapy as opposed to sequential treatment. There |
| Survival Impact of Prophylactic Cranial Irradiation in Limited-stage Small-cell Lung Cancer Presenter: M.E. GiulianiPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Among patients with small-cell lung cancer (SCLC), approximately 10-15% are found to have brain metastasis at diagnosis. In total, approximately 30-60% of patients develop brain |
| A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study Presenter: K.G. Tournoy, MD Affiliation: Ghent University Hospital, Ghent, Belgium Background Prognosis of patients with non-small cell lung cancer (NSCLC) depends heavily on nodal staging (Rusch, Journal of Thoracic Oncology 2007, 2:603-12) Appropriate treatment of NSCLC depends on accurate mediastinal lymph node staging. Non-operative |
| Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) Presenter: Y. Bang, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Background Efficacy of conventional chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) appeared to reach a plateau in the mid-1990s, at the same time that targeted therapeutics began to enter clinical trials. |
| Poor Glycemic Control During Radiochemotherapy Contributes to Reduced Local Control and Overall Survival in Patients with Non-Small Cell Lung Cancer Abstract Number: 171 Presenting Author: Mohamad Fakhreddine, MS Affiliation: University of Texas MD Anderson Cancer Center, Houston, TX Background Diabetes mellitus (DM) is known to be associated with a higher incidence of malignancies as well as a worse prognosis of cancer patients. There are few studies, however, looking at lung cancer |
| Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, |
| Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial Presenter: L. NovakovaPresenter's Affiliation: Czech Lung Cancer Cooperative GroupType of Session: PosterBackground Advanced non-small cell lung cancer has a poor survival. A majority of the patients fail distantly, with metastatic disease. Gemcitabine has been shown to have significant anti-tumor properties against NSCLC, a disease in which |
| Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) Presenter: C. SederholmPresenter's Affiliation: University Hospital, Linkoping, SwedenType of Session: ScientificBackground Chemotherapy is indicated in patients with locally advanced and metastatic lung cancer who have good performance status and minimal weight loss. The use of combined chemotherapeutic regimens (i.e. doublets) have better |
| Results of a randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) Presenter: T. LeChevalierPresenter's Affiliation: Institut Gustave RoussyType of Session: PlenaryBackground 1.2 million cases of NSCLC are diagnosed yearly worldwide. 30% of these are resectable but local therapy is not consistently curative. Distant metastases are common. The 1995 MRC lung cancer trial suggested a 5% 5 year OS benefit, but |
| Neoadjuvant Chemotherapy Followed by Preoperative Radiochemotherapy (hfRTCT) Plus Surgery or Surgery Plus Postoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer: Results of a Randomized Phase III Trial of the German Lung Cancer Cooperative Group Presenter: C. BuchePresenter's Affiliation: German Lung Cancer Cooperative GroupType of Session: PlenaryBackground The optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) is controversial. Ideally, patients with NSCLC should undergo surgical resection of their disease; however, the role of pre-operative radiation is |
| Phase III Trial of Amisfostine with Chemoradiation for Inoperable Non Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells? Presenter: Ritusko KomakiPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Several randomized studies have proven improved outcomes with chemoradiation vs. radiation alone in the treatment of inoperable NSCLC. More recently, there has been evidence that concurrent chemoradiation is more efficacious than |
| A Randomized Phase II Trial Comparing RhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus Carboplatinum/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Presenter: Russel DeVore, MD Affiliation: Vanderbilt University Background: For advanced and metastatic non-small cell lung cancer, current therapies are limited. These therapies at best may offer patients survival benefits on the order of approximately 4 months, and can still have side effects which may be serious. Newer therapies are in |
| GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study Presenter: Rudolf M. Huber, MD, PhD, FCCP Presenter's Affiliation: Medizinische Klinik Innenstadt, München, Germany Background Concurrent chemo-radiotherapy (CT-RT) is considered the standard treatment for patients with stage III NSCLC. Treatment failure in patients with NSCLC, particularly locally advanced NSCLC, is |
| Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Presenter: Gary M. StraussPresenter's Affiliation: Cancer and Leukemia Group BType of Session: ScientificBackground The role of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC) has been controversial Recently reported studies regarding the role of adjuvant chemotherapy with completely resected NSCLC have been conflicting |
| Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Presenter: G.M. Strauss Presenter's Affiliation: CALGB Type of Session: Scientific Background Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a marginally significant survival benefit with adjuvant cisplatin based chemotherapy in patients who received surgery for their |
| Patient Summary: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. The CALGB 9633 trial randomized patients with stage IB non small cell lung cancer NSCLC to either carboplatin/paclitaxel or no further therapy. This study had been stopped early because the investigators saw a |
| Chemoradiation With or Without Surgery for Stage IIIA Non-Small Cell Lung Cancer (NSCLC): A Comparison of Survival and Patterns of Failure Presenter: Mitchell Machtay, MD Affiliation: University of Pennsylvania Background:One of the most controversial topics in the management of NSCLC is the treatment of stage IIIA disease. Chemotherapy is generally accepted as an indicated treament in patients with good performance status. The management of local disease using surgery versus |
| Phase III Comparison of Sequential vs
Concurrent Chemoradiation for Patients (Pts)
with Unresected Stage III Non-Small Cell
Lung Cancer (NSCLC): Initial Report of Radiation Therapy Oncology Group (RTOG) 9410. Presenter: Walter Curran Affiliation: Bodine Ctr for Cancer Treatment Background: Radiation therapy with or without chemotherapy is standard therapy for locally advanced unresectable non-small cell lung cancer (NSCLC) The use of sequential cisplatin-based chemotherapy followed by thoracic radiation therapy has been shown to be |
| Impact of Tumor Control on Survival in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Thoracic Radiotherapy (TRT) and Chemotherapy (CT). Presenter: K. Furuse Affiliation: Health Insurance Union Osaka Cent Hosp, Osaka Background: Radiation therapy and chemotherapy is standard therapy in good performance status patients with locally advanced unresectable non-small cell lung cancer (NSCLC) A previously reported study by Furuse et al (J Clin Oncol 1999;17:2692) |
| Preliminary Results of a Radiation Therapy Oncology Group Trial (RTOG 9311), A Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with Inoperable Non-small Cell Lung Cancer Presenter: M.V. Graham Affiliation: Radiation Oncology, Phelps County Regional Medical Center, Rolla, MO Background Some investigators and clinicians are now questioning the utility of elective nodal irradiation in the treatment of lung cancer. Theoretically, if the volume of tissue to be irradiated were to exclude clinically uninvolved |
| Randomized Phase III Study of Amifostine in Patients Treated with Chemoradiation for Inoperable Stage II-III Non-Small Cell Lung Cancer (NSCLC) Presenter: R. Komaki Affiliation: Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX Background The radioprotective property of thiol-containing compounds has been well known for some time. Amifostine(WR-2721) is the most well known of these agents. The proposed mechanism of action is the scavenging of |
| Update in the Multidisciplinary Management of Early-stage Non-small Cell Lung Cancer Conference Dates: Friday, May 14, 2004 Conference Location: Marriott Hotel, 1201 Market Street, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine Conference Web Page URL: www.med.upenn.eduappscme_events Topics Covered: Early-stage Non-small Cell Lung Cancer Conference Objectives: At the conclusion of |
| Concurrent Chemo-Radiation Results in Equivalent Local and Overall Outcome as Induction Chemotherapy Followed by Surgery for Clinical Stage IIIA Non-Small Cell Lung Cancer
Presenter: N.A. TaylorPresenter's Affiliation: Department of Radiation Oncology, UT M.D. Anderson Cancer Center, Houston, TX, USAType of Session: ScientificBackground In this study, investigators looked at 2 different treatment regimens for clinical stage IIIa non-small cell lung cancer (NSCLC). Materials and Methods This is a retrospective |
| Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer. Interim analysis of a multicenter phase III trial Presenter: H. GroenPresenter's Affiliation: Dutch Chest Physicians AssociationType of Session: ScientificBackground Taxane-based chemotherapy has been shown to have a modest response rate of 10-30% in advanced non-small cell lung cancer (NSCLC). Taxanes are often given in conjunction with platinum-based chemotherapy for these patients. |
| RTOG 9705, A Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC) Patients - Promising Long Term Survival Results Presenter: Mary V. GrahamPresenter's Affiliation: Phelps County Regional Medical CenterType of Session: ScientificBackground The role of adjuvant chemotherapy in addition to radiotherapy (RT) for resected stage II and IIIA NSCLC patients is unclear. A previously published large randomized trial from ECOG showed a lack of benefit of the addition of |
| Amifostine As Mucosal Protectant in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Intensive Chemotherapy and Thoracic Radiotherapy (RT): Results of the Radiation Therapy Oncology Group (RTOG) 98-01 Study Presenter: Maria Werner-Wasik, MDPresenter's Affiliation: Thomas Jefferson UniversityType of Session: ScientificBackground 20-50% of patients receiving thoracic RT with concurrent chemotherapy experience severe esophagitis. Amifostine (AMI) is a radioprotectant that has been shown to improve esophagitis both in animal models and in early clinical |
| A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer. Intergroup JBR10 Presenter: Timothy WintonPresenter's Affiliation: National Cancer Institute of CanadaType of Session: ScientificBackground Recent studies have shown that adjuvant chemotherapy following complete resection of non-small cell lung cancer (NSCLC) improves overall survival The majority of this benefit has been seen in patients with higher stage |
| Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : 'the "LUCAS" study This presentation discusses off-label use of cetuximab in the treatment of NSCLC. Presenter: R. RosellPresenter's Affiliation: Institut Catala d'Oncologia, Barcelona, SpainType of Session: ScientificBackground The advent of molecular therapeutics and anti-tumor targetted agents has at its center the much discussed and studied epidermal growth |
| Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC) Presenter: P.A. KosmidisPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Early phase data has shown the combination of paclitaxel and gemcitabine may be as active and well tolerate as the combination of carboplatin and gemcitabine in patients with inoperable and advanced NSCLC This trial was |
| S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results Presenter: K. PistersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Five year Overall Survival (OS) for stages T2NO-T3N1 NSCLC are low, ranging from 9-38%. When this study was designed in the late 1990s, the benefit of adjuvant chemotherapy in resected lung cancer was not yet confirmed. The BLOT trial |
| A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) Presenter: J. van MeerbeeckPresenter's Affiliation: University Hospital, Ghent, BelgiumType of Session: PlenaryBackground There remains significant controversy in the optimal treatment of patients with locally advanced stage IIIA NSCLC with ipsilateral mediastinal lymph node involvement (N2). Chemotherapy has shown significant response rates in |
| Initial Report of a Prospective Phase II Trial of Stereotactic Body Radiation Therapy for Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer Presenter: R. TimmermanPresenter's Affiliation: UT-Southwestern Medical CenterType of Session: ScientificBackground Patients with medically inoperable stage I non-small cell lung cancer are potentially amenable to stereotactic body radiation therapy (SBRT), as therapeutic options in this population are limited, and local tumor control alone may |
| Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC). Presenter: J. E. Bekelman, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground In 1998, the PORT meta-analysis of nine clinical trials (2128 patients) concluded that when compared to surgery alone, the use of post-operative radiation therapy (PORT) for NSCLC patients with N0 and N1 |
| Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer Presenter: L.E. Gaspar Presenter's Affiliation: University of Colorado at Denver Health Sciences Center Type of Session: Scientific Background SWOG 0023 was a prospective, randomized, multi-institutional phase III trial evaluating the use of external beam radiotherapy with concurrent cisplatin/etoposide chemotherapy, followed by |
| Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer SWOG 0023 was a phase III trial evaluating the use of radiation therapy given with cisplatin and etoposide chemotherapy, followed by docetaxel chemotherapy, and then gefitinib |
| Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Scientific Session: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Chemotherapy (containing a platinum drug) combined with chest radiation (RT) has become a standard |
| FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Epidermal growth factor (EGFR) is over expressed in 80% of lung cancers. Cetuximab is a monoclonal antibody that interferes with |
| Discussions on Emerging Concepts and Controversies in the Treatment of Patients With Advanced Non–Small Cell Lung Cancer Conference Dates: June 19, 2010 Conference Location: Chicago, Illinois Sponsoring Group: Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and oneconsortium Conference Web Page URL: www.thecbce.com/lungtownhall Topics Covered: This interactive, town hall program focuses on the latest |
| Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863) Title: Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)Reviewer: Arpi Thukral, MD Presenter: Suresh. S. Ramalingam, MD Affiliation: Emory University This |
| Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer Presenter: V. Westeel, MD, on behalf of the Intergroupe Francophone de Cancerologie Thoracique Background This is an update of a previously reported French Phase III randomized trial (DePierre, JCO 2002) comparing neo-adjuvant chemotherapy followed by surgery to surgery alone for patients with resectable non-small cell lung cancer (NSCLC). |
| TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy Presenter: S. Lee, University College Hospital/UCL Cancer Institute, London, United KingdomBackground Patients with poor performance status (PS) represent 30-50% of those presenting with advanced (Stage IIIB/IV) NSCLC, and are under-studied. These patients are often not candidates for standard first line chemotherapy (platinum-based doublet |
| Phase II clinical studies of high-dose proton therapy in stage I/II and III non-small cell lung cancer Presenter: Joe Y. Chang, MD PhD Presenter's Affiliation: MD Anderson Cancer Center Background NSCLC is a prevalent and deadly disease. Over 160,000 cases are diagnosed per year in the U.S., and over 157,000 deaths occur. For early stage disease, surgery is the mainstay of therapy; however, limited surgery (or wedge resection) is not |
| FDG Uptake Predicts Recurrence and Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer treated with 74 Gy (RBE) Proton Therapy and Chemotherapy Presenting Author: J. Chang Institution: M.D. Anderson Cancer Center, HOUSTON, TX Background Concurrent chemoradiation is the standard of care for locally advanced, unresectable non-small cell lung cancer (Curran et al., RTOG 9410, JNCI, 2011). Chang et al. (Cancer, 2011) recently presented a phase 2 study of high-dose proton |
| Randomized Prospective Comparison of Adjuvant Mediastinal Radiation (RT) with or without Concurrent Chemotherapy with Cisplatin and Etoposide (PE) for Patients with Completely Resected T1-3N1-2M0 Non-Small Cell Lung Cancer (NSCLC): US Presenter: Keller SM et al Affiliation: Beth Israel Medical Center Summary:Multiple retrospective reviews as well as the prospective study from the Lung Cancer Study Group have demonstrated a local control advantage to adjuvant radiation therapy for NSCLC. However, the overwhelming pattern of failure remains distant. This trial was initiated |
| Sequential Vs. Concurrent Chemotherapy and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (NSCLC) Analysis of Failures in a Phase III Study (RTOG 9410) Presenter: R. Komaki, MD Affiliation: University of Texas MD Anderson Cancer Center Summary: Since the randomized trial reported by Dillman et al., the standard of care for the treatment of unresectable or inoperable non small cell lung cancer in patients with a good performance status has been sequential chemotherapy |
| A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Presenter: Joan H. Schulter Affiliation: ECOG Background: Since the initial randomized trials in the early 1990's which showed improved median and overall survival by adding chemotherapy to radiation therapy (RT) in NSCLC patients, several newer agents have been introduced. Some of these agents are used off protocol based on |
| An EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC) Presenter: J. P. Van Meerbeeck Affiliation: EORTC Background: Combination chemotherapy improves survival in advanced NSCLC based on numerous reports. Cisplatin based chemotherapy has remained the standard regimen used in most studies. This study was designed to compare 3 different chemotherapy regimens, 2 containing cisplatin and one |
| Non-Small Cell Lung Cancer Update Date: November 12, 2001 at 3pm EST Location: WebMD Online Event Symposium Web Page: To be provided. Sponsors: Alliance for Lung Cancer Advocacy, Support, and Education Who should attend: Lung Cancer Patients, Families, Caregivers Topics: Current therapies, healthy lifestyle tips, and the many forms of support available for |
| PET Response is the Most Powerful Predictor of Survival after Radical Radiotherapy/Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer Presenter: M.P. MacManus Presenter's Affiliation: Peter MacCallum Cancer Institute, East Melbourne, Australia Type of Session: Scientific Background Frequently, clinicians have difficulty interpreting CT scans and MRI's done on patients with cancer, particularly after surgery or radiation therapy. Positron emission tomography (PET) is an imaging |
| Improved Local Control with RSR-13 and Concurrent Radiation Therapy in a Phase II Study for Locally Advanced Inoperable Non-Small Cell Lung Cancer Presenter: H. Choy Presenter's Affiliation: Vanderbilt University Medical Center, Nashville, TN Type of Session: Scientific Background RSR13 is a synthetic allosteric modifier of hemeglobin (Hb). It decreases Hb-oxygen binding affinity by causing a change in the shape of the Hb tetramer molecule. This change results in an increase in tumor |
| Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC) Presenter: H. ChoyPresenter's Affiliation: ACRType of Session: ScientificBackground The majority of NSCLC patients present with inoperable disease. Therefore, the definitive treatment is with a combination of chemotherapy (most notably platinum containing regimens) and radiation therapy. It has been shown that chemoradiation is more efficacious |
| Final Results From A Phase II Trial Of Zd1839 ('Iressa') For Patients With Advanced Non-Small-Cell Lung Cancer (IDEAL 1) Presenter: Masahiro FukuokaPresenter's Affiliation: Kinki University, Osaka, JapanType of Session: PosterBackground Iressa is an oral preparation of a selective inhibitor of the epidermal growth factor receptor tyrosine kinase It interferes with signal transduction pathways implicated in proliferation and survival of cancer cells The IDEAL 1 |
| Single-Agent (SA) Versus Combination Chemotherapy (CC) In Advanced Non-Small Cell Lung Cancer (NSCLC): A CALGB Randomized Trial Of Efficacy, Quality Of Life (QoL), And Cost-Effectiveness Presenter: Rogerio C LilenbaumPresenter's Affiliation: CALGBType of Session: PlenaryBackground The standard of care for patients with locally advanced NSCLC and good performance status (PS) is combination chemotherapy (CC). However, while CC has demonstrated increased tumor response rates, these often have not translated to increased overall |
| Current Role of Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Date: December 11, 2004 Conference Location: San Francisco, CA Conference Date: January 8, 2005 Conference Location: Atlanta, GA Conference Date: February 5, 2005 Conference Location: Philadelphia, PA Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: This continuing medical education (CME) activity will |
| Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) Presenter: Minesh MehtaPresenter's Affiliation: University of Wisconsin/ ECOGType of Session: ScientificBackground The current standard of care for patients with inoperable NSCLC is combined modality chemotherapy and thoracic irradiation. Research is ongoing, however, to establish the optimal scheduling and dose fractionation of the radiation |
| Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) Presenter: Andrew Turrisi, M.D.Presenter's Affiliation: RTOGType of Session: PlenaryBackground Patients with stage IIIa NSCLC have a poor prognosis. Although definitive chemoradiotherapy (especially when delivered concurrently) remains standard for most patients with pathologic N2 disease, small phase III trials support the use of chemotherapy |
| Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) This presentation discusses the use of erlotinib for the treatment of NSCLC which has not been approved by the FDA. Presenter: U. GatzemeierPresenter's Affiliation: TALENT study investigatorsType of Session: ScientificBackground There is a growing body of preclinical data demonstrating the anti-tumor efficacy of erlotinib (OSI-774), |
| Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 Presenter: A.B. SandlerPresenter's Affiliation: Easteran Cooperative Oncology GroupType of Session: PlenaryBackground The standard therapy for patients with advanced NSCLC is platinum-containing doublet chemotherapy. Randomized trials of targeted therapies in chemotherapy-naïve patients with advanced NSCLC have all been negative, including |
| Phase III study of concurrent chemortherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Presenter: Kathy AlbainPresenter's Affiliation: RTOGType of Session: ScientificBackground Patients with stage IIIA NSCLC and N2 (mediastinal) disease have a poor outcome, with long term overall survival consistently reported to be approximately 20% Definitive concurrent chemoradiation is the standard of care in good performance status patients |
| ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens Presenter: N. ThatcherPresenter's Affiliation: Christie Hospital, Manchester, UKType of Session: PlenaryBackground Gefitinib (IRESSA) is an oral medication that acts as a small molecule inhibitor of EGFR. There have been two Phase II trials demonstrating 250 mg/day has activity in pretreated patients with advanced NSCLC, however a survival |
| ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts) Presenter: R. RosellPresenter's Affiliation: Catalan Institute of Oncology, Badalona, SpainType of Session: PlenaryBackground Recent studies have shown a significant improvement in overall survival with the addition of adjuvant chemotherapy after surgical resection of lung cancer. The ANITA study was designed to evaluate the survival impact of |
| Impact of Radiation on Survival After Complete Resection of Non Small Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial Anita 1 Presenter: Jean-Yves Douillard, M.D., Ph.D.Presenter's Affiliation: Centre Rene Gauducheau, FranceType of Session: PlenaryBackground Post-operative radiotherapy ( PORT ) in lung cancer is a controversial topic. The PORT Meta-analysis previously demonstrated that radiotherapy was actually detrimental in certain patients. The PORT Meta-analysis has |
| Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Presenter: Hanna, N.H.Presenter's Affiliation: Indiana University, Indianapolis, INType of Session: ScientificBackground Concurrent platinum-based chemotherapy and thoracic radiation treatment (RT) has become a standard of care in the treatment of unresectable non-small cell lung cancer (NSCLC). This treatment methodology is based on studies |
| Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Scientific Session: Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Bevacizumab (Avastin), a monoclonal antibody directed against the vascular endothelial growth factor |
| Outcome After Stereotactic Radiotherapy in 'High-Risk' Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Presenter: F. J. LagerwaardPresenter's Affiliation: VU University Medical Center, Amsterdam, The NetherlandsType of Session: ScientificBackground Surgical treatment with lobectomy or pneumonectomy is recognized as the optimal treatment for stage I non-small cell lung cancer (NSCLC) (Kraev A, Chest, 2007); however, many patients with this |
| Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non-small Cell Lung Cancer (NSCLC) Presenter: A. M. BradePresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground The current standard of care for operable patients with early stage lung cancer has been well established as surgical resection +/- adjuvant chemotherapy, with local control rates close to 90%. Treatment |
| Induction Chemotherapy versus Chemoradiotherapy for Stage III Non-small Cell Lung Cancer Presenter: Kristin HigginsPresenter's Affiliation: Duke University, North CarolinaType of Session: ScientificBackground Stage IIIa non-small cell lung cancer with N2 disease represents a heterogenous group of patients ranging from microscopic lymph node involvement on staging mediastinoscopy to bulky mediastinal disease on initial staging |
| Does Proton Beam Radiotherapy (PBT) Reduce Treatment Related Pneumonitis (TRP) Compared to Intensity Modulated Radiation Therapy (IMRT) in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy? Presenter: Ritsuko KOmaki, MD Presenter's Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background The risk of radiation pneumonitis limits both the dose of radiation that can be delivered as well as the volume of the thorax that can be treated. It appears that the dose of radiation, the amount of lung radiated, and the |
| A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study Presenter: Groen, M. M. Hochstenbag, J. W. van Putten, A. Vincent, O. Dalesio, B. Biesma, H. J. Smit, A. Termeer, B. E. van den Borne, F. M. SchramelPresenter's Affiliation: University Medical Center Gron, NetherlandsType of Session: ScientificBackground Cyclooxygenase-2 (COX-2) is an enzyme responsible for the conversion of arachidonic acid |
| A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214 Title: A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214 Reviewer: Arpi Thukral, MD Presenter: Elizabeth M. Gore, MD Affiliation: Medical College of Wisconsin The brain is a frequent site of |
| Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Title: Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Reviewer: Geoffrey Geiger, MD Author(s): M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green, |
| Clinical outcomes of proton beam therapy for early stage non-small cell lung cancer. A retrospective analysis of Shizuoka experiences Presenter: S. Murayama, H. FujiPresenter's Affiliation: Proton therapy division, Shizuoka Cancer Center Hospital, Nagaizumi, Shizuoka, JapanType of Session: ScientificBackground The standard of care for patients with operable stage non-small cell lung carcinomas (NSCLC) remains surgical resection. The best surgical series have |
| Phase III Study of Prophylactic Cranial Irradiation vs. Observation in Patients with Stage III Non–small-cell Lung Cancer: Neurocognitive and Quality of Life Analysis of RTOG 0214 Presenter: B. Movsas Presenter's Affiliation: Presenter's Affiliation: Henry Ford Hospital, Detroit, MIType of Session: PlenaryBackground Fifty percent of patients with locally advanced non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases at some time during the course of their disease, with the CNS as |
| A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 Presenter: G.D. Goss, MD Affiliation: The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Background Platinum-based adjuvant chemotherapy in completely resected NSCLC had demonstrated a modest survival benefit of 5% at 5 years when this study was initiated. EGFR expression in NSCLC has been correlated with aggressive morphology and |
| Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) Presenter: E. A. Quoix, on behalf of IFCT; Hôpitaux Universitaires, Strasbourg, France Background Lung cancer is the most common cause of cancer mortality in the US, accounting for 30% of cancer-related deaths in men and 26% of cancer-related deaths in women. Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung |
| Poor Pulmonary Function is not Associated with Increased Rates of Toxicity or Decreased Overall Survival after Stereotactic Body Radiotherapy for Early Stage Non-small Cell Lung Cancer: Results of a Multi-Institutional Analysis Authors: M. Guckenberger1, J. Belderbos2, A. Hope3, L. L. Kestin4, M. Werner-Wasik5, J. J. Sonke2, Y. Xiao5, D. Yan4, J. Wilbert1,I. S. Grills4 Institution: 1Julius-Maximilians University, Wuerzburg, Germany 2The Netherlands Cancer Institute, Amsterdam, Netherlands 3PrincessMargaret Hospital and University of Toronto, Toronto, ON, Canada |
| A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-small Cell Lung Cancer: Japan Clinical Oncology Group (JCOG0403) Authors: Y. Nagata, M. Hiraoka, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura Institution: Hiroshima University,, Hiroshima, Japan, Kyoto University, Kyoto, Japan, JCOG Data Center, National Cancer Center, Tokyo, Japan, Yamanashi University, Yamanashi, Japan, Institute of Biomedical Research and |
| Randomized Phase III Comparison of Standard Dose (60Gy) Versus High-Dose (74Gy) Conformal Chemoradiotherapy +/- Cetuximab for Stage IIIA/B Non-Small Cell Lung Cancer: Preliminary Findings on Radiation Dose in RTOG 0617 Presenter: Jeffrey Bradley, MD Background Dose escalation has been a controversial topic in definitive treatment of non-small cell lung cancer (NSCLC) with previous studies showing only 20% pathological complete response with 60 Gy and concurrent chemotherapy. Randomized trials of concurrent chemoradiation, although better than sequential |
| Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature Presenter: Satomi Yamamoto, MD Presenter's Affiliation: National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan Background About 30% of patients with NSCLC lung cancer present with locally advanced disease. Concurrent chemo-radiotherapy (CT-RT) is considered the standard treatment for patients with stage |
| Impact of Prophylactic Cranial Irradiation on Neurocognitive Function in Patients With Small Cell Lung Carcinoma Presenter: D.R. GrosshansPresenter's Affiliation: MD Andersen Cancer Center, Houston, TXType of Session: ScientificBackground Numerous reports have shown that limited-stage small cell lung cancer patients who receive prophylactic cranial irradiation (PCI), after achieving a clinical complete response from definitive thoracic treatment, have |
| Which Lung Volumes to Use for Radiotherapy Planning of Lung Cancer: Inspiration, Expiration, Averaged, or Free-breathing? Presenter: Yixiu Kang, MDPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: PlenaryBackground Local control in patients with early stage non-small cell lung cancer (NSCLC) after conventional radiotherapy has historically been poor. Doses of up to 70 Gy delivered with 3D conformal radiotherapy achieve local control in |
| New Diabetes Drug Helps Cancer Cells
Differentiate, Making them More Like
Normal Cells Researchers in Boston have used a new diabetes drug to push cancer cells to mature, shifting them from rapidly dividing and dangerous undifferentiated cells to slower growing and less aggressive cells. The study is the first to demonstrate that such so-called "differentiation therapy" can be effective in patients with certain solid tumors. The |
| Creating Human Cancer Cells out of Normal Cells to Better Understand the Disease Process: Biologist Robert Weinberg Describes His Lab's Successes A human cancer cell is the product of a series of genetic mutations that transform a normal cell into a progressively abnormal cell. Currently, it is impossible for researchers to retrace the complex series of steps that were actually involved in any given cancer cell's transformation-there are simply too many unknowns. So instead, cancer |
| Clinical Updates and New Approaches: Prostate Cancer, Lung Cancer, and Clinical Support & Outcomes Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to |
| Lung cancer patient utilization of an Internet based cancer clinical trials matching system Dr. James M Metz, MD, Editor-in-Chief of OncoLink, presenting research at the WCLC titled Lung cancer patient utilization of an Internet based cancer clinical trials matching system. Download the PowerPoint Presentation |
| Effect of screening on ovarian cancer mortality in the prostate, lung, colorectal, and ovarian (PLCO) cancer randomized screening trial Presenter: Saundra Buys, MD Presenter Affiliation: University of Utah Background Ovarian cancer is a deadly disease with high case fatality rate. Approximately 22,000 women are diagnosed yearly in the U.S, and 14,000 die from the disease. Women presenting with lower stage disease have better survival outcomes, but unfortunately |
| Monoclonal Antibody that Binds to Breast Cancer Cells Helps Stop Cancer Spread and Shrink Tumors This study analyzed Herceptin, a monoclonal antibody directed against the "HER2/Neu" surface protein on breast cancer cells and interfere with the cells' biological processes, which eventually causes cell death. The researchers recently completed a multinational, controlled, randomized phase III trial involoving 469 patients. The trial tested |
| New Combinations in Lung Cancer Panelists CHAIR: Paul A. Bunn, Jr., MD University of Colorado Cancer Center Robert Ginsberg, MD Memorial Sloan-Kettering Cancer Center William T. Sause, MD LDS Hospital Photo (l to r): Paul A. Bunn, Jr., MD.; Robert Ginsberg, MD; William T. Sause, MD SUMMARY The primary focus of this session was to compare and contrast the |
| Vinorelbine Plus Supportive Care Increases Survival and Quality of Life for Elderly Lung Cancer Patients Lung cancer is expected to claim the lives of more than 160,000 Americans this year -- many over the age of 65. Survival rates are improving, especially when the cancer is detected early. Treatment is often difficult, however, and is often palliative, directed only toward relieving symptoms as the disease progresses, rather than actively |
| Randomized Phase III Trial of Radiation +/- Amifostine in Patients with Advanced Stage Lung Cancer Presenter: Antonadou D Affiliation: Hellenic Group Clinical-Radiation Oncology, Greece Summary:Pneumonitis and esophagitis are two of the most problematic adverse effects associated with thoracic irradiation. Severe symptoms can cause patient distress and may necessitate treatment delays or possibly premature termination. This, in turn, could |
| PET Scans More Effective than Standard Technique at Accurately Staging Lung Cancer Classic "TNM" staging in lung cancer (an assessment of primary Tumor, regional lymph Node involvement, distant Metastasis) has only been partially effective at accurately predicting patient survival. Now, researchers at the University Hospital Gasthuisberg, Belgium, have examined the use of PET imaging to provide a more accurate, and |
| Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, |
| A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Of Novel Erythropoiesis Stimulating Protein (NESP) In Patients Undergoing Platinum Treatment For Lung Cancer Presenter: Robert Pirker Affiliation: NESP 980297 Study Group Background: Studies indicate that the carbohydrate content of erythropoietin influences serum half-life. The novel erythropoiesis stimulating protein darbepoetin alfa (NESP) is a glycoprotein with 2 more N linked carbohydrate side chains than Recombinant human erythropoietin |
| It's Time To Focus On Lung Cancer Date: November 4, 2001 Location: Philadelphia, Pennsylvania, USA Symposium Web Page: www.twcp.org Sponsors: The Wellness Community, Bristol-Myers Squibb, CancerCare, Oncology Nursing Society, The Chest Foundation |
 The Group Room: Special Remote broadcast on lung cancer, live from Philadelphia!The Group Room-the nationally syndicated radio call-in talk show about cancer-will feature a multidisciplinary panel of cancer experts discussing the latest advances in lung cancer research, screening and treatment from CHEST 2001--the American College of Chest Physicians' (ACCP) 67th annual scientific meeting, November 4th 4-6 pm ET (1-3 pm |
| The Second European Conference: Perspectives in Lung Cancer Date: December 6-8, 2001 Location: Barcelona, Spain Symposium Web Page: www.imedex.com/oncology.htm |
| 10th World Conference on Lung Cancer Conference Dates: August 10-14, 2003 Conference Location: Vancouver, British Columbia, Canada Sponsoring Group: International Association for the Study of Lung Cancer Conference Web Page URL: www.2003worldlungcancer.org Topics Covered: Review of eepidemiology of the global lung cancer problem Update on the monecular biology of lung |
| 4th European Conference: Perspectives in Lung Cancer Conference Dates: November 28-29, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Continuing Education: No |
| Brain Metastases in Lung Cancer: The Results of Radiosurgery in 238 Consecutive Patients Presenter: B.E. Amendola Presenter's Affiliation: Radiosurgery Department, Miami Neuroscience Center, Coral Gables, FL Type of Session: Scientific Background Lung cancer is the leading cause of cancer death in this country. 50% of all brain metastases have lung primary tumors Stereotactic radiosurgery is udergoing continued evaluation in the |
| PSA Testing Interval Reduction In Screening Intervals: Data From The Prostate, Lung, Colorectal And Ovarian Cancer (PLCO) Screening Trial Presenter: E. D CrawfordPresenter's Affiliation: Univ of Colorado Health Sciences Ctr, Denver, COType of Session: PlenaryBackground Prostate cancer is the most commonly diagnosed malignancy in males and the second leading cause of cancer mortality in males The prostate, lung, colorectal (PLCO) trial is a large, controlled randomized trial |
| 2nd Annual Atlanta Lung Cancer Symposium Conference Dates: March 19-20, 2004 Conference Location: Atlanta, GA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm |
| The 11th World Conference on Lung Cancer - IASLC Conference Dates: July 3-6, 2005 Conference Location: Barcelona, Spain Sponsoring Group: International Association for the Study of Lung Cancer Conference Web Page URL: www.2005worldlungcancer.com Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing |
| The 5th European Conference: Perspectives in Lung Cancer The 5th European Conference: Perspectives in Lung Cancer Conference Dates: November 19-20, 2004 Conference Location: Berlin, Germany Sponsoring Group: Imedex, inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: |
| Long-Term Changes in Pulmonary Function Tests Following Definitive Radiotherapy for Lung Cancer Presenter: Keith MillerPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground The majority of patients with lung cancer present in an inoperable stage and hence require radiation therapy. Thoracic radiation can affect Pulmonary Function Tests (PFT) and cause clinical pneumonitis. Prior studies have had either very short |
| Changes of Tumor Motion Patterns During a Course of Radiation Therapy for Lung Cancer Presenter: Kenneth M. Forster, PhDPresenter's Affiliation: MD Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Patient and target immobilization with daily reproducibility are the cornerstones of accurate and precise radiation therapy delivery. The treatment of lung cancers has long posed the challenge of retaining this |
| The 11th World Conference on Lung Cancer Conference Dates: July 3-6, 2005 Conference Location: Barcelona, Spain Sponsoring Group: International Association for the Study of Lung Cancer (IASLC) Conference Web Page URL: www.2005worldlungcancer.com Registration Information: Online at www.2005worldlungcancer.com,tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com |
| Fifth Annual Targeted Therapies for the Treatment of Lung Cancer Conference Dates: February 10-12, 2005 Conference Location: Steamboat Springs, ColoradoSponsoring Group: The Dannemiller Memorial Educational Foundation and Cadent Medical CommunicationsConference Web Page URL: http:/www.thecbce.com/futureprograms.aspTopics Covered: After participating in this conference, attendees should be able to: Explain the |
| Second Annual Winter Lung Cancer Conference Conference Dates: March 18-20, 2005 Conference Location: Sunny Isles Beach, Florida Sponsoring Group: Cadent Medical Communications Conference Web Page URL: www.thecbce.com Topics Covered: In this symposium, opinion leaders who specialize in medical radiation and surgical oncology will provide updates on the diagnosis, staging, and treatment of |
| Live Webcast - Learn about Diagnosis and Treatment of Lung Cancer and Chemotherapy Expectations and Management of Side Effects Conference Dates: Saturday, November 5, 2005 at 7:00 P.M. (EST) Conference Location: Webcast Sponsoring Group: Lung Cancer Alliance and provided as an educational service by Lilly Oncology Conference Web Page URL: medconference.net/lungcancerawareness Topics Covered: Learn about Diagnosis and Treatment of Lung Cancer and Chemotherapy |
| Tumor Markers and the Early Detection of Lung Cancer Presenter: James Mulshine, MD Affiliation: National Cancer Institute Lung cancer has recently outstripped coronary artery disease as the leading cause of smoking related death in the USA. One half of new lung cancers are diagnosed in former smokers. This indicates that smoking cessation alone is insufficient in reducing cancer related |
| IImpact and Therapeutic Implications of Anemia in Lung Cancer Presenter: Corey Langer, MD Affiliation: Fox Chase Cancer Center, Philadelphia, PA Anemia in cancer patients is a common problem with a multifactorial etiology. It is well recognized that the presence of malignancy is associated with a blunted response to anemia; as hemoglobin (Hb) levels decrease, the normal compensatory increase in |
| Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 This presentation discusses off-label use of gefitinib in BAC. Presenter: H. WestPresenter's Affiliation: Swedish Cancer Institute, Seattle, WAType of Session: ScientificBackground Bronchioloalveolar lung cancer (BAC) is a distinctive subtype of non-small cell lung cancer (NSCLC) with different pathologic, radiographic characteristics, and natural |
| Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans. Presenter: V. KhuranaPresenter's Affiliation: VA Medical Center, Shreveport, LouisianaType of Session: ScientificBackground - Statins (HMG CoA reducatse inhibitors) are a widely studied, effective class of medications used to lower cholesterol in an effort to reduce atherosclerosis and heart disease. |
| Potential differences between lung cancer patients using the Internet and patients in the clinic Maggie Hampshire, RN, BSN, OCN, Managing Editor of OncoLink, displaying research at the WCLC poster presentation session titled Potential differences between lung cancer patients using the Internet and patients in the clinic. Authors of this presentation included S. Jack Wei, MD, |
| Patient initiation of complementary and alternative medical therapies (CAM) during conventional lung cancer treatment Dr. James M Metz, MD, Editor-in-Chief of OncoLink, presenting research at the WCLC poster presentation session titled Patient initiation of complementary and alternative medical therapies (CAM) during conventional lung cancer treatment. Authors of this presentation include Neha |
| Third Annual Winter Lung Cancer Conference Conference Dates: March 10-12, 2006 Conference Location: The Fairmont Turnberry Isle Resort & Club Sponsoring Group: The Center for Biomedical Continuting Education (CBCE) Conference Web Page URL: www.thecbce.com/currentactivities.asp Conference Objectives: This conference offers clinicians the opportunity to discuss the latest advances |
| Sixth Annual Targeted Therapies for the Treatment of Lung Cancer Conference Conference Dates: January 26, 2006 Conference Location: Santa Monica, CA Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: EGFR Inhibitors, Angiogenesis Inhibitors, Proapoptotic Agents, mTor/Map kinase/Signal Transduction/Akt, Novel Cytotoxics, |
| ASTRO 2005 Lung Cancer Highlights OncoLink selected lung cancer topics from the Annual Meeting of the American Society for Therapeutic Radiology And Oncology October 16-20, 2005, held in Denver, Colorado. The Association Between the Mean Heart Dose, Mean Lung Dose, Tumor Location and RT-associated Heart and Lung Toxicity Clinical Application of Positron Emission Tomography (PET) |
| Fourth Annual Winter Lung Cancer Conference Conference Dates: March 16-18, 2007 Conference Location: The Eden Roc Renaissance Resort & Spa, Miami Beach, Florida Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please log onto www.thecbce.com to download conference brochure. Conference Objectives: For |
| Trends and Challenges in Community Oncology: A Focus on Lung Cancer Conference Dates: Thursday, November 13, 2007 Conference Location: Lynnwood Convention Center Sponsoring Group: Oncology Today and Puget Sound Cancer Centers Topics Covered: Hosted by community oncology practices, the CME/CE accredited series of multidisciplinary case-based meetings, Trends and Challenges in Community Oncology: A Focus on Lung |
| Specialists' Symposium on Advanced Management of Lung Cancer Conference Dates: November 16-17, 2007 Conference Location: Portland, Oregon Sponsoring Group: Providence Cancer Center Conference Web Page URL: Sixth Annual Providence Thoracic Oncology Symposium Website Topics Covered: Endobronchial Ultrasound Preoperative Evaluation for Lung Cancer Stereotactic Radio Surgery for Lung Cancer |
| Lung Cancer 2007: A Multidisciplinary Approach Conference Dates: October 20, 2007 Conference Location: Houston, Texas Sponsoring Group: Texas Oncology Sugar Land and Oncology Today Conference Web Page URL: http://www.lungcancer2007.com Topics Covered: The CME/CE accredited program, Lung Cancer Care in 2007: A Multidisciplinary Approach, offers a unique opportunity for community-based |
| Lung Cancer in 2007: A Multidisciplinary Approach Conference Dates: October 6, 2007 Conference Location: Minneapolis, Minnesota Sponsoring Group: Minnesota Oncology Hematology, PA Conference Web Page URL: http://www.lungcancer2007.com Topics Covered: The CME/CE accredited program, Lung Cancer Care in 2007: A Multidisciplinary Approach, offers a unique opportunity for community-based |
| Cumulative False-Positives (FP) in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial Presenter: J. H. MillerPresenter's Affiliation: National Institutes of HealthType of Session: ScientificBackground Cancer screening tests are recommended to the general public, however, the burden of multiple screening tests is not clear. Prior studies have examined the risk benefit ratios of individual screening tests, but in clinical |
| 9th European Congress: Perspectives in Lung Cancer Conference Dates: March 14-15, 2008 Conference Location: Torino, Italy Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Lung Cancer Who Should Attend: oncologists, internists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration |
| Fifth Annual Winter Lung Cancer Conference Conference Dates: March 14, 2008 - March 16, 2008 Conference Location: Trump International Sonesta Beach Resort, Sunny Isles Beach, Florida Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com Who Should Attend: Medical, surgical, and radiation oncologists; Thoracic surgeons; Pulmonologists; Nurses; Pharmacists; Advanced |
| Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiotherapy to Treat Medically Inoperable Early Stage Lung Cancer Patients Presenter: Robert Timmerman, MDPresenter's Affiliation: University of Texas SouthwesternType of Session: ScientificBackground The treatment of patients with non-small cell lung cancer (NSCLC) who are unable to undergo surgery can be very difficult as these patients often have poor lung function which limits radiation dose and volumes. |
| Dosimetric Advantages of Proton Simultaneous In-Field Boost (PSIB) Technique for Treating Lung Cancer Presenter: Lei Dong, PhDPresenter's Affiliation: Division of Radiation Oncology, the University of Texas M.D. Anderson Cancer CenterType of Session: ScientificBackground Despite continued efforts of behalf of the oncology community, prognosis for patients with locally advanced non-small cell lung cancer (NSCLC) remains poor. Radiotherapy |
| Lung Cancer and Proton Therapy Presenter: Joe Chang, MD, PhD Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Reporting Background Dr. Chang’s presentation focused on the use of image guided proton therapy in the treatment of non-small cell lung cancer. He discussed ways to decrease inter and intra-fraction tumor motion as well as how changes in |
| Sixth Annual Winter Lung Cancer Conference Conference Dates: March 6-8, 2009 Conference Location: Trump International Sonesta Beach Resort in Sunny Isles Beach, FL Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/wlcc Conference Objectives: Please see website for further information. Who Should Attend: This activity is |
| Sixth Annual New York Lung Cancer Symposium Conference Dates: November 9, 2010 Conference Location: The Westin New York at Times Square Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/565 Topics Covered: Assess molecular profiling of lung cancer based on tumor |
| 11th International Lung Cancer Congress Conference Dates: July 8-11, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/510 Conference Objectives: An update of research efforts from major Cooperative Groups from the United |
| Proton Therapy for Early-Stage Lung Cancer at Loma Linda University Medical Center Presenter: D. BushPresenter's Affiliation: Loma Linda University Medical CenterType of Session: ScientificBackground Non-small cell lung cancer (NSCLC) remains the most frequent cause of cancer-related death in the United States, and is a prominent cause of death worldwide. Survival correlates with disease stage at diagnosis, and |
| Proton Therapy for Lung Cancer at Loma Linda University Medical Center (LLUMC), Locally Advanced Disease Presenter: D. BushPresenter's Affiliation: Loma Linda, USAType of Session: ScientificBackground Despite aggressive treatment with chemoradiation, outcomes in patients with locally advanced NSCLC remain poor, with a median survival of approximately 18 months. There have been several advancements that have been made over time that have |
| Intrafractional and Interfractional Range Variation in Charged Particle Therapy of Lung Cancer Presenter: S. Mori, L. Dong, G. Starkschall, R. Mohan, J.D. Cox, T. ChenPresenter's Affiliation: National Institute of Radiological Sciences, Chiba, JapanType of Session: ScientificBackground The difference between charged particle and photon beams is their finite penetration and sensitivity to tissue density variations along a given pathway |
| Stereotactic Body Radiation Therapy for Medically Inoperable Early-stage Lung Cancer Patients: Analysis of RTOG 0236 Presenter: R.D. Timmerman Presenter's Affiliation: University of Texas Southwestern Medical Center, Dallas, TXType of Session: ScientificBackground Lung cancer remains the most frequent cause of cancer death among men and women in North America. Approximately 75% of patients with bronchogenic carcinoma are diagnosed with non-small cell |
| 12th European Conference: Perspectives in Lung Cancer Conference Dates: March 11-12, 2011 Conference Location: Lingotto Conference and Exhibition Centre Sponsoring Group: Imedex Conference Web Page URL: www.perspectivesinlungcancer.com Topics Covered: Lung Cancer Who Should Attend: This educational activity is intended for medical and radiation oncologists, thoracic surgeons, pulmonologists, |
| Beliefs About the Effectiveness of Palliative Radiation Therapy among Patients with Incurable Lung Cancer Abstract number: Plenary #6 Presenter: Aileen Chen, MD, MPP Affiliation: Brigham and Women's Hospital and Dana-Farber Cancer Institute Background Metastatic lung cancer is almost always incurable, and radiation therapy is a mainstay of palliative treatment. Providers are often overly optimistic in communicating prognosis and |
| Interferon Plus Chemotherapy Is Better Than Chemotherapy Alone In Renal Cell Cancer Seppo Pyrhönen, M.D., senior physician, chief, Outpatient Chemotherapy Unit, Helsinki University Central Hospital (Helsinki, Finland), presented the results of a multicenter trial which compared the effects of combination therapy with chemotherapy and interferon alfa-2a cersus chemotherapy alone on the overall survival of patients with |
| Interferon Plus Interleukin-2 Is The Optimal Treatment To Induce Responses In Metastatic Renal Cell Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in advanced renal cell carcinoma (RCC). According to Dr. Négrier, despite the large number of |
| Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx Presenter: Aebersold, DM Affiliation: Department of radiation oncology, Inselspital Berne, Switzerland Summary: Angiogenesis is thought to play a role in radiosensitivity. The differences in radiosensitivity are thought to be related to the influence of oxygenation, vasculotoxicity of radiation, and angiogenic factors that inhibit radiation |
| Tamoxifen Also Effective in Stopping Abnormal Breast Cells from Becoming Cancerous Last year a major study of 13,000 women demonstrated that tamoxifen can significantly reduce the risk of developing breast cancer in some women. In October 1998, the federal Food and Drug Administration (FDA) approved the drug for use in women at increase risk of developing the disease. Now, after further analysis of the data, researchers have |
| A clinical trial comparing concurrent Cisplatin and radiation therapy versus radiation alone for locally advanced Squamous Cell Carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group Presenter: Gavin Stuart Affiliation: NCI Canada, University of Alberta, Edmonton, Canada, others Background: In 1999, multiple abstracts of phase III trials comparing chemoradiation with radiation alone in localized cervix cancer were presented at ASCO. All of these trials showed that multiagent platinum-containing chemotherapy was |
| A Phase III Comparison of Standard
Radiation Therapy (RT) Versus RT Plus Concurrent Cisplatin (CDDP) Versus Split-Course RT Plus ConcurrentCDDPP and 5-Flourouracil (5-FU) in Patients with Unresectable Squamous Cell Head and Neck Cancer (SCHNC): An Intergroup Study Presenter: DJ Adelstein Affiliation: ECOG & SWOG Background: Unresectable squamous cell carcinoma of the head and neck region conotates a very poor prognosis overall. Recent Phase II trials have suggested the addition of concurrent chemotherapy to radiation therapy may improve survival. This study was performed to compare standard |
| Maximizing Local Control And Organ Preservation In Advanced Squamous Cell Head And Neck Cancer (SCHNC) With Hyperfractionated Radiation (HRT) And Concurrent Chemotherapy Presenter: David J. Adelstein Affiliation: Cleveland Clinic Foundation, Cleveland, OH. Background: 5Fu and cDDP are the best studied and most effective drugs for head and neck cancer. Both agents are radiosensitizers. Altered fractionation regimen is more effective than conventional therapy. Materials and Methods: 44 patients (pts) with |
| Renal Cell Cancer Symposium Conference Dates: January 25, 2003 Conference Location: Moffitt Cancer Center, Tampa, FL Sponsoring Group: Moffitt Cancer Center & Chiron Conference Web Page URL: www.moffittcancercenter.com Topics Covered: . Distinguished faculty will present information on surgical aspects, conventional therapy, underlying physiology of targeted |
| COX Inhibitors Markedly enhance Tumor Radiosensitization of Cultured Human Cancer Cells under Acidic Microenvironment Presenter: T.R. Shah Presenter's Affiliation: Henry Ford Hospital Type of Session: Scientific Background Prostaglandins are synthesized by COX enzymes. These prostaglandins have been implicated in carcinogenesis, angiogenesis, invasiveness, and metastatic potential, as well as resistance to treatment. COX inhibitors may stop the production of |
| Phase I Study of Docetaxel (D), Cisplatin (P), and Concomitant Boost Radiation for Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCHN) Presenter: B GlissonPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PosterBackground Both concurrent chemoradiation, with conventionally fractionated radiation (RT), and concomitant boost RT have been shown in randomized trials to improve the locoregional control in advanced SCHN. Docetaxel (D) has been shown to have |
| The Impact of Baseline Nutritional Support on Treatment Outcome in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck Treated with Definitive Radiotherapy: Report of the Radiation Therapy Oncology Group (RTOG) Trial 90-03 Presenter: Barbara EldridgePresenter's Affiliation: RTOGType of Session: ScientificBackground Head and neck cancers and treatment of these cancers are inherently associated with loss of appetite, swallowing dysfunction, and odynophagia. This leads to a decrease in nutritional uptake with obvious problems associated with it. However, there is |
| Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial Presenter: D.F. HayesPresenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MIType of Session: ScientificBackground The identification of markers that predict resistance to a treatment early in the course of therapy would allow termination of a futile treatment and initiation of an alternative regimen. |
| Risk-adapted management of stage I seminoma: the second Spanish Germ Cell Cancer Group (GG) study * This presentation discusses off-label use of carboplatin in the treatment of seminoma. Presenter: J. AparicioPresenter's Affiliation: Spanish Germ Cell Cancer GroupType of Session: ScientificBackground Seminoma represents 45% of all germ cell tumors and 70%-80% of patients present with Stage I disease. Management of patients with |
| Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck Presenter: James BonnerPresenter's Affiliation: Erbitux Head and Neck Study GroupType of Session: ScientificBackground More that 500,000 people worldwide develop head and neck cancers (HNC) annually including 40,000 people in the United States with 10,000 deaths annually The standard therapy for HNC is radiation therapy (RT) with or without |
| S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC) Presenter: D. AdelsteinPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground Several phase III cooperative studies have established radiation therapy and concurrent single agent cisplatin as a clear treatment standard for squamous head and neck cancer. Cooperative group trials (RTOG 9003) and |
| Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists’ group (BOOG) Presenter: E. Mamounas Affiliation: NSABP Operations & Biostatistical Centers, Pittsburgh, PA Background Decisions regarding use of chemotherapy and radiotherapy in the treatment of breast cancer patients may be partially based on axillary lymph node status. In recent years, more extensive pathologic examination of lymph nodes has |
| Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine Presenter: M.L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, Y. DangPresenter's Affiliation: University of Washington, Seattle, WA; Breastlink, Los Angeles, CAType of Session: ScientificBackground HER2/neu (also known as ErB-2) is a protein member of the ErbB protein family more commonly referred to as the |
| The Association Between the Mean Heart Dose, Mean Lung Dose, Tumor Location and RT-associated Heart and Lung Toxicity Presenter: L.B. MarksPresenter's Affiliation: Radiation Oncology, Duke University Medical Center, Durham, NCType of Session: ScientificBackground One of the side effects of lung irradiation is radiation pneumonitis, which can be manifested as dyspnea. However, dyspnea can be one of the presenting symptoms of cardiac disease and might cause |
| A Clinical Trial Of Antigen-Pulsed Dendritic Cells (DC) In The Treatment Of Patients With B-Cell Lymphoma Researchers at Stanford University Medical Center presented preliminary results of a study on a new vaccine treatment for B-cell lymphoma. Chemotherapy and/or radiation can cause remission in most patients with B-cell lymphoma. However, despite responsiveness to treatment, patients ultimately relapse and most cannot be cured with standard |
| Multicenter Phase III Trial to Compare Radical Nephrectomy Plus Adjuvant Autologous Tumor Cell-Lysate Vaccine Versus Radical Nephrectomy Without Adjuvant Treatment for Renal Cell Carcinoma Stages pT2-3bN0-3M0: a 3-year Analysis Presenter: C. DoehnPresenter's Affiliation: University of Luebeck Medical SchoolType of Session: ScientificBackground According to SEER data, 50% of renal cell carcinomas (RCC) are localized in extent. The five-year survival rate for localized tumors is 90%, but drops to 60% if disease is regional in extent and 10% if metastatic. Standard therapy |
| Clinical Implications of Stem Cell Plasticity: Repair of the Infarcted Heart by Cytokine-Mobilized Bone Marrow Stem Cells Presenter: Donald Orlic, PhD Stem cell plasticity refers to the recently discovered ability of bone marrow stem cells (BMSCs) to generate non-hematopoietic cell types, such as epithelial, skeletal muscle, bone, liver, and neural cells. Dr. Orlic and his group have investigated the ability of adult mouse BMSCs to differentiate into myocardial |
| Results of Myeloablative Allogenic Stem Cell Transplant (SCT) for Severe Sickle Cell Disease in France Presenter: Francoise BernaudinPresenter's Affiliation: SFGM-TC, FranceType of Session: PlenaryBackground Sickle cell disease effects the black population and is responsible for many hospitalizations and a high consumption of red blood cell transfusions. The only definitive cure remains a bone marrow transplant. However, the risks of a allogenic |
| In Vitro CD4+ T Cells Expansion: Induction of Regulatory T Cells with Sirolimus and CD3/CD28 Dynabeads Presenter: Borelli, GPresenter's Affiliation: Department of Cellular Therapy, Rikshospitalet-Radiumhospitalet HFType of Session: ScientificBackground T regulatory cells (Treg) are a subset of T lymphocytes defined by CD4+CD25+ markers and high FOXP3 expression. They play a key role in self-reactivity and alloreactivity control. Treg |
| Can We Predict Radiation (RT)-Induced Changes in Pulmonary Function Tests (PFTs) Based on the Lung Dose-Volume Histogram? Presenter: Ming Fan, M.D. Affiliation: Duke University Medical Center Summary: Radiation induced pulmonary changes can cause serious, even life-threatening problems in patients whose lung function is already compromised by tumor burden and smoking. There are many studies which qualitatively document pulmonary toxicity relative to dosing |
| A Phase II Trial Of Pemetrexed In Malignant Pleural Mesothelioma (MPM) Patients: Clinical Outcome, Role Of Vitamin Station, Respiratory Symptoms Upplemenand Lung Function Presenter: Dong M Shin,Presenter's Affiliation: University of PittsburghType of Session: ScientificBackground Malignant pleural mesothelia (MPM) is generally caused by exposure to asbestos and is commonly accompanied by pleural effusion, sometimes making radiologic images difficult to interpret. As the worldwide incidence of MPM increases, few |
| Radiotherapy (RT) Patterns of Care Study (PCS) in Lung Carcinoma
Presenter: B. MovsasPresenter's Affiliation: Fox Chase Cancer Center (FCCC), Phila, PA, USAType of Session: ScientificBackground This study was designed to determine the national patterns of radiation therapy (RT) practice in patients treated for non-metastatic lung cancer between 1998-1999. Materials and Methods A survey of randomly selected |
| Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Presenter: J.P. PignonPresenter's Affiliation: Institut Gustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a small but significant survival benefit with adjuvant cisplatin based chemotherapy in |
| Patient Summary: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients This study pooled the results (also called meta-analysis) of multiple studies of non small cell lung cancer treated with chemotherapy after surgical resection. In particular, this group looked at studies using cisplatin alone or |
| The Integrin-TGFbeta Axis: Inhibition of Integrin Alpha v Beta6 Prevents Radiation-Induced Lung Fibrosis. Presenter: S. ChengPresenter's Affiliation: New York University Medical Center, New York, NYType of Session: ScientificBackground Over 175,000 new cases of thoracic malignancies are diagnosed in the United States each year, and over half of them require treatment with radiation at some point. Treatment of thoracic malignancies is |
| A Small Molecular Inhibitor of TGFß Protects Against the Development of Radiation Induced Lung Injury Presenter: Mitchell S. Anscher, MDPresenter's Affiliation: Virginia Commonwealth University Medical Center, Richmond, VAType of Session: PlenaryBackground One of the primary limitations that inhibits dose escalation in the treatment of lung cancer is the risk of pulmonary toxicity, such as pulmonary fibrosis. Finding new agents to |
| Phase I/II Trial Results Of 131-I-Anti-B1 (Anti-CD20) Non-Myeloablative Radioimmunotherapy For Refractory B-Cell Lymphoma Researchers at the University of Michigan Medical Center (Ann Arbor, MI) presented results of a Phase I/II clinical trial of a new form of treatment for non-Hodgkin's lymphoma. There are approximately 51,000 new cases of non-Hodgkin's lymphoma in the U.S. each year. Chemotherapy and radiotherapy have been the mainstays of lymphoma |
| A Radiation Therapy Oncology Group (RTOG) Phase III Randomized Study to Compare Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinomas: Preliminary Results of RTOG Presenter: Karen K. Fu, MD Affiliation: RTOG and University of California San Francisco Summary:Various fractionation schemes have been advocated for the treatment of head and neck cancer based on single institution experiences. This multi-institutional Phase III trial was performed to evaluate disease free survival, overall survival, local |
| Impact of Hemoglobin (Hgb) Level and Use of Recombinant Human Erythropoieten (r-HuEPO) on Response to Neoadjuvant Chemoradiation Therapy, Tumor Control, and Survival in Patients With Oral or Oropharyngeal Squamous Cell Carcinoma (SCCA) Presenter: Christoph M. Glaser, MD Affiliation: General Hospital Vienna, Austria Summary:Anemia is a frequent finding in patients with head and neck cancer and has been found to be a poor prognostic factor. This study was performed to evaluate the impact of r-HuEPO on patients with a low Hgb level. Methods: All 187 patients in this |
| Radiation Therapy With Concurrent Weekly Carboplatin and Paclitaxol in Advanced Stage Unresectable Squamous Cell Carcinoma of the Head and Neck Presenter: Michael L. Haas, MD Affiliation: University of Maryland Summary:Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer. Methods: From |
| Anemia is associated with decreased local control of surically treated squamous cell carcinoma of the glottic larynx Presenter: Guttenberger R Affiliation: University of Freiberg, Freiberg, Germany Summary:-There is a known correlation between anemia and local control in head and neck cancer. -This study was performed to demonstrate a difference in treatment outcome in patients with a low pretreatment hemoglobin who recieved surgery alone. -From |
| Squamous Cell Carcinoma of the Base of Tongue Treated with External Beam Radiation Therapy: A Preferred Alternative to Surgery Presenter: Mendenhall WM et al Affiliation: University of Florida College of Medicine Summary:Surgery has traditionally been the mainstay of treatment for squamous cell carcinoma of the base of tongue. However, the morbidity with this surgery is significant. This retrospective study was performed to compare outcomes with definitive |
| Stem Cells May be Engineered to Resist Toxic Effects of Chemotherapy A research team led by the National Cancer Institute has taken the first steps toward making bone marrow stem cells resistant to the toxic effects of chemotherapy. Such an advance could potentially allow patients to undergo multiple rounds of high dose chemotherapy without having to remove their marrow, the source of "stem" cells that produce |
| Alternating Chemo-Radiotherapy Versus Partly Accelerated Radiotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial Presenter: M. Benasso Affiliation: Inst Nazionale per la Ricera sul Cancro and affiliated centers, Genoa, Italy Background: It has previously been shown that alternating chemo-radiotherapy (ALT) has improved outcome compared with conventional RT in advanced-stage Squamous cell carcinoma of the head and neck. This study compared the |
| Amifostine (AF) Cytoprotetion (CP) of Escalating Doses of Melphalan (MEL) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Final Results of a Phase I & II study Presenter: G. L. Phillips Affiliation: University of Maryland / Greenebaum Cancer Center Background: Alkylating agents show a steep dose response curve. Regimen related toxicity (RRT) is dose- limiting with AHSCT Growth factors and stem cell transplantation permits dose escalation to non- hematologic organ limit. Melphalan dose at 220 mg/ |
| Efficacy of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Reducing Mucositis in Patients with Hematologic Malignancies Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation (auto-PBPCT) After Radiation-Based Conditioning ? Resu Presenter: R. T. Spielberger Affiliation: City of Hope National Medical Center, Duarte, CA Background: TBI/VP16/Cyclophosphamide is the established conditioning regimen for auto-PBPCT and it causes approximaetly 80% of severe oral mucositis. Currently, no standard therapy is available to prevent or reduce severe oral mucositis rHuKGF |
| A Prospective Randomized Trial of Prophylactic Platelet Transfusion and Bleeding Incidence in Hematopoietic Stem Cell Transplant (HSCT) Recipients: 10, 000 μL vs. 20,000 μL Threshold Presenter: M.S. Zumberg Affiliation: University of Florida College of Medicine Background: Threshold of Prophylactic Platelet Transfusion (PPT) for HSCT has yet to be determined One retrospective review in bone marrow transplant patients showed no difference in the incidence of major bleeding episodes in pts that received PPT at 10,000 μL |
| Preliminary results of RTOG 9703 - a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced Squamous Cell Carcinomas (SCC) of the head and neck Presenter: A.S. Garden Affiliation: U.T.M.D. Anderson Cancer Center, Houston, TX Background: Concurrent chemoradiation may improve Survival for advanced Head and Neck cancer. 2. Numerous studies have evaluated different treatment approaches with different fractionation, chemotherapeutic agents, and timing of drug administration. Materials |
| Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy Presenter: Waun Ki Hong/Roy S. Herbst Affiliation: Anderson Cancer Center Background: Patients with recurrent SCCHN who fail to respond to platinum-based therapy rarely respond to second-line treatment This study was performed to evaluate IMC-C225 in patients that have failed standard chemotherapy. Materials and Methods: Patients (pts) with |
| Cost-Utility Analysis of RTOG 90-03: Phase III Randomized Study Comparing Altered Fractionation to Standard Fractionation Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Presenter: A. Konski Presenter's Affiliation: Toledo Radiation Oncology, Hickman Cancer Center, Adrian, MI Type of Session: Scientific Background RTOG 90-03 a four-arm study that evaluated various fractionation schedules for the treatment of locally advanced head and neck cancer. This study attempts to determine the cost-effectiveness using |
| Final Report of the Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody, Cetuximab (IMC-C225), in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing-Chemotherapy Presenter: Merrill S. KiesPresenter's Affiliation: MC Anderson Cancer CenterType of Session: PosterBackground Recurrent squamous cell cancer of the head and neck (SCCHN) is a clinical challenge, especially in the setting of disease that is refractory to platinum-based agents. Less than 5% of these patients will respond to second-line therapy. |
| Use of Low-dose Fractionated Radiation (LDFRT) as a Chemosensitizer of Neoadjuvant Paclitaxel (P) and Carboplatin (CBCDA) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Results of a New Treatment Paradigm Presenter: Susanne ArnoldPresenter's Affiliation: Markey Cancer Center, Lexington , KentuckyType of Session: PosterBackground Radiation resistance is a major cause of treatment failure in squamous cell cancer of the head and neck (SCCHN). Low dose fractionated radiation (LDFRT), defined as doses Materials and Methods 38 patients with advanced |
| Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) porgressing on a same dose and schedule platinum-based regimen Presenter: J. BaselgaPresenter's Affiliation: Institut Goustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)who fail first line therapy have a very poor prognosis, with a response rate of Materials and Methods Eligible patients had SCCHN |
| Combining an Allogeneic Graft-Vs-Myeloma Effect with High-Dose Autologous Stem Cell Rescue in the Treatment of Multiple Myeloma Presenter: David G. Maloney Presenter's Affiliation: Fred Hutchinson Cancer Research Center, Seatle, WA Type of Session: Plenary Background Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for Multiple Myeloma has been associated with high transplant-related mortality (TRM), limiting its clinical usefulness despite its |
| Monitoring the Anti-Tumor Activity of Expanded CD8+ NKT Cells After Allogeneic Bone Marrow Transplantation Using Bioluminescent Imaging Presenter: Matthias Edinger Presenter's Affiliation: Stanford University School of Medicine Type of Session: Plenary Background Biolumiscent imaging is an imaging technique that allows the visualization of labeled cells within a living animal. Cells labeled with the Luc gene emit low levels of light that can be detected and quantified with |
| Multiple Resistance Mechanisms Identified through Studies of Cell Lines Derived from Chronic Myelogenous Leukemia Patients Progressing on STI-571 Therapy Presenter: Nicholas J. Donato Presenter's Affiliation: MD Anderson Cancer Center Type of Session: Scientific Background STI-571 is known to be an effective inhibitor of the BCR-ABL fusion protein and therefore has become a common treatment for BCR-ABL positive leukemias. Disease progression while on STI-571 occurs frequently in accelerated |
| Neurocognitive Assessment and detection of Stroke in Patients Diagnosed with Sickle Cell Disease: Neuropsychological Functioning and Magnetic Resonance Imaging (MRI) Presenter: E. Vichinsky Presenter's Affiliation: Children's Hospital, Oakland, California Type of Session: Scientific Background Children who have sickle cell disease(SCD) are at risk for the development stroke or silent infarct, often resulting in cognitive impairment. It has been estimated that approximately 25% of all children with SCD will |
| Focus on Myeloma and Plasma Cell Disorders Conference Dates: April 2-3, 2004 Conference Location: Los Angeles, CA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Leading clinical and laboratory investigators will present cutting edge data on the diagnosis and management of multiple myeloma and other plasma cell disorders. |
| Medical Update in AML: New Treatments and Blood Stem Cell Transplantation Conference Dates: September 22, 2004 Conference Location: Telephone Conference Sponsoring Group: National Marrow Donor Program, CancerCare and The Leukemia & Lymphoma Society Conference Web Page URL: www.marrow.org/NEWS/EVENTS/aml_workshop.html Topics Covered: An overview of acute myelogenous leukemia (AML), by Dr. Selina Luger An overview |
| Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia. Presenter: Jeffrey J. MolldremPresenter's Affiliation: M.D. AndersonType of Session: PlenaryBackground Despite decades of research there are no FDA approved cancer vaccines. The concept of tumor immunosurveillance has recently become repopularized with recent research showing that tumor specific antigens do indeed exist. There is a known |
| A Decision Analysis of Allogeneic Stem Cell Transplantation for MDS: Delayed Transplantation for Low Risk MDS Is Associated with Imporved Outcome Presenter: Corey CutlerPresenter's Affiliation: Dana Farber, Boston, MAType of Session: ReportingBackground Therapies for MDS are limited and unrewarding. Allogeneic transplants can provide cure for 25-40% of the pts. Low risk MDS pts have a life expectancy of several years with minimal medical intervention. Eventually however, pts become |
| Allogeneic Stem Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) patients <50 years old in first complete remission(CR) A Donor vs no donor comparison in the EORTC ALL-3 Study. Presenter: Boris LabarPresenter's Affiliation: EORTCType of Session: ReportingBackground Allo transplant for ALL has been used for over 20 years but despite its' general application its role in adults remains unclear. The contraversy remains between an allo transplant and an autologous transplant followed by maintenance chemotherapy for this |
| Gene Expression Profiles in AIDS-Related Lymphomas (ARL): Burkitt Lymphoma (BL) and Diffuse Large B-Cell Lymphoma-Immunoblastic Variant (DLBCL-IBL) Presenter: Sven de VosPresenter's Affiliation: UCLAType of Session: ScientificBackground Primary CNS lymphoma and other malignant lymphomas continue to be a large problem in patients with AIDS. The most common type of lymphoma in these patients include Burkitt lymphoma (BL) and diffuse large B cell lymphoma, especially that of the immunoblastic |
| Replicating Attenuated Measles Virus Can Be Engineered to Enter Cells Through the CD20 Antigen Presenter: Adele FieldingPresenter's Affiliation: Mayo ClinicType of Session: ScientificBackground In laboratory models of Non-Hodgkin's Lymphoma (NHL), attenuated measles virus (MV) has been found to have therapeutic potential as a replicating, oncolytic virus. There are case reports of lymphoma regression after measles virus infection in |
| Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma Presenter: J.P. LeonardPresenter's Affiliation: Weill Medical College of Cornell UniversityType of Session: ScientificBackground Bcl-2 overexpression is involved in inhibition of apoptosis and therefore results in tumor cell growth. Bcl-2 is highly expressed in patients with Mantle Cell lymphoma. Bcl-2 has also been shown to be a major |
| Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free survival and survival in children and adolescents with gonadal malignant germ cell tumors (MGCT) A POG/CCG Study Presenter: T.A. OlsonPresenter's Affiliation: Children's Oncology GroupType of Session: ScientificBackground Bleomycin is a standard component of multi-drug chemotherapy for MGCT. It is the least effective single agent in this regimen. Concern for the pulmonary toxicity of bleomycin led to the development of this trial which employs reduced |
| Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: chemoradiation with and without surgery Presenter: M StahlPresenter's Affiliation: German Oesophageal Cancer Study GroupType of Session: ScientificBackground Treatment of locally advanced esophageal cancer remains difficult. Treatment with surgery alone results in overall survival (OS) of less than 15%. Recent studies have demonstrated improved outcomes by combining surgery with |
| Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of Session: ScientificBackground Non-Hodgkin's lymphoma (NHL) is the fifth most common malignancy in the United |
| Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) This study discusses an off-label use of rituximab for the treatment of MCL. Presenter: W. HiddemannPresenter's Affiliation: Ludwig-Maximilians-University, Munchen, GermanyType of Session: ScientificBackground Mantle cell lymphoma (MCL) accounts for up to 6% of all lymphomas. Most patients present with advanced stage and progress |
| Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Presenter: J. TrigoPresenter's Affiliation: Vall d'Hebron University, Barcelona, SpainType of Session: ScientificBackground There is no accepted standard therapy for recurrent squamous cell carcinoma of the head and neck. Patients refractory to platinum-based chemotherapy rarely respond to second-line treatment (2.6%) and display a median |
| Randomized Phase III Trial ion Locally Advanced Squamous Cell Carcinoma of the Esophagus: Neoadjuvant Radiochemotherapy Followed by Surgery vs. Definitive Radiochemotherapy Presenter: M. StuschkePresenter's Affiliation: University of Essen, Essen, Germany (German Multicenter Trial)Type of Session: ScientificBackground The optimal treatment for locally advanced squamous cell carcinoma (SCCA) of the esophagus is unclear While the addition of neoadjuvant radiochemotherapy (RTCT) followed by surgery has been shown to |
| Definitive Radiotherapy +/- Erythropoietin for Squamous Cell Carcinoma of the Head and Neck: Preliminary Report of RTOG 99-03 Presenter: Mitchell MachtayPresenter's Affiliation: RTOGType of Session: PlenaryBackground The presence of anemia has been associated with poor outcome in cancer patients undergoing radiation therapy. This has been particularly evident in patients with cervical and head and neck cancer. A proposed explanatory mechanism for |
| Lymphatic Metastasis is Predicted by Gene Expression Signature of the Primary Tumor in Squamous Cell Carcinoma of the Oral Cavity Lymphatic Metastasis is Predicted by Gene Expression Signature of the Primary Tumor in Squamous Cell Carcinoma of the Oral Cavity Presenter: S. Jack Wei, MD |
| Low-Dose, Monthly Craniospinal Irradiation for Central Nervous System Relapse of Pre B-Cell Acute Lymphoblastic Leukemia in Children: The University of Pennsylvania Experience Low-Dose, Monthly Craniospinal Irradiation for Central Nervous System Relapse of Pre B-Cell Acute Lymphoblastic Leukemia in Children: The University of Pennsylvania Experience Presenter: Roberto Santiago, MD |
| Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Presenter: B. EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground - Sorafenib (BAY 43-9006) is an oral inhibitor of a number of tyrosine kinases including Raf kinase. - Sorafenib has been |
| A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Presenter: E.E.VokesPresenter's Affiliation: National Cancer InstituteType of Session: ScientificBackground Recurrent or metastatic HNC is a challenging clinical problem. With conventional chemotherapy, Response Rate (RR) is < 30% and Median Survival (MS) is 6-8 months. Gefitinib, a small molecule EGFR receptor tyrosine kinase |
| Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Presenter: A. TrottiPresenter's Affiliation: Moffitt Cancer Center at Univ. South Florida, Tampa, FLType of Session: ScientificBackground In the late 1980's, a variety of radiation dose fractionation schedules were in use at different institutions. The standard of care at the time was to treat patients once daily with radiation. A |
| ASTRO Patient Summary: Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Long-Term Outcomes of RTOG 90-03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma Traditionally, radiation has been administered once a day for 5 days a week. In the late 1980's, some centers had been performing variations of |
| Bevacizumab/Erlotinib Combinations in the Treatment of Metastatic Renal Cell Carcinoma (RCC) Presenter: John D. Hainsworth, M.D.Presenter's Affiliation: Sarah Cannon Research Institute, Nashville, TNType of Session: ScientificBackground Most clear cell renal cancers have mutations or inactivations of the von Hippel Landau (VHL gene). As a result, multiple tumor growth-signaling agents are overexpressed, including VEGF, EGF, |
| Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Presenter: Breslow EJ et al.Presenter's Affiliation: Children's National Medical Center, Washington D.C.Type of Session: ScientificBackground CCSK originally described in early 1970s and characterized by tendency to metastasize to bone as well as propensity for late relapses Improvements in overall survival (OS) have been demonstrated |
| Site of metastases does not influence the clinical outcome of children with metastatic Germ Cell Tumors (GCT). A report from the Children's Oncology Group (COG) Presenter: Malogolowkin MH et al.Presenter's Affiliation: Children's Oncology Group, Arcadia, CAType of Session: ScientificBackground A previous protocol had randomized patients with either extragonadal GCT or high-risk gonadal GCT to high-dose versus standard-dose cisplatin/etoposide/bleomycin combination chemotherapy (PEB) This study |
| Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP or autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (MM) Presenter: Facon TPresenter's Affiliation: CHU, Lille, FranceType of Session: PlenaryBackground MP is the standard treatment for newly diagnosed elderly patients with MM, conferring a median overall survival (OS) of 3 years THAL has demonstrated activity in relapsed MM, and is currently being used with MP as well as stem cell |
| Induction cisplatin (P) and fluorouracil (F) with or without docetaxel (T) followed by chemoradiation (CTRT) and surgical resection as indicated for locally advanced squamous cell carcinoma (LASCC) of the head & neck: preliminary results from the TAX 324 study Presenter: Posner MRPresenter's Affiliation: Dana-Farber Cancer Institute, Boston, MAType of Session: ScientificBackground PF induction chemotherapy has thus far proven to be the sole induction chemotherapeutic regimen to be effective in locally advanced squamous cell carcinoma and has been shown to confer an absolute 5% overall survival (OS) |
| Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Presenter: Robert J. MotzerPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NYType of Session: PlenaryBackground Clear cell renal cell carcinoma (RCC) is characterized by mutation or silencing of the VHL gene, which in turn leads to increased activity of hypoxia inducible factor (HIF). This in turn leads to |
| A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) Presenter: Gary HudesPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PlenaryBackground Several recent advances in the treatment of advanced RCC using targeted therapy have been made Sorafenib, a multikinase inhibitor that targets Raf kinase and angiogenesis receptor tyrosine kinases, doubled |
| Patient Summary: Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Clear cell sarcoma of the kidney was first described in the 1970's and has a tendency to metastasize to the bone and can relapse long after treatment. The Wilm's Tumor Study has been looking at various combinations of chemotherapy to treat this |
| Patient Summary: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). This study looked at one of the recently approved drugs for renal cell carcinoma, Sutent (sunitinib malate), and compared it to standard therapy with interferon-alpha |
| Long-Term Survival Results of a Phase III Intergroup Trial (RTOG 95-01) of Surgery Followed by Radiotherapy vs. Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck Presenter: Jay S. Cooper, MDPresenter's Affiliation: Maimonides Cancer Center; NY, NYType of Session: ScientificBackground Preliminary results of this study suggested a benefit in locoregional control and disease-free survival in patients with high-risk head and neck cancer receiving concurrent cisplatin and radiotherapy following resection. |
| Accelerated Versus Conventional Fractionated Radiotherapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN: A Randomized International Multicenter Trial with 908 Patients Conducted by the IAEA-ACC Study Group Presenter: J. OvergaardPresenter's Affiliation: Aarhus University Hospital, DenmarkType of Session: ScientificBackground Multiple prospective randomized trials have suggested that accelerated fractionation schedules may increase the efficacy of radiation therapy for SCCHN Because these trials have been performed in Europe and the United |
| Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL) Presenter: Cottliar, A.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Mantle cell lymphoma (MCL) is a rare (6% of NHL), but aggressive NHL with median survival of 3-4 years. MCL is genetically characterized by the t(11;14)(q13;q32) translocation (Cyclin D1:IgH) and up-regulation of Cyclin |
| Results of the "Mexican method" to conduct allogeneic hematopoietic stem cell transplantation Presenter: Ruiz-Argüelles, GJPresenter's Affiliation: Centro de Hematologia y Medicina Interna de Puebla, MexicoType of Session: ScientificBackground Myeloablative allogeneic bone marrow transplantation is used for several hematopoietic diseases, and is extremely expensive. Non-myeloablative transplants, sometimes called |
| Allogeneic Stem Cell Transplant with TBI/CY/Cytarabine Conditioning for Childhood Philadelphia-Positive ALL Presenter: Yoo, K.H.Presenter's Affiliation: Samsung Medical Center, KoreaType of Session: ScientificBackground Allogeneic stem cell transplantation (ASCT) is generally felt to be the optimal curative treatment of Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). The standard conditioning regimen to prepare these patients for |
| Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia (ALL). Presenter: Gómez-Almaguer, DPresenter's Affiliation: Hospital Universitario de Nuevo León, MexicoType of Session: ScientificBackground Adult acute lymphoblastic leukemia (ALL) is associated with a far worse prognosis than in the pediatric population. Despite the optimal use of the antileukemic agents, reported cure rates range from |
| siRNA-Inhibition OF E2A-PBX1 in Pre-B Leukemia Cells Presenter: Casagrande, GPresenter's Affiliation: University of Padova - Lab. Pediatric Onco-Hematology, ItalyType of Session: ScientificBackground The t(1;19)(q23;p13) chromosomal translocation is detected in ~5-6% of childhood pre-B acute lymphoblastic leukemias (ALLs) and usually results in E2A-PBX1 gene expression. The role of this |
| Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Multiple myeloma is commonly treated with stem cell transplantation in younger patients. A randomized study in 1996 found that double (or “tandem”) transplants resulted in an increase in overall survival, from 21% to 42% of patients. As a result, many institutions perform tandem transplants for these patients. This study aimed to assess the long |
| Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) Scientific Session: Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) With the recent approval of a vaccine for HPV and a second approval pending, there has been much discussion of how these vaccines may affect other cancers in addition to |
| A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma Presenter: Bernard EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: PlenaryBackground Until recently, treatment of metastatic renal cell carcinoma (RCC) included immunotherapy as the standard of care. Treatment with interferon (IFN) provided modest clinical benefit and toxicity with an expected |
| A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma Scientific Session: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma This was a phase III, randomized study for patients with metastatic renal cell cancer. Patients were randomized to receive either interferon-alpha |
| A CME/CNE Regional Dinner Program Series: New Molecular Targets and Novel Agents for the Treatment of Advanced Renal Cell Carcinoma: From Rational Design to Clinical Efficacy Conference Dates: January 14-30, 2008 Conference Location: Nationwide Sponsoring Group: The CBCE Conference Web Page URL: http://www.thecbce.com/rcc Topics Covered: This interactive dinner discussion/presentation forum, including key abstracts presented at the 43rd American Society of Clinical Oncology Annual Meeting, will utilize multiple |
| Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) Presenter: Paul Harari, MDPresenter's Affiliation: University of WisconsinType of Session: ScientificBackground Prior studies have demonstrated an improvement in local control and overall survival in post operative, high risk patients with locally advanced squamous cell carcinoma of the head and neck treated with concurrent chemotherapy and |
| Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial Presenter: Harousseau J.L.Presenter's Affiliation: Hoteldieu Hospital, Nantes, FranceType of Session: ScientificBackground Multiple Myeloma (MM) remains an incurable condition, with a median survival of 48-68 months. Autologous stem cell transplant (ASCT) is the standard of care for MM patients aged ≤65 years old and is associated |
| RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study Presenter: R.J. MotzerPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NYType of Session: ScientificBackground Treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past several years with the availability of targeted agents. As the role of angiogenesis and tumor proliferation in |
| Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial Bortezomib/dexamethasone versus VAD as Induction Prior to Autologous Stem Cell Transplant (ASCT) in Previously Untreated Multiple Myeloma (MM): Updated Data from IFM 2005/01 Trial The use of autologous stem cell transplant in treating multiple myeloma patients over 65 years of age has become standard therapy. Traditionally, the VAD chemotherapy |
| RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase III study RAD001 (Everolimus) is an oral targeted therapy medication that inhibits mTOR, which regulates cell proliferation (growth) and angiogenesis (development of blood |
| Targeted Therapies for Advanced Renal Cell Carcinoma: New Standards of Care Conference Dates: February 26, 2009 Conference Location: Orlando, FL Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL:www.thecbce.com/renalcell2009 Topics Covered: renal cell carcinoma, gene mutations, cellular signaling defects, metastasectomy, cytoreductive nephrectomy Conference Objectives: |
| Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-?2a (IFN) in metastatic renal cell carcinoma (mRCC) Presenter: B.J. Escudier, et al.Presenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground Renal cell carcinoma (RCC) is diagnosed in more than 120,000 patients in the United States and Europe every year. The most common histology is clear cell carcinoma. The 5-year survival rate for |
| Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) Title: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) Reviewer: Geoffrey Geiger, MD Author(s): B. J. Escudier, J. Bellmunt, S. Negrier, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, on behalf of the |
| Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm) Presenter: B. A. Campbell Affiliation: British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL), and accounts for approximately 30-35% of patients with NHL. Limited stage DLBCL is defined as Ann |
| Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN) Presenter: K. J. Harrington, Royal Marsden Hospital, UK Background Lapatinib is an oral small-molecule dual tyrosine kinase (TK) inhibitor of EGFR (epidermal growth factor receptor), which targets Her2 receptors. This drug has been approved for use in treatment of locally advanced metastatic Her 2+ breast cancer. |
| Proton beam therapy for locally advanced Sinonasal squamous cell carcinoma Presenter: Marco Cianchetti, M.D., Annie W. Chan, M.D., Minh T. Truong, M.D., Judy G. Adams, C.M.D., Paul M. Busse, M.D., Norbert J. Liebsch, M.D., and Jing J. Wang, M.P.H. Presenter's Affiliation: Department of Radiation Oncology, Harvard Cancer Center Background Sinonasal carcinomas are tumors found within the nasal cavity and paranasal |
| A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC) Presenter: Kian K. Ang, MD, PhD Presenter’s Institution: University of Texas M. D. Anderson Cancer Center, Houston, TX Background/Introduction The concurrent use of cisplatin or cetuximab with radiation (RT) has been shown to improve survival of patients with locally advanced stage III-IV head and neck squamous cell carcinoma. A |
| Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II Presenter: Robert Glynne-Jones, MD Presenter's Affiliation: Mount Vernon Centre for Cancer Treatment, Middlesex, United Kingdom Background Localized anal cancer is typically treated with definitive chemoradiotherapy (CRT). Patients with persistent or locally progressive disease after treatment require salvage surgical resection, which |
| DeCIDE: A phase III randomized trial of docetaxel, cisplatin, 5-fluorouracil, (TPF) induction chemotherapy in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck Presenter: Ezra E.W. Cohen, MD Presenter's Affiliation: The University of Chicago, Chicago, IL Background Locoregionally advanced head and neck squamous cell carcinoma (H&N SCC) presents clinicians with a challenging scenario with historic poor overall survival of less than 50% at 3 years and local and distant recurrence occurring in a |
| Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study Presenter: Mathias J. Rummel MD, PhD Presenter's Affiliation: Universitaetsklinik, Giessen, Germany Background There are about 25,000 new cases of indolent B-cell lymphoma and mantle cell lymphoma per year, with a median overall survival of about 5 years for mantle cell lymphoma and about 10 years for the more indolent histologies. |
| New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study Presenter: Chaya S. Moskowitz, PhD Presenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY Background With recent improvements in pediatric oncology, modern overall survival rates approach 80% for childhood cancers. Unfortunately, second malignant neoplasms are the leading cause of death among long-term survivors of |
| Clinical Updates and New Approaches: Ovarian Cancer, Head and Neck Cancer, and Adjuvant Therapy for Breast Cancer Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to |
| Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group (GOG) study Presenter: Robert Burger, MD for the Gynecologic Oncology Group and Fox Chase Cancer Center, Philadelphia, PA Background Ovarian cancer is the most common gynecologic cancer, and is the 4th leading cause of cancer death in women. Annually, 22, 000 women are diagnosed with ovarian cancer and 15,000 women die of this disease per |
| 2012 Science of Global Prostate Cancer Disparities Conference: The Global Burden of Prostate Cancer: Economic, Clinical and Humanistic Outcomes Dates: November 1-4, 2012 Location: Nassau, The Bahamas Sponsoring Group: University of Florida, University of West Indies Website:cancer.ufl.edu/research/symposia-and-conferences-2/symposia-and-conferences/ Objectives: The goals of this conference are to: Provide opportunities for mutual learning, knowledge transfer, and collaborations among |
| Raloxifene Reduces Incidence of Breast Cancer by 58-66% and May Reduce Risk of Endometrial Cancer in Postmenopausal Women Raloxifene is a novel selective estrogen receptor modulator that has estrogenic effects on bone and lipids, but estrogen antagonist effects on the breast and uterus. A new study indicates that Raloxifene, widely used for the treatment of osteoporosis, can substantially reduce the risk of breast cancer in postmenopausal women who are at normal |
| Pre-cancerous Prostate Lesions Indicate Increased Risk of Cancer Prostate lesions known as PIN (prostatic intraepithelial neoplasia) have generally been suspected to be precancerous by the prostate research community. However, little is known about the long-term significance of these lesions. Now a research team at the Boston VA Hospital and the Boston University School of Medicine has shown that the presence |
| 3 Versus 6 Cycles of CMF in Breast Cancer Patients with 1 to 9 Positive Nodes: Results of the German Adjuvant Breast Cancer Group (GABG) III Trial Presenter: H. Maass Affiliation: GABC Background: For breast cancer, one of the standard adjuvant chemotherapy regimens is CMF for 6 cycles. Although there is clear data that prolonging CMF for more than 6 cycles is not beneficial, there are limited data evaluating the efficacy of fever cycle of CMF. This study was performed to better |
| Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus
Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC]
Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results (Abstract 1502) Presenter: Jean Louis Misset Affiliation: Htpital Paul Brousse, Villejuif, France; Ctr Oscar Lambret, Lille, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Curie, Paris, France; Ctr Hospitalier, Bourg en Bresse, France; Clin St Pierre, Perpignan, France; Ctr Val d'Aurelle, Montpellier, France; Policlinico Umberto, Rome, Italy; Ctr Paul |
| The Quality of Non-Cancer Care Delivered to Elderly Breast Cancer Survivors Presenter: C.C. Earle, H. f Burstein, F. P. Winer, J. C. Weeks Affiliation: Dana-Farber Cancer institute, Boston, MA Background: There are currently more than 2 million breast cancer survivors in the US; as screening and treatment improve we expect that this number will increase. Elderly survivors of breast cancer, like their non-breast cancer |
| Second Primary Neoplasms (SPNS) Of The Central Nervous System (CNS) In Survivors Of Childhood Cancer - A Report From The Childhood Cancer Survivor Study (CCSS) Presenter: J. Neglia Affiliation: Childhood Caner Survivor Study, University of Minnesota, Minneapolis, MN Background: Second neoplasms of the CNS are well- recognized events among survivors of childhood cancer, often following leukemia or primary CNS tumors. The CCSS is a multi-institutional retrospective cohort study created as a |
| Surgical Resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group Presenter: P. Clark Affiliation: MRC Clinical Trials Unit, London, UK Background: The poor survival of patients with clinically localized squamous cell or adenocarcinoma of the esophagus suggests that occult dissemination of disease is present in most patients at diagnosis. This provides a rationale for adding a systemic therapy to local |
| Incidence And Prognostic Impact Of Amenorrhea During Adjuvant Therapy In High Risk Premenopausal Breast Cancer Patients: Analysis Of A National Cancer Institute Of Canada Clinical Trials Group (NCIC CTG) Phase III Study Presenter: W. Parulekar Affiliation: Kingston, ON, Canada Background: One of the consequences of adjuvant therapy for breast cancer is drug-induced amenorrhea. The incidence and prognostic impact of drug induced amenorrhea (DIA) during adjuvant therapy with anthracycline containing regimens compared to standard CMF chemotherapy is poorly |
| American Cancer Society Award Winner Sidney Winawer, MD, Discusses the Progress and Promise of Colorectal Cancer Screening "The best screening test is the screening test that gets done." That was the central point repeatedly made by Sidney Winawer, MD, Chief of Gastroenterology at Memorial Sloan Kettering Cancer Center, as he sketched out a twenty-five year history of developments in colorectal cancer screening on the final morning of ASCO 2001. Winawer's |
| The 3rd Genolier-Geneva-MSKCC Cancer Conference: Upper Gastrointestinal Cancers Date: February 7-8, 2002 Location: Geneva, Switzerland Symposium Web Page: www.imedex.com/Imedex%20website/images/Flash/GI02.htm Sponsors: Genolier Hospital, Switzerland; Memorial Sloan-Kettering Cancer Center, New York Who Should Attend: Medical Oncologists, Gastroenterologists, GI Surgeons and Radiation Therapists Topics: |
| 13th Annual Cancer Control Conference: Supportive care throughout the cancer continuum Date: March 6, 2002 Location: The Modern Maturity Center, Inc. Dover, Delaware, USA Symposium Web Page: www.christianacare.org Sponsors: Christiana Care Health System and Delaware Diamond Chapter Oncology Nursing Society Who Should Attend: NursesSocial workersPastoral care providersStudents from these disciplines Conference |
| Nutrition After Cancer: A Conference on the Role of Diet and Cancer Survivorship Conference Dates: May 8, 2002 Conference Location: Chicago, Illinois, USA Sponsoring Group: American Institute for Cancer Research Conference Web Page URL: www.aicr.org Topics Covered: Specific topics include soy, flaxseed, vegetables, exercise and obesity. Conference Objectives: This one-day conference has three important |
| 2002 Cancer Symposium: "Controversies in Cancer Care" Conference Dates: October 1, 2002 Conference Location: Newark, Delaware, USA Sponsoring Group: Medical Society of Delaware and Christiana Care Health System Topics Covered: Lung Cancer Screening: Pros and Cons Controversy Surrounding Screening Mammography Prostate Cancer Treatment: Radical Prostatectomy, Radiation and Watchful |
| Cancer Survivorship and Late Effects of Cancer Treatment Conference Dates: Saturday, April 26, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Long term side effects of cancer treatment, sexuality issues, coping with the fear of recurrence, etc. Conference Objectives: |
| Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- And NOGGO-Intergroup Study Presenter: Jens U BlohmerPresenter's Affiliation: Humboldt University, Berlin, GermanyType of Session: PosterBackground The aim of the study was to compare the disease-free survival achieved by an adjuvant sequential chemoradiotherapy regimen with vs. without Erythropoeitin (EPO) for patients with high-risk cervical cancer The second endpoints of |
| Real Men Do Get Cancer: Risks, Prevention and Treatment of Male-Specific Cancers Conference Dates: March 20, 2004 Conference Location: City of Hope National Medical Center, Duarte, CA Sponsoring Group: City of Hope Clinical Cancer Genetics Education Program and Divisions of Medical Oncology & Surgery Conference Web Page URL: www.cityofhope.org/ccgp Topics Covered: This topic will address important advances in |
| Cancer, Culture and Literacy: Innovative Approaches for Advancing Cancer Communications and Research Conference Dates: May 20-22, 2004 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute Conference Web Page URL: www.moffitt.usf.edu/promotions/ccl Topics Covered: Health Education Health Literacy Cancer Communications Cancer Control |
| Changing Trends in the National Practice for External Beam Radiotherapy for Clinically Localized Prostate Cancer: The 1999 Patterns of Care Survey for Prostate Cancer Presenter: M.J. ZelefskyPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USAType of Session: ScientificBackground This study is an evaluation of the changing trends in external beam radiotherapy (EBRT) delivery practice for clinically localized prostate cancer based on the 1999 survey from the American College of |
| Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02 Presenter: H.M. SandlerPresenter's Affiliation: RTOGType of Session: ScientificBackground Prostate cancer is a disease with a long natural history, so the use of survival as an endpoint requires a very long follow-up to reach conclusions Therefore, PSA-defined failure has been used as a surrogate endpoint, shortening the time needed for reporting |
| Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience Presenter: H. B. MussPresenter's Affiliation: Univ. of Vermont, CALGBType of Session: ScientificBackground This study is an analysis of the benefits and toxicities by age of adjuvant chemotherapy in N+ breast cancer patients. Little data exists regarding the benefit of cytotoxic chemotherapy in elderly (>65) breast cancer patients. The |
| Subsequent neoplasms (SNs) of the central nervous system (CNS) in survivors of childhood cancer: a case/control study from the Children's Cancer Survivor Study (CCSS) Presenter: J.P. NegliaPresenter's Affiliation: University of MinnesotaType of Session: ScientificBackground Childhood cancer patients survivors are known to be at increased risk of subsequent CNS malignancies. An association between subsequent meningiomas and previous irradiation has been shown previously. A 23-fold increased risk of CNS |
| The Role of Mammography and Physical Examination in Detecting Recurrent Tumor and Contralateral Breast Cancer for Patients with Stage I-II Breast Cancer Treated with Breast Conservation Treatment Presenter: Changhu ChenPresenter's Affiliation: University of Pennsylvania and University of ColoradoType of Session: ScientificBackground Breast cancer is the most common malignancy in women Women who want to preserve their breast and are appropriate candidates can receive breast conservation treatment (BCT) which uses lumpectomy combined with |
| Adjuvant versus Neoadjuvant Combined Modality Treatment for Locally Advanced Rectal Cancer: First Results of the German Rectal Cancer Study (CAO/ARO/AIO-94) Presenter: Rolf Sauer, M.D.Presenter's Affiliation: German Rectal Cancer GroupType of Session: PlenaryBackground The addition of adjuvant chemoradiotherapy (CRT) to the surgical resection of stage II-III rectal cancers has been proven to improve the local control and survival of patients when compared to surgery alone. Building on these results |
| Innovations in Cancer Therapy, 1st International Symposium on Image-Guided Therapies for Cancer Conference Dates: May 1-4, 2005 Conference Location: London, England Sponsoring Group: PRRI Conference Web Page URL: www.cancerinnovations.org Topics Covered: Lung Cancer, Liver Tumors: Imaging, Hepatocellular Carcinoma, Liver Transplantation, Liver Metastases, Renal Cell Carcinoma, Central Venous Pathology and Interventions, Bone Tumors, |
| Eliminating the Suffering and Death from Cancer: A Cancer Center Director's Experience New this year at ASCO is a plenary science presentation. To mark the beginning of this tradition Dr. Leland H. Harwell was chosen for this honorable task. Dr. Harwell won a Nobel Prize in medicine in 2001 for his work in yeast genetics. He is credited with understanding how normal cells divide and the mechanisms leading to the uncontrolled growth |
| Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG) Presenter: M.J. MoorePresenter's Affiliation: NCICType of Session: PlenaryBackground Advanced and metastatic pancreatic cancer has an extremely poor prognosis, with median survival times between 4-6 months. Multiple attempts at combination chemotherapy have shown no efficacy Attempts at targeted agents have also been negative trials Targeting |
| Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: K.C. OeffingerPresenter's Affiliation: University of Texas Southwestern Medical CenterType of Session: PlenaryBackground The cure rate of childhood cancers is now >78% Currently, 1 out of every 640 people age 18-45 are childhood cancer survivors The effects of the cancer itself or the toxic treatment needed for cure can |
| Fifth Annual California Cancer Consortium: Recent Advances and New Directions in Cancer Therapy Conference Dates: March 24-26, 2006 Conference Location: The Fairmont San Francisco, San Francisco, CA Sponsoring Group: The Center for Biomedical Continuing Education (CBCE) Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: After participating in this educational activity, physicians should be able to: |
| Colon Cancer Alliance (CCA) 6th Annual Colorectal Cancer Conference Conference Dates: September 15-17th, 2006 Conference Location: Oak Brook, Illinois (just outside Chicago) Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: http://www.ccalliance.org/events/current/conference/index.html Conference Objectives: This conference will offer attendees HOPE because it provides: The most |
| New Directions in the Treatment of Breast Cancer: Updates from the 29th Annual San Antonio Breast Cancer Symposium (SABCS) Conference Dates: February 1, 2007 Conference Location: Seattle, WA Conference Dates: February 5, 2007 Conference Location: Pittsburgh, PA Conference Dates: February 6, 2007 Conference Location: Cleveland, OH Conference Dates: February 7, 2007 Conference Location: Southfield, MI Conference Dates: February 8, 2007 Conference |
| 4th International Congress on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management Conference Dates: November 15-17, 2007 Conference Location: Metro Toronto Convention Center Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Conference Objectives: Updating attendees on standard cancer therapies and new experimental programs Who Should Attend: physicians, physicians-in-training, and healthcare |
| 2007 Update on Breast Cancer: Presented by the Abramson Cancer Center of the University of Pennsylvania: Coverage of the American Society of Clinical Oncology Annual Meeting Conference Dates: Thursday, June 21, 2007 5:30 PM - 9:00 PM Conference Location: University of Pennsylvania Museum of Archaeology and Anthropology (Lower Egyptian Gallery) Sponsoring Group: University of Pennsylvania School of Medicine Conference Brochure: View the conference brochure Conference Objectives: Identify chemotherapy |
| Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 Presenter: M.Y. Halyard Presenter's Affiliation: Mayo Clinic, Rochester, MN Type of Session: Scientific Background Breast cancer affects more than 200,000 American women every year and is responsible for 40,000 deaths. Some of the effective therapies for breast cancer can potentially cause heart failure including anthracyclines, |
| Patient Summary: Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 NCCTG N9831 is a 3-arm randomized Phase III trial involving stage I-IIA breast cancer patients comparing the safety and efficacy of doxorubicin / cyclophosphamide (AC) followed by weekly paclitaxel |
| Risk based care in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Presenter: Nathan, P.C.Presenter's Affiliation: The Hospital for Sick Children, Toronto, ON, CanadaType of Session: ScientificBackground An estimated 270,000 childhood cancer survivors (CCS) were residing in the United Stages in 1997. As survival rates after childhood cancer continue to increase, this number is expected to grow: Currently, |
| The journey from cancer patient to cancer survivor: A 5-year longitudinal study Presenter: Snyder, C.F.Presenter's Affiliation: Johns Hopkins School of Medicine, Baltimore, MDType of Session: ScientificBackground Over 10 million cancer survivors currently reside in the United States, and this number is estimated to continue to rise at a rate of approximately 3% each year. Cancer survivors require attentive medical |
| A Double-Blind, Placebo Controlled, Randomized Phase III trial of Gemcitabine (G) plus Bevacizumab (B) Versus Gemcitabine Plus Placebo (P) in Patients (pts) with Advanced Pancreatic Cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB) Presenter: H. L. KindlerPresenter's Affiliation: University of Chicago Medical CenterType of Session: ScientificBackground Advanced pancreatic cancer continues to have an extremely poor prognosis. Gemcitabine is the cornerstone of treatment and objective response rates of 5-10% are seen when gemcitibine is used alone. Treatment with |
| Seventh Annual Recent Advances and New Directions in Cancer Therapy Conference, in Partnership With the California Cancer Consortium Conference Dates: March 28-30, 2008 Conference Location: San Francisco, CA Sponsoring Group: The CBCE™ (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please visit www.thecbce.com or e-mail info@thecbce.com for information regarding the topics covered. Conference Objectives: |
| 8th Princess Margaret Hospital Conference, Developments in Cancer Management: Conquering Cancer in our Lifetime Conference Dates: October 16 -18, 2008 Conference Location: Toronto, Ontario, Canada – Hilton, Toronto Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/appweb/announcements/a038-01.asp Organizers: Pamela Catton, MD, Ronald Feld, MD, and Richard Hill, PhD The 8th Princess Margaret Hospital Objectives: New Developments |
| Randomized Phase III Study of Capecitabine, Oxaliplatin, and Bevacizumab with or without Cetuximab in Advanced Colorectal Cancer (ACC), the CAIRO2 Study of the Dutch Colorectal Cancer Group (DCCG) Presenter: Punt C.J.Presenter's Affiliation: UMC St Radboud, Nijmegen, NetherlandsType of Session: ScientificBackground Prior studies have found an overall survival benefit in patients with advanced colorectal cancers (ACC) treated with fluoropyrimidine-based chemotherapy combined with bevacizumab (bev), as compared to |
| Ninth Annual Recent Advances and New Directions in Cancer Therapy Conference, in Cooperation With the California Cancer Consortium Conference Dates: May 14-16, 2010 Conference Location: Pasadena Sponsoring Group: Physicians’ Education Resource in conjunction with the California Cancer Consortium Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/543 Topics Covered: At the conclusion of this |
| Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients Title: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patientsReviewer: Arpi Thukral, MD Presenter: J. L. Ryan, PhD, MPH Affiliation: URCC CCOP Nausea is one side effect that almost every person facing cancer therapy fears. It affects their |
| Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Title: Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Reviewer: Christine Hill-Kayser, MD Presenter: Paul Nathan, MD, MSc Affiliation: The Hospital for Sick Children, Toronto, Canada Due to numerous clinical trials in pediatric oncology, the |
| Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Title: Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Reviewer: Presenter: Hiroko Kunitake, MD Affiliation: David Geffen School of Medicine at UCLA Over 11 million cancer survivors currently reside in the United States, and this number is estimated to |
| Risk Factors Predicting Failure and Prostate Cancer Mortality in High Risk Prostate Cancer Patients Treated with Definitive External Beam Radiation Therapy Authors: Q. Nguyen, L. B. Levy, A. K. Lee, S. Choi, S. J. Frank, K. Hoffman, S. McGuire, D. A. Kuban Institution: M.D. Anderson Cancer Center, Houston, TX Background Prostate cancer is the most common non-cutaneous malignancy in men and is the second most common cause of cancer deaths in the United States. High-risk prostate cancer is |
| Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: A. S. Pappo Presenter's Institution: St. Jude Children's Research Hospital, Memphis, TN Background Survivors of childhood cancer are at increased risk of developing secondary malignant neoplasms (SMN). Generally speaking, children treated for malignant disease are acknowledged to be at greatly increased risk for SMN following |
| Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: Gregory Armstrong, MD Presenter's Affiliation: St. Judes Children's Research Hospital Background As progress in the treatment of childhood cancers has improved survival, late effects of therapy have become more pronounced and widely recognized. The Childhood Cancer Survivor Study (CCSS) was established to monitor these late |
| Toward a rationale strategy for prostate cancer screening based on long term risk of prostate cancer metastases and death: data from a large, unscreened, population-based cohort followed for up to 30 years Presenter: H. Lilja, MD Presenter's Institution: Memorial Sloan-Kettering Cancer Center, New York, NY Background/Introduction Routine screening for prostate cancer using prostate-specific antigen (PSA) testing remains controversial. A European study demonstrated that PSA screening reduced the rate of death from prostate cancer by |
| Evaluation of the effect of care at NCI comprehensive cancer centers on disparities in outcome within adolescents and young adults with cancer Presenter: Dr. Can-Lan Sun, PhD on behalf of Julie Anna Wolfson, M.D. Presenter's Affiliation: City of Hope, Duarte, CA Background The National Cancer Institute defines adolescents and young adults (AYAs) with cancer as individuals aged 15-39 years of age at the time of diagnosis with cancer. Despite sharing similar diagnoses, this |
| Increasing risk of chronic health conditions in aging survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: Gregory T. Armstrong, M.D., MSCE Presenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TN Background While recent advances in pediatric oncology have improved outcomes with more than 80% of children surviving, there is an increased cumulative incidence of treatment-related chronic health conditions and late |
| A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus from Prostate Cancer-specific Mortality to Distant Metastasis-Free Survival Abstract Number: 140 Presenter: Arie Dosoretz, MD Presenter's Affiliation: Yale-New Haven Hospital Background Prostate cancer is the most common cancer in men and the 2nd leading cause of cancer death. Prostate cancer screening has been performed using a non-invasive blood test, prostate specific antigen (PSA) The precise magnitude of |
| Global Conference on Perioperative Medicine: Care of the Elderly and the Cancer Patient Dates: November 28 - December 2, 2012 Location: The University of Texas MD Anderson Cancer Center, Houston-Texas Sponsoring Group: Department of Anesthesiology & Perioperative Medicine Web Page URL: http://www.mdanderson.org/anesthesiology Topics Covered: At the conclusion of the meeting participants should be able to: Understand the |
| Concurrent Dose-Escalated Proton Therapy and IMRT for Sinonasal Cancer: Initial Clinical Experience Presenting Author/Institution: Mark William McDonald, MD Indiana University Health Proton Therapy Background Sinonasal malignancies are often managed with radiotherapy and chemotherapy alone without surgical resection. In this definitive setting, high doses are needed and therefore the long-term risk to critical structures, particularly the |
| The Value of Dose Constraints for Organs at Risk in Proton Therapy for Prostate Cancer Presenting Author/Institution: Nancy Mendenhall, MD, University of Florida Proton Therapy Institute Background Prostate cancer is the leading cancer diagnosis in men. Treatment options include radical prostatectomy, radiotherapy, and/or hormone therapy. Proton radiotherapy for prostate cancer has the potential to spare dose the bowel and |
| Preliminary Patient Reported Outcomes after Proton Therapy for Prostate Cancer Presenter: James Metz, Christine Hill-Kayser Presenter's Institution: Hospital of the University of Penn, Philadelphia, PA Background Cancer survivorship is on the rise, with an estimated 12 million cancer survivors living in the United States today. Unfortunately, all cancer treatments cause side effects and the subsequent consequences |
| Optimal Timing of Breast Cancer Surgery Within Menstrual Cycle Mark Norman Levine, M.D., Ontario Cancer Foundation, Hamilton University and professor of medicine, McMaster University, National Cancer Institute of Canada Clinical Trials Group (Kingston, Ontario, Canada), presented a study which examined the relationship between the timing of breast cancer surgery during the menstrual cycle and the risk of |
| National Cancer Insitute Director's Address Note: Dr. Richard Klausner, Director of the National Cancer Institute since August 1995, was today inducted into the membership of ASCO by Dr. John Glick, outgoing president of ASCO. He addressed a packed Exhibit Hall in Philadelphia's Convention Center; parts of his speech follow. (Portions of the speech will be placed online in RealAudio |
| New Discoveries in Treating Women's Cancer Reported at ASCO Meeting Philadelphia, PA, May 20, 1996 -- Exciting new discoveries in the treatment of ovarian and breast cancer were reported today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Ovarian Cancer is the second most common gynecological cancer, and half of all cases occur in women over the age of 65. An estimated 14,500 |
| Randomized Trial Of 2 Vs. 5 Years Of Adjuvant Tamoxifen In Postmenopausal Women With Early-Stage Breast Cancer Lars E. Rutqvist, M.D., Ph.D., director, Oncology Center, Karolinska Hospital (Stockholm, Sweden), presented the results of a study which aimed to determine the optimal duration of tamoxifen treatment for early-stage breast cancer patients. Adjuvant treatment with tamoxifen in some patients with early-stage breast cancer has conclusively been |
| Combined Modality Therapy Shows Improvements in Survival for Certain Cancer Patients Philadelphia, PA, May 20, 1996 -- Important new data regarding the use of combined modality therapy were reported today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Combined modality therapy refers to the use of more than on technique for fighting cancer. These modalities include chemotherapy surgery, |
| Superiority of Chemo-Radiotherapy Vs. Radiotherapy In Patients with Esophageal Cancer Arnold Herskovic, M.D., medical director, Radiation Oncology Department, Oakwood Hospital and Medical Center (Dearborn, MI), presented the results o a study which compared the overall survival of esophageal cancer patients treated with radiotherapy (RT) alone versus treatment with chemo-radiotherapy (CT-RT). The study was conducted by the |
| What PSA Nadir Level Should Be Achieved After Irradiation For Prostate Cancer? Arnold Herskovic, M.D., medical director, Radiation Oncology Department, Oakwood Hospital and Medical Center (Dearborn, MI), presented the results o a study which compared the overall survival of esophageal cancer patients treated with radiotherapy (RT) alone versus treatment with chemo-radiotherapy (CT-RT). The study was conducted by the |
| Immediate Hormonal Therapy Improves Survival In Patients With Locally Advanced Prostate Cancer Michel Bolla, M.D., professor of radiation oncology, University Joseph Fourier Grenoble (Grenoble, France) presented a study which aimed to increase the survival of patients suffering from locally advanced prostate cancers by combining radiation with adjuvant hormone therapy administered from the start of treatment. Prostate cancer is the |
| Patterns of Care for Women with Ovarian Cancer in the United States Michel Bolla, M.D., professor of radiation oncology, University Joseph Fourier Grenoble (Grenoble, France) presented a study which aimed to increase the survival of patients suffering from locally advanced prostate cancers by combining radiation with adjuvant hormone therapy administered from the start of treatment. Prostate cancer is the |
| Reduction of Skeletal Morbidity and Prevention of Bone Metastases with Oral Clodronate in Women with Recurrent Breast Cancer in the Absence of Skeletal Metastases A.H.G. Paterson, MD, head, Division of Medical Oncology, Department of Medicine, University of Calgary (Alberta, Canada), presented the results of a study which examined the effect of clodronate on the incidence of skeletal metastases and skeletal morbidity in women with recurrent breast cancer. Bone is a frequent site for recurrent breast |
| Canadian Study is First to Show Screening Reduces Prostate Cancer Deaths An eight-year large-scale randomized study, begun in 1988, was designed to evaluate the survival benefit of prostate cancer screening. The study randomly divided 46,193 men aged 45 to 80 into those who would be screened and those who would not. Those screened received a PSA (prostate-specific antigen) test and digital rectal examination at the |
| Higher Doses of Paclitaxel Fail to Improve Survival Rates in Women with Metastatic Breast Cancer Each year approximately 45,000 women in the U.S. are diagnosed with metastatic breast cancer. New research demonstrates that higher doses of Paclitaxel (Taxol) are not necessarily more effective in patients with advanced breast cancers, and that patients can be spared the increased toxicities associated with high doses. This study of 475 |
| Taxol Use Results in Significant Survival Benefit When used in Adjuvant Setting for Node-Positive Breast Cancer Patients For the first time, researchers have found that Paclitaxel (Taxol), the widely-used chemotherapy agent originally developed from compounds found in the bark of the yew tree, increases a woman's chance of survival when used in combination with other chemotherapy drugs after surgery. Previously, no randomized trial had found an adjuvant |
| Cancer Vaccine Triggers Immune System to Recognize Melanoma Unlike vaccines that are used to prevent infectious disease, cancer vaccines attempt to stimulate the body's own immune system to recognize cancer cells as foreign and destroy them. These researchers examined tyrosinase, a normal protein present in melanin (which gives moles their color), and in melanoma cells. Patients were treated with |
| Herpes Gene May Help Attack Prostate Cancer A certain herpes gene may help fight prostate cancer, according to the first study to demonstrate that gene therapy is safe and active against prostate cancer. This phase I trial examined 18 patients who had local recurrence of prostate cancer following initial treatment with radiation. The herpes gene (thymidine kinase) activates a normally |
| New Drug Expands Limited Treatment Arsenal for for Colorectal Cancer Colorectal cancer is one of the most common malignancies, with over 131,000 new cases diagnosed in the U.S. each year. 5FU has been used as the primary treatment for colon cancer for decades, with few effective new drugs to complement this therapy. Patients who do not respond to the standard chemotherapy treatment for metastatic colorectal |
| CAF Slightly Improves Survival for High-Risk Localized Breast Cancer Patients
Adjuvant chemotherapy — chemotherapy administered to prevent the recurrence of cancer after surgery — has been an important contributor to improved survival rates for many breast cancer patients. This study compared the newer chemotherapy regimen CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) to the standard CMF |
| Tamoxifen Reduces Breast Cancer Incidence by 45% in Women at High Risk of Developing the Disease
Tamoxifen has been used for the past twenty years to treat breast cancer and prevent its recurrence. Knowledge of its benefit in preventing breast cancer remained unknown, however. Today researchers from the National Surgical Breast and Bowel Project (NSABP) presented the results of a trial examining the breast cancer prevention benefits of |
| Chemical Derived from Naturally-Occurring Mold May Slow Growth of Metastatic Kidney Cancer by Inhibiting Growth of Tumor Blood Supply Anti-angiogenesis agents are showing promise in inhibiting tumor growth by attacking the tumor's blood supply. In this Phase II study of 33 patients, researchers used an anti-angiogenesis agent called TNP-470, a synthetic form of a chemical secreted by the aspergillus fumigatus mold, to slow the growth of metastatic kidney cancer, which claims |
| New Antisense Agent Stops Production of Cancer-Causing Protein Antisense therapy is a novel cancer treatment approach that works at the genetic level to interrupt the process by which cancerous cells produce certain proteins. An antisense compound consists of a single strand of DNA designed in the laboratory to complement the single strand of messenger RNA (mRNA) produced by the cancer cell. These two |
| Six-Month Chemotherapy Regimen for Colon Cancer Replaces Conventional 12-Month Regimen Adjuvant chemotherapy -- drugs used to prevent the recurrence of cancer after surgery -- is an important weapon in the treatment of the disease. Until now, the combination most often used included fluorouracil (FU) and levamisole (LEV) for a full year after surgery . This major 5-year study of 3,759 patients -- the largest trial to evaluate |
| Standard Chemotherapy Shows Increased Toxicity for Elderly with Node-Positive Breast Cancer While another study presented yesterday demonstrates that older breast cancer patients with early stage breast cancer can tolerate standard adjuvant chemotherapy, this study finds that elderly patients whose breast cancer has spread to the lymph nodes do not appear to be able to tolerate standard chemotherapy as well as younger patients when |
| Older Breast Cancer Patients can Tolerate Adjuvant Therapy with Doxorubicin and Cyclophosphamide Traditionally, older women with breast cancer are given less aggressive chemotherapy than younger women, primarily because of concern about increased toxicity. This study demonstrates that older women receiving adjuvant chemotherapy do not experience clinically significant increases in toxicity. In this study, 44 women aged 35 to 79 with |
| Primary Breast Cancers are Reduced by Raloxifene In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers |
| Energy and intensity modulated electron beams for treatment of breast cancer Presenter: Charles Ma Affiliation: Stanford University School of Medicine Summary:Breast cancer has traditionaly been treated with photon beams. The purpose of this study was to investigate the feasibility of using energy and intensity modulated electron beams for breast cancer treatment. The use of Electron Intensity Modulated Radiation |
| Prelimimary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer Presenter: Alan Pollack Affiliation: MD Anderson Cancer Center Summary:- The purpose of this study was to compare the impact of 70 Gy versus 78 Gy on relapsing/rising PSA and biopsy positivity. Methods: 298 patients were enrolled in a single institution randomized clinical trial comparing 70 Gy vs. 78 Gy in the treatment of prostate cancer. |
| Improved Conformality and Reduced Toxicity with High-Dose Intensity Modulated Radiation Therapy (IMRT) for Patients with Prostate Cancer Presenter: Michael J. Zelefsky, M.D. Affiliation: Memorial Sloan Kettering Cancer Center Summary: There has been recent evidence to suggest that with increased radiation dose comes increased efficacy in the treatment of prostate cancer. However, the ability to deliver dose is most often limited by the tolerance of normal tissues proximal to |
| Long Term Results of Immediate Adjuvant Hormonal Therapy with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy (Phase III EORTC Study) Presenter: Bolla M et al Affiliation: EORTC Radiotherapy Cooperative Group Summary:Traditionally, patients with locally advanced, high risk adenocarcinoma of the prostate have been treated with radiation therapy. However, local control and survival have been somewhat disappointing. This study was initiated to investigate whether concurrent |
| Internal Mammary Node Irradiation Does Not Decrease Distant Metastases or Improve Survival in Stages I and II Breast Cancer Presenter: Barbara Fowble, MD Affiliation: Fox Chase Cancer Center Background:Internal mammary node (IMN) irradiation has remained a controversial subject. Though historical data demonstrate that high-risk patients (axillary lymph node positive) have a significant rate of pathological IMN involvement, it continues to be debatable whether |
| Extracapsular Axillary Nodal Extension (ECE) in Breast Cancer: Patterns of Recurrence, Arm Edema, and Survival after Mastectomy with and Without Irradiation Presenter: Robert Kuske, MD Affiliation: Ochsner Clinic/Tulane University School of Medicine, New Orleans, LA Background:The prognostic implications of extracapsular extension (ECE) in breast cancer with axillary lymph node (ALN) disease is debatable. It has not been conclusively demonstrated that having ECE in positive ALNs is an indication |
| Final Report of a Phase III Randomized Trial of Amifostine as a Radioprotectant in Head and Neck Cancer Presenter: Brizel DM et al Affiliation: Duke University Medical Center Summary:Xerostomia (dry mouth) is a difficult and often permanent complication of head and neck radiotherapy. Life long consequences include difficulty with eating, speaking, and dental complications. This phase III randomized trial of radiation therapy with or without |
| Panel Discusses the Rapidly Evolving Standards of Care for Cervix Cancer In February 1999, the National Cancer Institute issued a clinical alert stating that concurrent cisplatin-based chemotherapy plus radiation therapy appears to be a superior treatment to radiation alone for women with cervix cancer. This statement was based on the results of five phase III trials that demonstrated a significant survival |
| Chemoprevention for Head and Neck Cancer "Can chemopreventive therapy restore molecular defects in target tissues?" That was the key question posed by Dr. Wang Ki Hong, Chair of Thoracic Oncology at the University of Texas M.D. Anderson Cancer Center, in his keynote address to a packed hall this morning. Speaking on "The Genetic and Molecular Basis for Prevention: Head and Neck |
| Impact of Risk Factors and Total Time for Combined Surgery and Radiotherapy on the Outcome of Patients with Advanced Head and Neck Cancer Presenter: Ang, KK Affiliation: MD Anderson Cancer Center Background:We know from the literature that certain patients are at higher risk for postoperative recurrence based on previously described adverse prognostic features. This prospective study was performed to determine: The validity of these previously defined risk groups and Whether the |
| Postoperative Irradiation for Stage T4 Colon Cancer Presenter: Christopher Willett, MD Affiliation: Massachusetts General Hospital, Boston, MA and Roswell Park Cancer Institute, Buffalo, NY Background:Postoperative systemic therapy is the standard of care for intermediate to advanced colon cancer. Radiation therapy (RT) has been utilized far less due to the technical considerations such as not |
| Preliminary Analysis of Radiotherapy Data from CALGB 9082: Variability of Treatment Fields for Local/Regional Breast Cancer and the Impact of High Dose Chemotherapy on the Ability to Deliver Radiation Therapy Presenter: Lawrence B. Marks, M.D. Affiliation: Duke University/CALGB/SWOG Summary:Positive contributions of radiotherapy (RT) and chemotherapy in patients with high-risk breast cancer are well documented, but the sequencing of these modalities and dosage of chemotherapy in such patients remains controversial. This offering examines the effect |
| Timescale of Evolution of Late Radiation Injury after Postoperative Radiotherapy of Breast Cancer Patients Presenter: Silvia Johansson Affiliation: Umea University Hospital, Sweden Summary:Most of the modern randomized trials in breast cancer document toxicity associated with treatment, but none document these toxicities over the scale of decades. These data are important because many women are diagnosed with breast cancer at a relatively young age, |
| Second Malignancies after Treatment of Early Stage Breast Cancer with Lumpectomy and Radiation or Mastectomy without Radiation Presenter: E. Obedian Affiliation: Yale University School of Medicine Summary:Multiple studies have demonstrated the clinical efficacy of breast conserving therapy (BCT) for early stage breast cancer. Despite decades of experience, however, there are limited data regarding the safety of this treatment, specificially the risk of second |
| Local-Regional Control in in Breast Cancer Patients with a Presumed Genetic Predisposition Presenter: LM Freedman Affiliation: University of Texas M.D. Anderson Cancer Center Summary:Breast cancers associated with a genetic predisposition (e.g., BRCA-1 & BRCA-2 mutations) may behave more aggressively than sporadically occurring tumors. In particular, they tend to present at higher grades, lack hormone receptors, and have mutations |
| Intensity Modulated Radiation Therapy (IMRT) May Reduce Small Bowel, Rectum, and Bladder Complications in Patients with Cervical Cancer Treated to the Pelvis and Paraaortic Area Presenter: Lorraine Portelance Affiliation: Mallinckrodt Institute of Radiology, St Louis, MO Background:Combined modality therapy (chemotherapy plus radiation therapy) has made a major impact on treatment of cervix cancer from bulky Stage I disease up to Stage IV. With the improvement of local control and survival with the use of combined |
| Health Futurist Dr. Leland Kaiser Urges Radiation Oncologists to Chart The Future of Cancer Care "We don't predict the future . . . we create it." This was the central theme of Dr. Leland Kaiser's keynote address this morning on "Cancer Care in the 21st Century." Describing himself as a "health futurist," Dr. Kaiser, who is both a consultant and a professor of business at the University of Colorado at Denver, urged his audience to |
| Small French Study Shows Longer Time to Relapse for High-Dose Chemotherapy in Metastatic Breast Cancer Begun in 1992, this study of 61 women with metastatic breast cancer responsive to chemotherapy, who were randomized to receive either high-dose chemotherapy supported by stem cell transplant, or standard doses of chemotherapy. The chemotherapy regimen used in the high-dose arm was cyclophosphamide, mitoxantrone and Melphalan (CMA), while |
| Hepatic Infusion Increases Survival and Reduces Liver Metastases from Colorectal Cancer when Combined with Chemotherapy Approximately 138,000 new cases of colorectal cancer are diagnosed in the US every year. Eventually, 60% of these patients will develop liver metastasis but only a small percentage of these patients respond to systemic chemotherapy, a common treatment. Now, researches at Memorial Sloan-Kettering Cancer Center have found that a novel |
| Novel Immunotherapy Targets Her2-Positive Prostate Cancer A novel immunotherapy that directly links immune cells to Her2-positive prostate cancer cells shows the first documented responses to immunotherapy in prostate cancer. As in breast cancer, some prostate cancer cells produce excessive amounts of the Her2 protein that tells cells to divide, making the cancer particularly aggressive and unresponsive |
| Replacing P53 Gene in Prostate Cancer Helps Shrink Tumors A team of investigators from the M.D. Anderson Cancer Center, led by Dr. Christopher Logothetis, has demonstrated evidence that replacement of the p53 gene may shrink prostate cancers. The function of the p53 gene, which induces damaged cells to activate "programmed cell death," is lost as cancer progresses and spreads. Therefore, replacing |
| Male Bone Density Decreases at a Steady Rate During Hormone-Suppressing Prostate Cancer Treatment The same bone loss seen in women who aren't producing estrogen is now being seen soon after men suppress testosterone and androgen production during prostate cancer therapy. These male hormones are known to stimulate the early growth of prostate cancer, so at the first signs of a rising PSA level -- a test that measures a protein produced by |
| Carboplatin/Paclitaxel Preferable to Cisplatin/Paclitaxel in Optimal Stage III Epithelial Ovarian Cancer Robert Ozols, M.D. from the Fox Chase Cancer Center presented data from the Gynecologic Oncology Group (GOG) Protocol #158 a randomized Phase III clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimally surgically cytoreduced epithelial ovarian cancer. This important study is the largest reported randomized trial in |
| Cyclophosphamide/Cisplatin Possibly Preferable Preferable to 32P in Treament of Early High-Risk Ovarian Cancer Robert Young, M.D. from the Fox Chase Cancer Center presented the data from Gynecologic Oncology Group (GOG) Protocol #95 a randomized clinical trial of adjuvant treatment of early (Stage IA-IIA high-risk) ovarian cancer patients. The regimen of GOG #95: Regimen 1: 15 mc intraperitoneal 32P given once (n= 98) Regimen 2: Cyclophosphamide 1 |
| Sequential Couplets of Cisplatin/Topotecan and Cisplatin/Paclitaxel
as First-Line Therapy in Advanced Epithelial
Ovarian Cancer Dr. P. Hoskins presented a Phase II trial of sequential couplets of cisplatin (DDP) and topotecan (TOP) and cisplatin and paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer on behalf of the National Cancer Institute of Canada. The dosage used were as follows: DDP/TOP cycles: DDP 50 mg/m2 and TOP 0.75 mg/m2 DDP/T |
| Study of High-Dose Chemotherapy in Metastatic Breast Cancer Finds No Survival Benefit Analysis of data as of March 31, 1999, from the largest randomized trial of high-dose chemotherapy with stem cell transplant in the treatment of responding metastatic breast cancer has shown no significant difference in overall survival or lethal toxicity when compared to conventional dose maintenance chemotherapy. The study was led by Edward |
| Combination Chemotherapy Regimen Yields Impressive Results in Late-Stage Prostate Cancer Atlanta, GA, May 17, 1999 -- The chemotherapeutic taxane agent docetaxel, combined with the nitrogen mustard estramustine phosphate and low dose hydrocortisone, appears to be a promising treatment for men with an advanced form of prostate cancer, according to the results of a phase II trial conducted by the Cancer and Leukemia Group B (CALGB) |
| Preliminary Results of High-Dose Chemotherapy in Primary Breast Cancer Show Equivalency to Intermediate-Dose Treatment; 3 Years of Additional Follow-up Required 783 women with primary breast cancer that has spread to 10 or more lymph nodes under the arm were randomized to receive either high-dose chemotherapy (cyclophosphamide, cisplatin and BCNU) with bone marrow and peripheral blood stem cell support, or intermediate-dose chemotherapy using the same drugs at doses that could be safely administered |
| Scandinavian Study Finds No Overall Survival Benefit to High-Dose Chemotherapy in Primary Breast Cancer A randomized Scandinavian study of 525 women with high-risk breast cancer, conducted over a four year period betwen 1994-1998 at a constant inclusion rate, indicates that there is no overall benefit to high-dose chemotherapy with bone marrow stem cell support versus those who received "tailored" chemotherapy doses tailored according to blood |
| South African Study Finds Survival Benefit to High-Dose Chemotherapy in Primary Breast Cancer UPDATE: The data from this study have since been called into question. For more information concerning this, please consult: OncoLink NCI/PDQ: Misconduct Suspected in South African Breast Cancer Study. A South African study of 154 women with high-risk breast cancer involving 10 or more lymph nodes shows increased survival rates and lower |
| Soy Remedy Not Effective for Hot Flashes with Breast Cancer Researchers have found that a soy phytoestrogen preparation was ineffective for diminishing hot flashes in breast cancer survivors. This is despite soy phytoestrogen being touted by some to be helpful for diminishing hot flashes. Charles Loprinzi, MD, and colleagues developed a double-blind, placebo-controlled clinical trial in which breast |
| First Independent Assessment of Breast Cancer Risk Reduction Drugs Supports a Role for Tamoxifen Therapy Atlanta, GA -- The first independent assessment of tamoxifen and raloxifene, conducted by a special American Society of Clinical Oncology (ASCO) Working Group, confirms that, based on an examination of all available literature since 1990, tamoxifen may be offered to reduce the risk of developing breast cancer for some women, but that it is |
| First Kidney Cancer Blood Test Could Prevent Removal of Kidneys Researchers at New York Presbyterian Hospital have devised the first kidney cancer blood test that may spare some patients removal of their kidneys. Although not yet accurate enough to be used as a screening tool for the general population, the test did detect 60 percent of cancers in a test group of kidney cancer patients. It did not detect any |
| Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC boost versus no boost trial Presenter: H. Bartelink Affiliation: The Netherlands Cancer Institute Summary: Breast conservation therapy (BCT) is a standard of care in the management of patients with early stage breast cancers. BCT results have consistently shown survival equivalence to mastectomy. However, the question remains whether boost is |
| Panel Presentation Examines the Use of Unconventional Medical Therapies by Cancer Patients Some recent scientific studies, combined with anecdotal evidence from doctors and nurses, suggest that many cancer patients are using so-called "unconventional medical therapies" while they are undergoing radiation, chemotherapy, or other conventional cancer treatments. The most commonly used unconventional therapies range from vitamins and |
| The Impact of Hormonal Therapy on Outcome in Moderate to High Risk Prostate Cancer Treated with Permanent Radioactive Seed Implantation Presenter: L. N. Lee Affiliation: Mount Sinai School of Medicine, New York, NY Background: Prostate radioactive seed implantation is an effective treatment option for clinically organ- confined prostate carcinoma. Hormonal therapy (HT) has been used in addition to local therapy in selected group of patients in an attempt to improve |
| The Role of Sentinel Node Lymphoscintigraphy in Identifying Patterns of Internal Mammary Node Drainage in Breast Cancer Presenter: M. C. Smitt Affiliation: Stanford University, Stanford, CA Background: Postmastectomy radiation therapy has recently been shown in randomized studies to improve overall survival for patients with node-positive breast cancer. It remains controversial whether or not to treat internal mammary node (IMN). Both Danish and |
| Conformal Proton Beam Therapy of Prostate cancer — Report of Long-term PSA Based Outcomes in Over Twelve Hundred Patients Presenter: C. J. Rossi Affiliation: Loma Linda University Background: Conformal proton beam therapy for prostate cancer has been performed for almost a decade at Loma Linda University Medical Center. This presentation is an update of the outcomes based on PSA. Materials and Methods: 1257 patients with localized prostate |
| Quality of Life After Definitive Treatment for Prostate Cancer. Differences Based on Treatment Modality Presenter: J. W. Davis Affiliation: Eastern Virginia Medical School, Norfolk, VA Background: This is a retrospective study comparing the general health and disease-specific quality of life (HRQOL) in patients with localized prostate cancer treated with brachytherapy (PD103), external beam radiation therapy (XRT), and radical |
| Update of Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 9406 Presenter: J.M. Michalski Affiliation: Radiation Therapy Oncology Group Background: Randomized data have been reported that show improvements in biochemical outcomes for high risk prostate cancer patients treated with 3D conformal dose escalation. However, the therapeutic window has yet to be defined regarding the perceived |
| Is Breast Cancer in the Elderly An Indolent Disease? Presenter: R. Singh Affiliation: The University of Chicago Hospital, Chicago, IL Background: Among elderly women with early-stage breast cancer, age has a strong influence on treatment patterns, and many elderly women are not offered the full range of options. This is partly due to a long-held perception that breast cancer in elderly women |
| Fatigue During Radiation Therapy of Patients with Breast Cancer Presenter: H. Geinitz Affiliation: Technical University Munich, Muenchen, Germany Background: The purpose of this study was to evaluate the course and the possible causes of fatigue during postoperative radiation therapy (RT) of patients with breast cancer. Materials and Methods: 41 patients with postoperative RT after breast |
| Final Keynote Address Highlights the Uncertainties Surrounding Prostate Cancer Screening and Treatment In this "PSA era" — that is, a time when PSA (prostate-specific antigen) blood tests are detecting prostate cancer at a much earlier stage than in the past — there is a great deal of uncertainty about what the best treatments are and whether finding and treating the cancer early makes a difference in survival. Dr. Michael Barry, the |
| Effective First Line Therapy of Ovarian Cancer with Cisplatin and Prolonged Topotecan Infusion - A NYGOG/ECOG Study Presenter: J. Speyer Affiliation: Mt. Sinai Sch of Med, NYU Sch of Med, Albert Einstein Sch of Med Background: Becuase of the known activity of cisplatin and topotecan as second line treatment of ovarian cancer and the favorable results with a Phase II 21-day prolonged infusion of topotecan the authors combined these agents in a first line |
| Preliminary Results of Intergroup INT 0123 Randomized Trial of Combined Modality
Therapy (CMT) for Esophagel Cancer: Standard vs. High Dose Radiation Therapy Presenter: B.D. Minsky Affiliation: RTOG, ECOG, NCCTG, others Background: Although definitive chemoradiation for esophageal cancer is a relatively good treatment option for patients with non-metastatic disease, survival rates remain disappointing. This intergroup trial tests the dose escalation hypothesis in this population receiving |
| A Multi-Center Study of the Costs of Enrolling Cancer Patients on Phase II Clinical Trials Presenter: T.J. Stinson Affiliation: Northwestern University Background: It has long been assumed by health insurance companies that clinical trial costs are much larger than those incurred in standard practice. For this reason, both medicare and private insurers have not reimbursed charges for patients in clinical trials. Only 3-8% of |
| Does pretreatment PSA add to predicting long-term survival from prostate cancer? Presenter: M. Roach III Affiliation: Univ of California San Francisco, Univ of Michigan Background: Numerous prognostic indicators, such as Gleason score and tumor stage are known to be significant in assessing risk of recurrence of or death from prostate cancer. Although prostate specific antigen (PSA) is useful in predicting |
| Comparative Cost-Effectiveness of
Paclitaxel-Cisplatin (TP) vs
Cyclophosphamide-Cisplatin (CP) in Women
with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial Presenter: Hugh Walker Affiliation: Queens Univ. and Tom Baker Cancer Ctr, Canada Background: This sub-analysis of 160 patients in the intergroup trial (EORTC-GCCG, NOCOVA, NCIC-CTG, SGCSG) compares the cost effectiveness of paclitaxel (Taxol) - cisplatin (TP) vs. cyclophosfamide-cisplatin in the treatment of epithelial ovarian cancer. |
| The Role of Radiotherpay and Tamoxifen in the Management of Node Negative Invasive Breast Cancer </= 1.0 cm Treated with Lumpectomy: Preliminary Results of NSABP Protocol B-21 Presenter: N. Wolmark Affiliation: NSABP Background: Although definitive radiation therapy after lumpectomy has been standard of care for breast conservation for breast cancer, there has been some debate if radiation therapy is needed for small tumors (< 1.0cm) when the patient is treated with Tamoxifen. This study was performed to |
| Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of
Southwest Oncology Group Trial 8949 Presenter: Robert Charles Flanigan Affiliation: Southwest Oncology Group Background: Metastatic renal cancer has a poor prognisis and is classically highly resistant to chemotherapy. A number of case series have reported a benefit to neprhectomy in patients with metastatic renal cancer. This prospective randomized trial was |
| A Randomized Trial Comparing Two Fractionation Schedules for Breast
Irradiation Postlumpectomy in Node-Negative Breast Cancer Presenter: Timothy J. Whelan Affiliation: Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Kingston Regional Cancer Ctr, Kingston, ON, Canada; Ottawa Regional Cancer Ctr, Ottawa, Background: Many women with early stage |
| Comparison of health-related quality of life (HRQOL) after brachytherapy, radical prostatectomy, or external beam radiation for localized prostate cancer Presenter: M.G. Sanda Affiliation: University of Michigan Background: Many oncologists believe that in selected patients, the differences between disease free survival and overall survival for radical prostatectomy (RP), external beam radiation therapy (ERT), and brachytherapy (BT) are negligable. Given the rough equivalence of |
| Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial. Presenter: Hugh Walker Affiliation: Queens Univ, Kingston, NC, Canada Background: Postoperative paclitaxel and cisplatin (TP) chemotherapy improves survival compared with cyclophosphamide and cisplatin (CP) in patients with advanced ovarian cancer The combination of TP is considerably more expensive than CP, and may raise |
| Keeping cancer guidelines current: results of a comprehensive prospective literature monitoring strategy Presenter: M.C. Brouwers/G. P.Browman Affiliation: McMaster University, Hamilton Regional Cancer Centre, Hamilton, Canada Background: A Clinical Practice Guideline (CPG) is an evidence-based statement that assists patients and health care providers make appropriate decisions about cancer care. CPGs are developed and updated through the |
| A single Dose of Pegylated Filgrastim (SD/01) is as effective as Daily Filgrastim for Hematologic Support of Chemotherapy in Breast Cancer Patients: Results of a Randomized,k Double-Blind, Phase 3 Trial Presenter: F.A. Holmes Affiliation: US Oncology, Houston, TX Background: Neutropenia is a frequent result of cytotoxic chemotherapy and increases patient risk for serious infection and treatment failure due to dose-reduction or delay. Pegylated Filgrastim (long acting, once per cycle) single dose SD/01 has been shown previously to |
| Informed consent to cancer clinical trials Presenter: S. Joffe Affiliation: Dana-Farber Cancer Institute, Boston, MA Background: For valid informed consent to be obtained, the prospective subject must have an understanding of the medical and research issues involved to make an informed and enlightened decision. Assuring an understanding of the research procedure requires thorough and |
| A Randomized, Double-blind, Phase III Study Evaluating Fixed Dose, Once-Per-Cycle Pegylated Filgrastim (SD/01) vs Daily Filgrastim to Support Chemotherapy for Breast Cancer Presenter: M. Green Affiliation: Multicenter Trial Background: It has been shown prolonged neutropenia associated with chemotherapy administration can be significantly decreased by daily Filgrastim. Pegylated Filgrastim is a sustained duration form administered once per chemotherapy cycle. This study was performed to compare the |
| Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women with Breast Cancer: a Multi-Site Randomized Controlled Trial Presenter: T. Hack Affiliation: University of Manitoba, Winnipeg, MB, Canada; British Columbia Cancer Agency, Vancouver; BC, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Cross Cancer Institute, Edmonton, AB, Canada Background: Patient education is an important part of a patient therapeutic plan. Empirical evidence supports the use of |
| Non-Adherence with Adjuvant Tamoxifen Therapy in Women with Early Stage Breast Cancer Presenter: A. H. Partridge, P. S. Wang, E. P. Winer, J. L. Avorn Affiliation: Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA Background: Tamoxifen has been shown to help prevent breast cancer recurrence and death in women with early breast cancer. Yet, non-compliance for a number of reasons appears to be an |
| The Effect of Hospital Volume and Socioeconomic Status on Colostomy Rates for Rectal Cancer Presenter: D. C. Hodgson Affiliation: Background: Loss of sphincter function due to rectal cancer is associated with significant impairment in the quality of a patient?s life. This study evaluated the impact of surgical case-volume or patient demographics on the risk of undergoing permanent colostomy for rectal cancer. Materials and |
| How Much Chemotherapy Are Cancer Patients Receiving at the End of Life? Presenter: E.J. Emanuel Affiliation: National Institutes of Health Background: End of life issues are an important part of oncology care. This study was performed to determine the proportion of cancer patients getting chemotherapy at the end-of-life, their characteristics, and how chemotherapy relates to receiving hospice. Materials and |
| A Phase I study of oxaliplatin in cancer patients with impaired renal function Presenter: M.A. Graham Affiliation: University of Texas Health Science Center, San Antonio Background: Oxaliplatin is a new platinum derivative with activity in several solid tumors, especially in some cisplatin/carboplatin-refractory neoplasms. Oxaliplatin clinical toxicity is also distinct from other platinum drugs: it has minimal renal |
| Primary Chemotherapy (PCT) For Patients With Operable Oral Cavity Cancer: Results Of A Randomized Study Presenter: Lisa Licitra Affiliation: Istituto Nazionale Tumori, Milan, Italy Background: This study was designed to investigate the impact of neoadjuvant chemotherapy on primary surgery in operable oral cavity cancer. Materials and Methods: Randomized trial of 195 patients with operable squamous cell carcinoma of the oral cavity |
| Phase III Study Comparing Cisplatin (C) & 5-Flurouracil (F) Versus Cisplatin & Paclitaxel (T) In Metastatic/Recurrent Head & Neck Cancer (MHNC) Presenter: B Murphy Affiliation: Vanderbilt-Ingram Cancer Center Background: CF is the standard combination regimen for MHNC. With expected response rate of 30%, medium survival (MS) 6 mos, 1 yr overal survival (OS) of 20%. An ECOG trial found paclitaxel is an active agent for the treatment of squamous cell carcinoma of the head and neck. |
| A Phase III Study Of Concomitant Oral Pilocarpine To Reduce Hypo-Salivation And Mucositis Assocated With Curative Radiation Therapy (RT) In Head And Neck (H&N) Cancer Patients. RTOG 9709 Presenter: Charles W. Scarantino/Charles B. Scott Affiliation: Multi-institutional Background: Radiotherapy plays a major role in the management of H&N cancer. The major treatment side effects are mucositis and xerostomia (dry mouth), which can affect tolerance and result in treatment interuptions. For patients recieving > 50Gy of radiation, |
| Nutrition and Cancer: An Update What definite positive associations have researchers found between certain nutrients or dietary components and the development of cancer? Very few, according to three researchers who attempted to summarize the state of nutritional research at ASCO this afternoon. Arthur Schatzkin, MD, of the National Cancer Institute, Maria Elana |
| The Shape of Things to Come: Sunday Afternoon Special Session Focuses on the Biology of Cancer During a panel presentation that ASCO members "are likely to be talking about ten years from now," to use the words of ASCO president- elect Dr. Larry Norton, four leading researchers in the molecular biology of cancer looked back, looked ahead, and also talked about some of the current exciting developments in the field. Harold Varmus, |
| Recombinant Human Keratinocyte Growth Factor (RHUKGF) Prevents Chemotherapy-Induced Mucositis In Patients With Advanced Colorectal Cancer: A Randomized Phase II Trial Presenter: Stephen John Clarke Affiliation: Royal Prince Alfred Hospital, Camperdown, Australia Background: Oral mucositis in cancer patients receiving chemotherapy can lead to dose reduction and/or treatment breaks, both of which could have a negative impact on treatment outcomes. The use of 5-fluorouracil (5-FU) and folinic acid for the |
| Fluoxetine Versus Placebo In Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial Of The Hoosier Oncology Group Presenter: Michael Jordan Fisch Affiliation: UT/MD Anderson Cancer Center, Houston, TX Background: Depressive symptoms are prevalent in advanced cancer patients, and no standard of care exists regarding assessment and management of this clinical problem. Studies have demonstrated that Serotonin reuptake inhibitors such as fluoxetine are |
| Effect Of An SSRI Antidepressant On Fatigue And Depression In Seven Hundred Thirty-Eight Cancer Patients Treated With Chemotherapy: A URCC CCOP Study Presenter: Gary R. Morrow Affiliation: University of Rochester Cancer Center, Rochester, NY Background: Fatigue can significantly interfere with a cancer patient's ability to fulfill daily responsibilities and enjoy everyday life. It commonly co-exists with depression in patients undergoing chemotherapy, suggesting that administration of an |
| Clinicians' Assessment Of Quality Of Life (QOL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study Presenter: Michael L. Titzer Affiliation: Indiana University Cancer Center and the Walther Cancer Institute, Indianapolis, IN Background: Cancer and its related symptoms, such as depression and fatigue, can have substantial impact on a cancer patient's quality of life (QOL). Studies indicate that QOL can be and important prognostic factor. QOL |
| SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC+Cystectomy Versus Cystectomy Alone in Patients With Locally Advanced Bladder Cancer Presenter: R.B. Natale Affiliation: SWOG Background: Radical cystectomy has been the gold standard for the treatment of locally advanced bladder cancer. However, 50-60% develop recurrent or metastatic disease after cystectomy. It has been hypothesized that neoadjuvant therapy for advanced bladder cancer will 1)immediately treat |
| International Symposium Takes a Global Look at Treatment for Advanced Breast Cancer What's the single biggest risk factor for dying of breast cancer, both in the U.S. and worldwide? Poverty, according to a series of presentations given by international researchers at ASCO this morning. Oncologists from the United States, Brazil, India, Australia, South Africa, and Germany came together to take their audience on a |
| Clinical Significance Of Axillary Micrometastases In Breast Cancer: How Small Is Too Small? Presenter: Nora M Hansen Affiliation: John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA Background: Lymph node metastases are the most significant prognostic indicator for patients with breast cancer. a. 15-20% LN ? pts die within 5 yrs b. 20-30% LN ? pts recurs > 10 yrs Historically hematoxylin and eosin (H&E) |
| Overall Survival After Cyclophosphamide, Adriamycin, 5-FU, And Tamoxifen (CAFT) Is Superior To T Alone In Postmenopausal, Receptor (+), Node (+) Breast Cancer: New Findings From Phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) Presenter: Kathy Albain Affiliation: Loyola Univ. Med. Center, Maywood, IL Background: The treatment of older women with breast cancer presents many unique treatment issues. One such issue is the use of anthracyclines to treat older patients who are receptor positive and node positive. The objectives of INT-0100 were to determine 1) if |
| Effect Of Raloxifene After Tamoxifen On Breast And Endometrial Cancer Growth Presenter: Ruth M. O'Regan Affiliation: Northwestern University, Chicago, IL Background: After the completion of 5 years of tamoxifen therapy, breast cancer patients are still at risk for osteoporosis and breast cancer recurrence. Raloxifene (RAL) is a selective estrogen receptor modulator, approved for the prevention of osteoporosis in |
| Preventing Chemotherapy-associated Amenorrhea (CRA) With Leuprolide In Young Women With Early-stage Breast Cancer Presenter: Kevin R. Fox Affiliation: University of Pennsylvania Cancer Center, Philadelphia, PA Background: Premature amenorrhea is often associated with adjuvant chemotherapy treatment for breast cancer. The rate of amenorrhea varies to 10 to 100% in studies depending on the age of patients and the type of chemotherapy used. Whether or |
| Perspectives in Breast Cancer Date: November 10, 2001 Location: Philadelphia, Pennsylvania, USA Symposium Web Page: www.lindacreed.org, www.joanborysenko.comand www.drsavard.com Sponsors: Linda Creed Breast Cancer Foundation and the Center for Integrative Medicine at Thomas Jefferson University Hospital Objectives: To discover and integrate alternative |
| Perpectives in Bladder Cancer Date: November 14-16, 2001 Location: Clearwater Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/faptp Sponsors: Florida Association of Pediatric Tumor Programs Who Should Attend: Health care professionals working in pediatric hematology and oncology Objectives: Learn the latest treatments and trends in childhood |
| Improving Quality of Life: Integrative Approaches to Pain & Cancer Date: November 2, 2001 Location: Woodbridge, New Jersey, USA Symposium Web Page: www.medsch.ucla.edu/som/medicine/cewm/education.asp Sponsors: New Jersey Pain Initiative, American Cancer Society, Eastern Division, Inc., New Jersey Commission on Cancer Research Who Should Attend: Health Professionals Topics: Summarize |
| Endocrine prevention and treatment of breast and gynaecological cancer Date: November 2, 2001 Location: Woodbridge, New Jersey, USA Symposium Web Page: www.medsch.ucla.edu/som/medicine/cewm/education.asp Sponsors: New Jersey Pain Initiative, American Cancer Society, Eastern Division, Inc., New Jersey Commission on Cancer Research Who Should Attend: Health Professionals Topics: Summarize |
| Chemotherapy Foundation Symposium XIX: Innovative Cancer Therapy For Tomorrow Date: November 7-10, 2001 Location: Marriott Marquis, New York, New York, USA Symposium Web Page: www.mssmtv.org Sponsors: Page & William Black Post-Graduate School and Chemotherapy Foundation Who Should Attend: Oncologists, immunologists, radiologists, hematologists, physicians with secondary in oncology, nurses, pharmacists, |
| The Psychologist and the supportive home care in terminal cancer patient: The diagnostic process Date: November 24, 2001 Location: Milan, Italy Symposium Web Page: www.vidas.it Sponsors: VIDAS Topics: Palliative Care Agenda: Nursing of terminal patient. A therapeutic chance? Questions about addressing the patient to the psychologist. Home as setting: the importance to keep it under observation. The |
| 24th Annual San Antonio Breast Cancer Symposium Date: December 10-13, 2001 Location: San Antonio, Texas, USA Symposium Web Page: www.sabcs.org Sponsors: Cancer Therapy & Research Center, and UTHSCSA Who Should Attend: Academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other |
| Cancer, Culture and Literacy Conference Date: January 8-12, 2002 Location: Tampa, Florida, USA Symposium Web Page: www.moffitt.usf.edu/promotions/cclinstitute/ Sponsors: H. Lee Moffitt Cancer Center & Research Institute Who Should Attend: Recent Doctorates or mid career investigators (PhD, DrPH, MD, DNS, SCD or equivalent) Topics: The Cancer, Culture and Literacy |
| Cellular & Molecular Biology of Cancer Date: February 25 - March 1, 2002 Location: Wolfson Conference Centre, Imperial College, Hammersmith Hospital Campus, Du Cane Road, London, England Symposium Web Page: www.med.ic.ac.uk/divisions/cc/wolfson.asp Objectives: This is the 7th year of an intensive 5-day course presented by international distinguished experts.The format |
| Focus on Breast Cancer Date: February 9, 2002 Location: The Wellness Community fo Philadelphia, Ridgeland mansion, Chamounix drive, West Fairmount Park, Philadelphia, Pennsylvania, USA Symposium Web Page: www.twcp.org Sponsors: The Wellness Community of Philadelphia Who Should Attend: Women with breast cancer and their support people Objective: |
| American Cancer Society CareCast Date: February 26, 2002 Location: Washington, DC, USA Symposium Web Page: www.aicr.org Sponsors: American Cancer Society & Cancer Survivors Network Topics: On February 26, from 7:00PM to 8:00PM EST, the Cancer Survivors Network will host a live web cast, focusing on cancer-related issues in the workplace. This forum was created |
| International Conference on Emerging Trends in Cancer Research Date: March 14-16, 2002 Location: University, New Delhi, India Symposium Web Page: in.geocities.com/jnucancerconf Sponsors: JNU Who Should Attend: Cancer researchers, Clinicians, Students Objectives: Share and discuss current trends in cellular and molecular concept of causation, prevention and cure of cancer Topics: |
| Fourth Annual Palm Beach Cancer Symposium: Moving Beyond the Ordinary Date: March 22-23, 2002 Location: Delray Beach, Florida, USA Symposium Web Page: www.cbcbiomed.com Sponsors: Boca Raton Community Hospital CME Committee Who Should Attend: Medical Oncologists, Radiation Oncologists, Surgical Oncologists, Gynecologic Oncologists, Pulmonologists, Gastroenterologists, Urologists, Primary Care |
| Gastrointestinal Cancers: Critical Advances in Risk Assessment, Screening and Management Date: March 23, 2002 Location: City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California, USA Symposium Web Page: www.cityofhope.org/ccgp/ Sponsors: Primary care physicians, surgical oncolgoists, gastroenterologists, pathologists, nurses, genetic counselors Who Should Attend: Medical Oncologists, Radiation |
| Colon Cancer: Genetics to Prevention Date: March 7-10, 2002 Location: Loews Philadelphia Hotel, Philadelphia, Pennsylvania, USA Symposium Web Page: www.aacr.org/4310x.asp Sponsors: American Association for Cancer Research Who Should Attend: Basic Scientists, Clinicians and Trainees Conference Objectives: Education for the Multiple Myeloma patient on the latest |
| Trauma to Triumph: Coping with the Cancer Experience Featuring Edward Leigh, MA This program features the Trauma-to-Triumph story of Edward Leigh, a motivational speaker and colorectal cancer survivor who has appeared on The Today Show. "His amazing story will inspire and encourage you to get tested for colon cancer." Katie Couric, co-anchor The Today Show Join us for an |
| CCA's 2nd Annual Colorectal Cancer Conference Date: March 1-3, 2002 Location: Marriot Downtown Courtyard, Philadelphia, Pennsylvania, USA Symposium Web Page: www.CCAlliance.org Sponsors: Colon Cancer Alliance Who Should Attend: This event, intended for colorectal cancer survivors, caregivers, friends, family, health care professionals, members of the crc community and |
| 2nd Annual Colorectal Cancer Survivors Conference Date: April 19-22, 2002 Location: Newport Beach, California, USA Symposium Web Page: www.colorectal-cancer.net Sponsors: Colorectal Cancer Network Who Should Attend: Colon and rectal cancer survivors, caregivers and advocates Topics: Meet and hear notable colon and rectal cancer experts, survivors, and advocacy leaders |
| Focus on Gynecologic Cancers: 3rd Annual Conference Date: Friday, April 26, 2002 Location: Adams Mark Hotel, City Line and Monument Road, Philadelphia, Pennsylvania, USA Sponsors: The University of Pennsylvania Cancer Center Who Should Attend: Women Whose Lives have Been Touched by Gynecologic Cancer Conference Objectives: Learn about the latest advances in diagnosis, surgical |
| It's Time to FOCUS ON Ovarian and Gynecologic Cancers Conference Dates: April 6, 2002 Conference Location: Philadelphia, Pennsylvania, USA Sponsoring Group: The Wellness Community of Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Disscussion of Treatment Options followed by questions and answers Questions and Answers about Symptom Management during and after |
| Florida Prostate Cancer Symposium 2002 Date: May 3-4, 2002 Location: Tradewinds Sirata Beach Resort, St. Pete Beach, Florida, USA Symposium Web Page: www.cment.med.usf.edu Sponsors: University of South Florida College of Medicine, Florida Prostate Cancer Network, Maia Associates, Inc. Who Should Attend: Physicians and nurses treating prostate cancer in the |
| The Group Room® Cancer Talk Radio Show to Present Two Broadcasts at ASCO Meeting:
Live Remote Show, Sunday, May 19 and OncoLink Webcast, Saturday, May 18 LOS ANGELES, May 15, 2002 This year, The Group Room, the nationally syndicated weekly radio call-in cancer talk show, will present two broadcasts from the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida's Orange County Convention Center. On Saturday, May 18, The Group Room and OncoLink will collaborate |
| Emerging Concepts in the Treatment of Prostate Cancer Conference Dates: May 24, 2002 Conference Location: The Rosen Centre Hotel Sponsoring Group: PIM & Intramed Conference Web Page URL: www.intramedgroup.com/huggins Topics Covered: Emerging Concepts in the Treatment of Prostate Cancer 2nd Annual Charles Huggins Symposium A CME Symposium held just prior to the AUA?s 97th Annual Meeting |
| 14th International Symposium on Supportive Care in Cancer - MASCC/ISOO Date: June 23 - 26, 2002 Location: Boston, Massachusetts, USA Sponsors: MASCC/ISOO Web Site: www.imedex.com |
| World Conference on Breast Cancer Date: June 4-8, 2002 Location: Victoria Conference Centre, Victoria, BC, Canada Sponsors: WCBC Web Site: www.brcancerconf.kos.net Who Should Attend: Survivors, health care professionals, scientists, physicians, advocates, environmental professionals, educators, journalists, government representatives Objectives: Educate |
| 3rd International BCIRG Conference Breast Cancer: Current Evidence and Translational Research Opportunities for Improving Patient Outcomes Date: January 18-20, 2002 Location: Anaheim, California, USA Symposium Web Page: www.larad.org/meetings/index.htm Sponsors: Southern California Radiation Oncology Society Who should attend: Radiation Oncologists, Physicists, Radiation Therapists, Oncology Specialists, and Physicians with an interest in cancer treatment |
| Third International Laryngeal Cancer Conference: The Management of Laryngeal Carcinoma in the New Millennium This conference is supported by an educational grant from eMedicine.com. Date: June 14-15, 2002 Location: University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Call for |
| The Group Room® Cancer Talk Radio Show to Broadcast Special Taped Program on International High-Dose Chemotherapy Conference in Canada LOS ANGELES--July 1, 2002--The Group Room--the nationally syndicated weekly radio call-in cancer talk show--will broadcast a special taped program from the "Second International Conference on High-Dose Chemotherapy: Innovation and Evolution," Sunday, July 7 from 4-6 pm ET (1-3 pm PT). The conference, held this past spring in Banff, Alberta, |
| The Era of Hope Meeting for the
Department of Defense (DOD) Breast Cancer Research Program (BCRP) Date: September 25-28, 2002 Location: Orange County Convention Center, Orlando, Florida, USA Symposium Web Page: http://cdmrp.army.mil/bcrp/ Sponsors: US Department of Defense Congressionally Directed Medical Research Program Objectives: To gain greater insight into breast cancer through the scientific exchange between |
| Cancer As a Turning Point, From Surviving to Thrivingtm Date: September 14-15, 2002 Location: Chabot College, Hayward, California, USA Symposium Web Page: www.HealingJourneys.org Sponsors: Healing Journeys, Chabot College, A.C.S., Komen Foundation Who Should Attend: Any one whose life has been touched by cancer. Survivors, health professionals, family and care-givers. Topics: A |
| Changing Concepts in Breast Cancer 2002 Conference Dates: Friday, September 13, 2002 Conference Location: The Rittenhouse Hotel , 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics |
| The 3rd Annual Perspectives in Colorectal Cancer Conference Dates: September 19 - 20, 2002 Conference Location: Chicago, Illinois, USA Sponsoring Group: Imedex Conference Web Page URL: http://www.imedex.com/Imedex%20website/images/Flash/USColo02.htm Topics Covered: Biology, Prevention, Testing and Screening, Operable Colorectal Cancer, Management of Hepatic Metastases, Innovative |
| The 2nd Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 19 - 21, 2002 Conference Location: Toronto, Ontario Canada Sponsoring Group: Princess Margaret Hospital and Imedex, Inc. Conference Web Page URL: http://www.imedex.com/Imedex%20website/images/Flash/pmh02.htm Topics Covered: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, |
| The 7th International Conference on Geriatric Oncology - Cancer in the Elderly. The 3rd Meeting of SIOG Conference Dates: September 27 - 28, 2002 Conference Location: Boston, Massachusetts, USA Sponsoring Group: SIOG - International Society of Geriatric Oncology Conference Web Page URL: www.imedex.com/Imedex%20website/images/Flash/siog02.htm Topics Covered: Progress in the Past year in Surgical Oncology, Biology of Aging, Radiation |
| Beyond Tomorrow: New Horizons in Targeted Breast Cancer Therapies Town Meeting Conference Dates: September 19, 2002 Conference Location: People can attend in Houston in person, over the phone or on the Internet Sponsoring Group: This program is produced by the HealthTalk? Breast Cancer Education Network in partnership with The University of Texas M. D. Anderson Cancer Center in association with the University of |
| Molecular Targets for Cancer Therapay & Prevention: Second Biennial Meeting Date: October 11-15, 2002 Location: St. Petersburg Beach, Florida, USA Symposium Web Page: www.moffitt.usf.edu/promotions/molecular/index.htm Sponsors: H. Lee Moffitt Cancer Center & Research Institute Topics: The purpose of this meeting is to foster exchange of the most recent findings and ideas in cancer biology. Special |
| Cancer and Aging: A Call to Action Conference Dates: October 4-5, 2002 Conference Location: Princeton, New Jersey, USA Sponsoring Group: Saint Barnabas Health Care System, Meridian HEalth System, NJ Commission on Cancer Research Conference Web Page URL: www.cancerandaging.org Topics Covered: Co-Morbidities Best Treatment Practices Pain Management Economic |
| The 7th Annual Perspectives in Thoracic Cancer Conference Dates: October 4 - 5, 2002 Conference Location: New York, New York, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/uslung02.htm Topics Covered: Imaging and Surgical Staging in NSCLC, Management of Resectable Disease, Management of Metastatic/Recurrent Disease, Malignant Mesothelioma |
| 8th Annual Perspectives in Breast Cancer Conference Dates: October 17 - 18, 2002 Conference Location: Atlanta, Georgia, USA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/announcements/breast02.html Topics Covered: Breast Cancer Biology, Screening and Diagnosis, DCIS and Early Breast Cancer, DCIS and Early Breast Cancer, Systemic Therapies, New |
| Eleventh Annual Life After Breast Cancer Conference Conference Dates: October 21, 2002 Conference Location: Philadelphia, Pennsylvania, USA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Cancer Detection and Diagnosis Mammography: What's All the Fuss? The Use of Ductal Lavage for Detection and Risk Assessment Understanding Your |
| Colon Cancer Conference Conference Dates: Friday, November 8, 2002 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Topics Covered: TBA Conference Objectives: TBA ---> Who Should Attend: Surgeons, Medical Oncologists, Radiation Oncologists, Nurses, and other |
| How to talk with your doctor about cancer clinical trials Selma Schimmel, CEO and founder of Vital Options International, will be joining Dr. Robert Comis, leading national oncologist, President and Chairman, CNCCG, on Wednesday Dec. 4, 2002 12:00 Noon EST, for a clinical trials discussion online. Join the live on-line discussion at either Washington Post Live Online or MSNBC Newsweek Viewpoint. Hosted |
| New Targets and Innovative Strategies in Cancer Treatment: A Short Course for Clinicians Conference Dates: February 6-8, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: The course has been designed with three specific objectives in mind. The first objective is to explain, and to clarify in an often somewhat simplified |
| Prostate Cancer Conference Conference Dates: Friday, March 28, 2003 Conference Location: Loews Philadelphia Hotel, 1200 Market Street, Philadelphia, PA Sponsoring Group: University of Pennsylvania Cancer Center Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics Covered: |
| Issues In Women's Healthcare: Genetics, Cancer and the Hormone Controversy Conference Dates: March 15, 2003 Conference Location: City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California, USA Conference Web Page URL: www.cityofhope.org/ccgp Topics Covered: Primary care physicians, ob/gyn physicians, oncologists, surgeons and other allied health care professionals who participate in this course |
| Ask The Doctor About Colorectal Cancer Conference Dates: Monday, March 10, 2003/6:30-8:00P.M. Conference Location: The Wellness Community Philadelphia Sponsoring Group: Roche Conference Web Page URL: www.twcp.org Topics Covered: Join Weijing Sun, M.D. from the University of Pennsylvania and learn about new treatment for colorectal cancers. Conference Objectives: education |
| Third International "North Adriatic Sea" Symposium on Novel Targets for Cancer Therapy Conference Dates: April 28-29, 2003 Conference Location: Trieste, Italy Sponsoring Group: Conference Web Page URL: www.augustea.net/north_adriatic_sea Topics Covered: This year you will discuss about proteomics, immunology, innovations in cancer treatment, and about what help could arrive from research for clinicians. We are sure that, |
| Cancer Survivors Conference Conference Dates: Saturday, April 12, 2003 Conference Location: Holiday Inn, City Line Avenue, Philadelphia, PA Sponsoring Group: American Cancer Society Topics Covered: Medical, emotional and nutritional needs after treatment ends; humor and mindfulness healing; breathing for relaxation; family communications; movement; complementary |
| Third Annual Colorectal Cancer Conference Conference Dates: April 4-6, 2003 Conference Location: Washington, DC Sponsoring Group: Colon Cancer Alliance Conference Web Page URL: www.ccalliance.org/cca/events/conference2003/index.html Topics Covered: Conference Objectives: To provide attendees with the most up-to date colorectal cancer (crc) information in a supportive and |
| The Patient Active Guide to Living with Ovarian Cancer Conference Dates: May 12, 2003, 6:30-8:30PM Conference Location: The Wellness Community Philadelphia Sponsoring Group: GlaxoSmithKline Oncology Conference Web Page URL: www.twcp.org Topics Covered: Dr. Christina S. Chu, a gynecologic oncologist from the University of Pennsylvania Health System will provide information about treatment |
| MASCC/ISOO 15th International Symposium Supportive Care in Cancer Conference Dates: June 18 - 21, 2003 Conference Location: Hotel Inter-Continental, Berlin, Germany Sponsoring Group: Conference Web Page URL: www.symposium-online.de/mascc Topics Covered: growth factors, mucositis, emesis, pain management, late toxicity, fatigue, psychosocial aspects, Conference Objectives: Who Should Attend: |
| PICC 03 - The 5th International Conference: Perspectives in Colorectal Cancer Conference Dates: June 26-28, 2003 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.picccongress.com Topics Covered: Molecular Biology & Prevention, Imaging Techniques in Staging and Diagnosis of Colorectal Cancer, The Management of Hepatic Mestases, Chemotherapy of Colorectal Cancer, |
| 6th Annual Changing Concepts in Breast Cancer Conference Dates: September 11-12, 2003 Conference Location: Philadelphia, PA Sponsoring Group: The University of Pennsylvania Abramson Cancer Center and The School of Medicine Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Topics Covered: This |
| Perspectives in Colorectal Cancer Conference Dates: September 12-13, 2003 Conference Location: Washington, D.C. Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Conference Objectives: Who Should Attend: oncologists, gastroenterologists, colorectal surgeons, radiation oncologists Conference Agenda: |
| The 3rd Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 11-13, 2003 Conference Location: Toronto, Ontario Canada Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: online: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334 Continuing Education: Yes |
| CDC's 2003 Cancer Conference Conference Dates: September 15-18, 2003 Conference Location: Marriott Marquis hotel, Atlanta, GA, USA Sponsoring Group: Centers for Disease Control and Prevention, American Cancer Society, Chronic Disease Directors, National Cancer Institute, North American Association of Central Cancer Registries Conference Web Page URL: |
| Ovarian Cancer National Alliance 6th Annual Advocacy Conference Conference Dates: September 17-19, 2003 Conference Location: San Francisco, CA Sponsoring Group: Ovarian Cancer National Alliance Conference Web Page URL: www.ovariancancer.org Topics Covered: Current & emerging therapies, outreach across barriers, palliative support care, nutrition & complementary healing, cutting edge research, |
| 2003 Cancer Symposium - Hormone Replacement Therapy: Benefits and Risks Conference Dates: September 24, 2003 Conference Location: Harry's Savoy Ballroom - Wilmington, Delaware Sponsoring Group: Medical Society of Delaware, in joint sponsorship with Christiana Care Health System Topics Covered: Benefits of Hormone Replacement Therapy Risks Associated with the use of Hormone Replacement Therapy Recent |
| 9th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy (ISPCC) Conference Dates: October 8-11, 2003 Conference Location: New York, NY Sponsoring Group: New York University Conference Web Page URL: www.imedex.com/announcements/platinum03.html Topics Covered: This symposium combines the latest information on both the clinical and mechanistic aspects of the use of platinum-based anticancer agents. The |
| 9th Annual Conference: Perspectives in Breast Cancer Conference Dates: November 13-14, 2003 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Who Should Attend: oncologists, radiation oncologists Registration Information: www.imedex.com, tel: 770-751-7332, fax:770-751-7334, h.drew@imedex.com |
| The 6th International Thyroid Cancer Survivors' Conference Conference Dates: October 24-26, 2003 Conference Location: Houston, Texas Sponsoring Group: ThyCa: Thyroid Cancer Survivors' Association, Inc. Conference Web Page URL: www.thyca.org Topics Covered: Endocrinologists, surgeons, nuclear medicine physicians, a pathologist, and a palliative care physician will address issues ranging from |
| Frankly Speaking about Colorectal Cancer Conference Dates: October 25, 2003 Conference Location: The Wellness Community Philadelphia Sponsoring Group: The Wellness Community Philadelphia Conference Web Page URL: www.twcp.org Topics Covered: Dr. Weijing Sun of the University of Pennsylvania will discuss new treatment for colorectal cancers. Liz Goodman, Health Educator, will |
| The 8th International Conference on Geriatric Oncology - Cancer in the Elderly. The 4th Meeting of SIOG. Conference Dates: November 21-22, 2003 Conference Location: Rome, Italy Sponsoring Group: SIOG, Imedex Conference Web Page URL: www.cancerworld.org Who Should Attend: oncologists, radiation therapists, physicians, nurses, nurse practitioners and other health care professionals in active clinical practice interested and/or involved with |
| 3rd Annual Perspectives in Bladder Cancer Conference Dates: November 14-15, 2003 Conference Location: Padova, Italy Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Who Should Attend: oncologists, urologists Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: |
| 3rd European Conference: Perspectives in Breast Cancer Conference Dates: November 7-8, 2003 Conference Location: Nice, France Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: No |
| Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow Conference Dates: November 12-15, 2003 Conference Location: Marriott Marquis Hotel, New York, NY Sponsoring Group: Chemotherapy Foundation Conference Web Page URL: www.mssm.edu/tcf Topics Covered: Novel strategies for control and cure of breast, ovarian, prostate, GI, bladder, hematologic malignancies, melanomas, head and neck, lung and |
| PICC 04 - The 6th International Conference: Perspectives in Colorectal Cancer Conference Dates: June 17-19, 2004 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.picccongress.com Registration Information: www.picccongress.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: No |
| The 9th International Conference on Geriatric Oncology: Cancer in the Elderly The 5th Meeting of SIOG Conference Dates: October 15-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: SIOG, Imedex, Inc. Conference Web Page URL: www.cancerworld.org Registration Information: www.imedex.com, tel: 770-751-7332, fax: 770-751-7334, h.drew@imedex.com Continuing Education: Yes |
| Selective Bladder Preservation by Combined Modality Treatment of Invasive Bladder Cancer: 10 Year Outcome Presenter: W. U. Shipley Affiliation: Massachusetts General Hospital BackgroundThe standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, to improve quality of life in these patients, there is much interest in bladder-conserving therapies, using transurethral |
| Biclutamide ("Casodex") 150 mg as Adjuvant to Radiotherapy in Localized or Locally Advanced Prostate Cancer Presenter: C. Tyrrell Affiliation: Plymouth Oncology Centre, Plymouth, United Kingdom BackgroundBiclutamide (Casodex) is often used as adjuvant therapy in patients who have biochemical failure after definitve therapy. This is a study to evaluate the use of biclutamide as an immediate therapy or as adjuvant to therapy of curative intent in |
| Preoperative Chemoradiation using Capecitabine in Locally Advanced Rectal Cancer Presenter: J.S. Kim Affiliation: Department of Therapeutic Radiology, Chungnam National University, Taejon, South Korea BackgroundStudies indicate that preoperative chemoradiation can result in tumor downstaging with increase resectability and sphincter preservation in locally advanced rectal lesions. Capecitabine is a new fluoropyrimidine |
| Impact of TNM Stage on Survival and Disease Control in Adjuvant Rectal Cancer Pooled Analysis Presenter: L.L. Gunderson Affiliation: Institution: Oncology, Mayo Clinic, Rochester, MN BackgroundThis study attempts to evaluate the TMN staging and the MAC staging as predictors of outcome such as overall survival and patterns of failure for patients with rectal cancer who have undergone adjuvant therapy. The study evaluates patients from 3 |
| Epidermal Growth Factor Receptor is a Predictor of Tumor Response in Locally Advanced Rectal Cancer Patients treated with Preoperative Radiotherapy Presenter: J.S. Kim Affiliation: Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain Background Epidermal growth factor receptor (EGFR) is a member of the tyrosine kinase receptor family and is expressed in a variety of different cell lines. EGFR overexpression is observed in 50- 70% of colorectal carcinomas and is associated with |
| Phase II Trial of Preoperative Chemoradiation with a Hyperfractionated RT Boost in Locally Advanced Rectal Cancer Presenter: H. Diratzouian Affiliation: Fox Chase Cancer Center, Philadelphia, PA Background Studies have reported a dose response relationship for preoperative radiation therapy. The Fox Chase group has previously reported the results of a phase I dose escalation trial demonstrating the tolerability of preoperative chemoradiation with a |
| Survival Benefit for Early Initiation of Hormone Ablation Therapy in Patients who Fail Definitive XRT for Prostate Cancer (ACP) Presenter: T.C. Tenenholz Affiliation: Medical College of Virginia Background There is a dispute over the timing of starting hormones after biochemical failure. This study was initiated to determine when the benefits of hormonal ablation outweighs its potential morbidity. Materials and Methods Retrospective study of 931 patients who |
| Quantitation of the Early Effects of Radiation and Hormonal Therapy on Hemoglobin Levels in Men Treated for Prostate Cancer Presenter: J. Wilson Affiliation: University of Pennsylvania BackgroundAnemia has been shown to be a prognostic factor in head and neck and cervical cancer. However, unless hemoglobin falls to values Materials and Methods This is a retrospective study of 198 men with stage T1-4N0M0 prostate cancer. Hemoglobin levels were measured before |
| A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12 Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year This is a new approach to the management of pancreatic cancer, using paclitaxel (Taxol) and radiation therapy to improve |
| CANCER AND LEUKEMIA GROUP B (CALGB) 89805: Phase II Chemoradiation Trial using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas Presenter: A.W. Blackstock Affiliation: CALGB Type of Session: Scientific Background Pancreatic cancer has a high mortality without significant changes in life expectancy over the past several years 50% have distant disease at diagnosis and cure rates remain low even in locally advanced disease. Gemcitabine administered twice-weekly produces |
| Mature Survival Results with Preoperative Cisplatin, Protracted Infusion 5-FU, and 45 GY Radiotherapy for Esophageal Cancer Presenter: L. Kleinberg Presenter's Affiliation: Johns Hopkins Oncology Center, Baltimore, MD Type of Session: Scientific Background Neoadjuvant chemoradiation for Esophageal cancer is controversial, however, many patients are offered this therapy as a standard of treatment. Randomized trials has shown mixed results The US Intergroup study |
| Chemo-Radiotherapy, as Compared to Radiotherapy Alone, Significantly Increases Disease-Free and Overall Survival in Head and Neck Cancer Patients After Surgery: Results of EORTC Phase III Trial 22931 Presenter: J. Bernier Presenter's Affiliation: Radio-Oncology, Ospedale San Giovanni, Bellinzona, Switzerland Type of Session: Plenary Background Standard adjuvant therapy for advanced head and neck cancer in the post-operative setting is radiation alone. This study was designed to determine if there is an advantage of treating patients with |
| A Phase I/II Trial of Escalating Doses of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Head & Neck Cancer (HNC) Patients Receiving Radiotherapy (RT) with Concurrent Chemotherapy (CCT) Presenter: D.M. Brizel Presenter's Affiliation: Duke University Type of Session: Scientific Background Evidence from recent studies suggest that the combination of chemotherapy and radiation therapy improves outcome in advanced head and neck cancers, compared to single modality therapy. But these aggressive therapies frequently cause increases in |
| Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial Presenter: T. Dipetrillo Presenter's Affiliation: Brown University Type of Session: Scientific Background Locally advanced pancreatic cancer has Gemcitabine and paclitaxel are both radiation sensitizers The use of paclitaxel has demonstrated efficacy in RTOG 98-12 The feasibility of concurrent weekly paclitaxel and gemcitabine with |
| Sequencing of Chemotherapy and Radiation Therapy for Patients with Early Stage Breast Cancer: Updated Results of a Prospective Randomized Trial Presenter: Bellon, JR Presenter's Affiliation: Harvard Medical School Type of Session: Plenary Background This study was designed to evaluate the optimal sequencing of radiation therapy and chemotherapy in early stage breast cancer patients treated initially with lumpectomy The initial report with 5 yrs of follow-up showed for patients at |
| The Impact of Anemia on PSA Outcome following Radiation and Androgen Suppression Therapy in Patients with High-Risk Prostate Cancer Presenter: A.V. DAmico Presenter's Affiliation: Brigham and Women's Hospital, Boston, MA Type of Session: Scientific Background It is well known that in men testosterone has a permissive effect on hemeglobin (Hb)levels in the bone marrow and on erythropoetin levels in the kidney. Androgen suppression therapy (AST), frequently used in the treatment |
| Molecular Markers of Patient Outcome in Prostate Cancer Treated with Radiotherapy: Ki-67, Bcl-2, Bax, and Bcl-x Presenter: A. Pollack Presenter's Affiliation: UT MD Anderson Cancer Center, Houston, TX Type of Session: Scientific Background Abnormal expression of certain proteins have been found to alter the normal process of dying, or apoptosis, in cells. To date, there is little data correlating the presence of these proteins with outcome after radiation |
| Patterns of Local Regional Failure in Head and Neck Cancer Treated with IMRT Presenter: Tran, BN Presenter's Affiliation: Mallinckrodt Institute of Radiology, Radiation Oncology Center, Washington University Medical Center, St. Louis, MO Type of Session: Scientific Background Intensity modulated radiation therapy allows sparing of the parotid glands when treating head and neck cancer. However, the effect on local regional |
| A Phase II Trial of Subcutaneous Amifostine and Radiation Therapy in Patients with Head and Neck Cancer (WR-B060) Presenter: P. Anne Presenter's Affiliation: Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA Type of Session: Scientific Background Amifostine is an organic thiophosphate that protects normal tissues from the cytotoxic effects of radiation therapy (RT) and has been shown, in a Phase III trial of RT ± amifostine in head and |
| Treatment, Patient and Tumor Characteristics Impact Quality of Life (QOL) in Patients with Locally Advanced Head and Neck Cancer: Report of the Radiation Therapy Oncology Group (RTOG) Trial 90-03 Presenter: J. Fisher Presenter's Affiliation: Bon Secours Cottage Health Services, Grosse Pointe Farms, MI Type of Session: Scientific Background The RTOG 90-03 was a four-arm trial that enrolled patients with locally advanced head and neck cancer. This study evaluated the factors that could potentially affect the QOL for patients randomized to |
| Preliminary Report of Toxicity Following 3D Conformal Radiation Therapy (3DCRT) for Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 Gy) Presenter: J. Ryu Presenter's Affiliation: Rad Onc, UCD, Sacramento, CA Type of Session: Scientific Background The high rates of local relapse observed in prostate cancer patients with conventional radiation techniques have stimulated research to develop high precision radiation to decrease the risks of local recurrence. The three dimensional |
| Sildenafil (Viagra) and Erectile Dysfunction following Conformal Radiotherapy for Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Presenter: L. Incrocci Presenter's Affiliation: University Hospital Rotterdam-Daniel Type of Session: Scientific Background The incidence of Erectile Dysfunction (ED) following external beam radiation therapy is commonly reported as 35-45%. With the author's form of conformal therapy, the first 1/3 of the penis lies within the radiation field, |
| Treatment of Prostate Cancer with Radiotherapy: Should the Entire Seminal Vesicles be Included in the CTV Presenter: L.L. Kestin Presenter's Affiliation: William Beaumont Hospital Type of Session: Scientific Background Dose escalation (to upper 70s to >80 Gy) has been shown to be efficacious in the treatment of prostate cancer. With this escalation, patients will likely experience toxicity directly related to volume treated, and the inclusion of |
| Results of Whole Brain Radiation Therapy in Breast Cancer Patients with Brain Metastases Presenter: A.S. Mahmoud-ahmed Presenter's Affiliation: Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH Type of Session: Scientific Background Brain metastasis is the most common neurologic complication experienced breast cancer patients. Whole brain irradiation is a known methods of palliation for these lesions. Some previous |
| Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from INT 0114 Presenter: M O'ConnellPresenter's Affiliation: National Intergroup TrialType of Session: ScientificBackground Although rectal cancer is usually an aggressive cancer, the resection of metastatic disease is thought to be efficacious. Although this thought is eminent among oncologists, there is little prospective data regarding the resection of |
| Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II & stage III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials Presenter: C.M. RibicPresenter's Affiliation: Lunenfeld Research InstituteType of Session: ScientificBackground Adding adjuvant chemoradiation therapy to resected T3-4 and N+ colon cancer increases survival, based on several large randomized studies. However, since these trials were completed, new information on the carcinogenesis of colon cancer |
| Cancer Patients in US Nursing Homes: Quality of End of Life Care Presenter: V.M.P. JohnsonPresenter's Affiliation: Brown University Medical SchoolType of Session: ScientificBackground As the American population ages, increasing numbers of Americans are receiving their end of life care in nursing homes. Little information has been published regarding care in these nursing homes. Materials and Methods Secondary |
| Weekly taxol (T) and carboplatin (P) as first-line therapy in advanced ovarian cancer (AOC): a phase II study Presenter: J. SehouliPresenter's Affiliation: North-East Society of Gynaecological Oncology (NOGGO), Berlin, GermanyType of Session: ScientificBackground Ovarian cancer often remains asymptomatic until it progresses to an advanced stage. This causes delay in diagnosis until patients have advanced disease. Therefore, chemotherapy remains an |
| Parenteral Opioid Rotation in Advanced Cancer Presenter: F.A. MahmoudPresenter's Affiliation: Cleveland Clinic FoundationType of Session: ScientificBackground Opioid side effects sometimes can limit upward titration of dosage to levels adequate for effective pain relief. Opioid rotation, utilizing equianalgesic amounts of medication, has been reported as efficacious in these situations. |
| Phase III Quality Of Life (QOL) Study: Reduction In Hyposalivation Does Not Improve Qol For Head And Neck (H&N) Cancer Patients Post Radiation Therapy (P-Rt). Rtog 9709 Presenter: Jacquelyn J FisherPresenter's Affiliation: RTOGType of Session: ScientificBackground When radiation therapy treatment fields include the major salivary glands, many patients will experience dryness of the oral mucosa during the first 1 or 2 weeks of treatment. Not only is the quantity of saliva reduced, but its composition and physical |
| Issues in the Access of Promising New Cancer Agents "Miracle Cure for Cancer," "New Drug Gives Hope to Cancer Patients". Headlines like these make us cringe as health professionals, but are reported in the media on a daily basis, playing on the desperation of many cancer patients. Often times, patients do not hear that a drug or test is still in early development, or the bad outcomes that were |
| Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy versus 78 Gy, in preventing biochemical and/or clinical relapse of prostate cancer. Materials and Methods Of 301 |
| Caelyx (Ca) And Carboplatin (Pa) In Patients With Advanced Ovarian Cancer In Late Relapse (> 6 Months) (AOCLR): A GINECO Phase II Trial Presenter: JM FerreroPresenter's Affiliation: GINECO, Paris, FranceType of Session: PosterBackground Previous studies have demonstrated that patients with ovarian cancer who have a time-to-relapse interval > 6 months retain sensitivity to platinum-derivatives Caelyx (Ca, doxil) is a liposomal doxorubicin that has been shown to be as effective as |
| Weekly Erythropoietin For Patients With Chemotherapy Induced Anemia: A Randomized, Placebo-Controlled Trial In The North Central Cancer Treatment Group Presenter: Peter T SilbersteinPresenter's Affiliation: The North Central Cancer Treatment Group RTOGType of Session: ScientificBackground Anemia occurs in a significant number of patients with cancer, and is associated with symptoms of fatigue, dizziness, headache and decreased health-related quality of life (QoL). Clinical trials have |
| Prostate Cancer Radiation Dose Response: Final Planned Analysis Of A Phase III Randomized Trial Presenter: Alan PollackPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: PosterBackground Between 1993 and 1998, a randomized trial at MDACC was conducted to assess the effectiveness of two radiotherapy doses, 70 Gy versus 78 Gy, in preventing biochemical and/or clinical relapse of prostate cancer Materials and |
| Cetuximab (C225) Plus Irinotecan (CPT-11) Plus Infusional 5FU/Folinic Acid (FA) is Safe and Active in Metastatic Colorectal Cancer (MCRC) that Expresses Epidermal Growth Factor Receptor (EGFR) Presenter: P. SchoffskiPresenter's Affiliation: Hannover Medical School (Hannover, Germany)Type of Session: PosterBackground EGFR is a transmembrane glycoprotein receptor overexpressed in many human solid tumors. EGFR is a mediator of intracellular signals involved in cancer growth/metastatic spread. C225 is one of a few monoclonal antibodies |
| Lymphatic Mapping And Sentinel Lymph Node Sampling In Breast Cancer: A Meta-Analysis Presenter: T. KimPresenter's Affiliation: Albany Medical CenterType of Session: ScientificBackground Sentinel lymph node sampling (SLNS) in breast cancer has become a common practice There is a lack of randomized clinical trials comparing SLNS to standard axillary lymph node dissection in the staging of breast cancer. This trial was designed to |
| Phase III Trail Comparing TAC (docetaxel, dosorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 Study Presenter: J-M NabholtzPresenter's Affiliation: Breast Cancer International Research Group (BCIRG)Type of Session: ScientificBackground Doxorubin and cyclophosphamide, with or without 5-fluorouracil, are standard chemotherapy agents in the adjuvant treatment of node positive breast cancer. Taxanes are a novel class of chemotherapeutic agents with |
| A Phase II Trial of Celecoxib (CX), Irinotecan (I), 5-Fluorouracil (5FU), and Leucovorin (LCV) in Patients with Unresectable or Metastatic Colorectal Cancer (CRC) Presenter: C.D. BlankePresenter's Affiliation: Oregeon Health Sciences UniversityType of Session: ScientificBackground Previous studies have shown that cyclooxygenase-II (COX-2) is present in the majority of CRCs, with expression associated with worse prognosis. Celecoxib is a selective COX-2 inhibitor which has demonstrable anti-angiogenesis |
| Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Presenter: L. SaltzPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground In a previous trial (reported at ASCO last year), IMC-C225, in combination with CPT-11, was demonstrated to have a 22.5% response rate in 120 patients with CRC refractory to CPT-11 treatment. A tumor xenograft model of |
| Incorporating Angiogenesis Inhibition with Bevacizumab (anti-VEGF) into Frontline Chemotherapy with Irinotecan (CPT-11), Fluorouracil and Leucovorin (FU/LV) for Advanced Colorectal Cancer (advCRC): A Toxicity Analysis of ECOG Study E2200 Presenter: B.J. GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Anti-angiogenesis therapy has received much publicity recently. Such molecularly-targeted therapies hold promise as the next wave of directed therapies against cancer. Early studies of these therapies have held some promise, but more |
| Cetuximab (IMC-C225) plus Weekly Irinotecan (CPT-11), Fluorouracil (5FU), and Leucovorin (LV) in Colorectal Cancer (CRC) that Expresses the Epidermal Growth Factor Receptor (EGFR) Presenter: Arthur RosenbergPresenter's Affiliation: The Bendheim Cancer Center of Greenwich Hospital, ConnecticutType of Session: PosterBackground Previous studies have shown that increased expression of Epidermal Growth Factor Receptor (EGFR) conveys an unfavorable prognosis in multitude of cancers, including colorectal cancer. Cetuximab |
| A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus Presenter: B. H. BurmeisterPresenter's Affiliation: Trans Tasmanian Radiation Oncology Group, Australasian Gastrointestinal Trials Group, and Clinical Trials Centre, Sydney, AustraliaType of Session: ScientificBackground Previous randomized studies have suggested a role for pre-operative chemoradiation in the treatment of esophageal cancer, not |
| Efficacy and Tolerability of Two Dosing Regimens of R115777 (Zarnestra), a Farnesyl Protein Transferase Inhibitor, in Patients with Advanced Breast Cancer Presenter: Stephen R. JohnstonPresenter's Affiliation: Royal Bournemouth Hospital, Bournemouth, UKType of Session: ScientificBackground Farnesylation is a process that activates proteins involved in growth factor dependent signal transduction pathways. Farnesyl transferase inhibitors are a novel class of agents that specifically block this process. |
| Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) Presenter: L. BedennePresenter's Affiliation: Sevice de Hepato-Gastroenterologie-Chu-Le Bocage, Dijon-Cedex, FranceType of Session: ScientificBackground While surgical resection remains part of the standard of care for locally advanced esophageal cancer, non-randomized studies have demonstrated outcomes for radiochemotherapy alone that are |
| Survival and Long-Term Toxicity Results in the SCOTROC Study: Docetaxel-Carboplatin (DC) vs. Paclitaxel-Carboplatin (PC) in Epithelial Ovarian Cancer (EOC) Presenter: P.A. VaseyPresenter's Affiliation: Scottish Gynaecological Cancer Trials GroupType of Session: ScientificBackground The Scottish Gynaecological Cancer Trials Group undertook a study of DC vs. PC in FIGO stage 1C-4 EOC. Data presented at ASCO last year demonstrated equivalent response rates in both arms. However, it was noted the DC |
| p21 and p53 as prognostic factors for bladder preservation and survival in patients with bladder cancer treated with neoadjuvant chemotherapy Presenter: Garcia Del MuroPresenter's Affiliation: Institut Catala d'Oncologia-Ciutat Sanitaria de BellvitgeType of Session: ScientificBackground Muscle invasive cancer has traditionally been treated with cystectomy. However, more recently, combined chemoradiation has been used as a bladder sparing regimen in selected patients. This study |
| Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer Presenter: R.R. HallPresenter's Affiliation: MRC Clinical Trials UnitType of Session: ScientificBackground Muscle-invasive bladder cancer continues to have a high rate of failure, with the majority with distant metastases. The use of chemotherapy, both in the adjuvant and neoadjuvant setting has been used to try to increase survival and decrease |
| Protective Effect Of Vitamin E (VE ) In Head And Neck Cancer Radiation Induced Mucositis: A Double-Blind Randomized Trial Presenter: Paulo R FerreiraPresenter's Affiliation: Hospital de Clinicas de Porto Alegre, Porto Alegre, BrazilType of Session: ScientificBackground Vitamin E is the most important antioxidant in the human body It scavenges free radicals and prevents lipid membrane peroxidation Vitamin E has been proposed as a potential radioprotectant agent A |
| The Epidemiology and Economics of Neutropenia in Hospitalized Adult Cancer Patients: Data From the University HealthSystem Consortium Presenter: Gary H. Lyman Presenter's Affiliation: Albany Medical College Type of Session: Poster Background Neutropenia is a common toxicity of conventional chemotherapy accounting for a large percentage of inpatient hospital expenditures, particularly when neutropenia related fever results. Febrile neutropenia patients generally require |
| Third International Laryngeal Cancer Conference: Call for Posters maxwords){ alert("Sorry, but you have exceeded the 150 word limit. Please reduce the length of your abstract. Thank you.") return false } } //--> This conference is supported by an educational grant from eMedicine.com. Call for Posters The deadline for receipt of abstracts is Wednesday, May 15, 2002. The Abramson Cancer |
| New Targets and Innovative Strategies in Cancer Treatment: A course for clinicians Conference Dates: February 13-14, 2004 Conference Location: Monte Carlo, Monaco Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Topics Covered: Introduction (Intracellular communication and signaling, Why cancer cells proliferate, Growth factors and growth factor receptors in normal |
| Fourth International Laryngeal Cancer Conference Date: March 11-12, 2004 Location: Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. Sponsors: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Who Should |
| Emerging Cancer Treatment Modalities Conference Dates: March 21-23, 2004 Conference Location: Copper Mountain Colorado Sponsoring Group: University of S. Florida and Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu/promotions/modalities Topics Covered: Molecular targeted therapies, clinical drug resistance, immunotherapy, functional genomics, stem cells |
| Path to Wellness: Coping with Nutrition, Weight and Fitness Issues Related to Breast and Gynecoloical Cancers Conference Dates: Wednesday, March 10, 2004 Conference Location: PENN Medicine at Radnor, 250 King of Prussia Road, Radnor, PA Sponsoring Group: Abramson Cancer Center Topics Covered: Women who have had treatment for breast and gynecologic cancers often find themselves coping with health issues such as weight gain and changes in strength |
| 5th Annual Focus on Gynecologic Cancers Conference Dates: Friday, April 2, 2004 Conference Location: Adam's Mark Hotel, City Avenue and Monument Road, Philadelphia, PA Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Agenda: A Conference for Women Whose Lives Have Been Touched by Gynecologic Cancer. Registration Information: To |
| Breast Cancer Genetics: What You and Your Family Need to Know Conference Dates: April 24, 2004, 9:00 a.m.-12:00 p.m. Conference Location: Philadelphia Marriott West, West Conshohocken, PA Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org Topics Covered: Two cancer genetics experts from the University of Pennsylvania will address questions and concerns about breast |
| World Congress on Gastrointestinal Cancers Formerly PICC - Perspectives in Colorectal Cancer Conference Dates: June 17-19, 2004 Conference Location: Barcelona, Spain Sponsoring Group: Imedex Conference Web Page URL: www.picccongress.com Registration Information: Online at www.imedex.com, tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com Continuing |
| World Congress on Gastrointestinal Cancer Conference Dates: June 15-18, 2005 Conference Location: Barcelona, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.worldgicancer.com Conference Agenda: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| WCRF/AICR International Research Conference on Food, Nutrition, and Cancer Conference Dates: July 15-16, 2004 Conference Location: Washington DC Sponsoring Group: World Cancer Research Fund International and American Institute for Cancer Research Conference Web Page URL: www.aicr.org/conference/ Topics Covered: Energy Restriction and Physical Activity Phytochemicals, Vitamins: Interactions and Effects |
| 6th International Conference on Head and Neck Cancer Date: August 7-11, 2004 Location: Washingotn DC, USA Symposium Web Page: www.headandneckcancer.org Sponsors: The American Head and Neck Society Who Should Attend: Recent Doctorates or mid career investigators (PhD, DrPH, MD, DNS, SCD or equivalent) Objectives: Develop an understanding of current issues in the diagnosis in |
| The 4th European Conference: Perspectives in Breast Cancer Conference Dates: September 23-25, 2004 Conference Location: Madrid, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| The 4th Princess Margaret Hospital Conference on New Developments in Cancer Management Conference Dates: September 22-24, 2004 Conference Location: Toronto, Ontario, Canada Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| The 5th Annual Prespectives on Colorectal Cancer Conference Dates: September 10-11, 2004 Conference Location: Chicago, Illinois Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| Life After Breast Cancer Conference Date: September 11, 2004 Location: Adam's Mark Hotel, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Who Should Attend: Breast cancer survivors and their loved ones Conference Objectives: Patient Education Conference Fees: $20 Continuing Education: No *Required *Name: Street |
| Utilizing Integrative Medicine Throughout the Cancer Journey: A Conference for Patients, Survivors and Healthcare Professionals Conference Dates: September 27, 2004Conference Location: Hyatt Regency Philadelphia at Penns Landing Sponsoring Group: Leukemia & Lymphoma Society and Lance Armstrong Foundation Conference Web Page URL: www.lls.org/epa/edprogram Topics Covered: Finding Hope in Integrative Medicine; Mindfulness-Based approaches to well-being; reiki, music |
| Frankly Speaking About Cancer Treatment Conference Dates: September 18, 2004 Conference Location: The Wellness Community of Philadelphia Sponsoring Group: Amgen Conference Web Page URL: www.twcp.org Topics Covered: Prevent and manage symptoms and side effects. Strengthen the partnership with the health care team Feel more in control by using strategies that integrate mind, body |
| Molecular Targets for Cancer Therapy Conference Dates: October 1-5, 2004 Conference Location: Don Cesar, St. Petersburg Beach, FL Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu/promotions Topics Covered: The purpose of this meeting is to foster exchange of the most recent findings and ideas in molecular targets for cancer therapy. |
| The 9th International Conference on Geriatric Oncology: Cancer in the Elderly. The 5th Meeting of SIOG. Conference Dates: October 15-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: SIOG Conference Web Page URL: www.cancerworld.org/siog/default.asp Registration Information: Online at www.imedex.com, tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com |
| The 10th Conference on Cancer therapy with Antibodies and Immunoconjugates Conference Dates: October 21-23, 2004 Conference Location: Princeton, NJ Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| The 10th Annual Perspectives in Breast Cancer Conference Dates: October 15-16, 2004 Conference Location: Boston, MA Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| The 9th International Conference on Geriatric Oncology: Cancer in the Elderly. The 5th Meeting of SIOG Conference Dates: October 14-16, 2004 Conference Location: San Francisco, CA Sponsoring Group: International Society of Geriatric Oncology Conference Web Page URL: www.cancerworld.org Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| Thyroid Cancer Survivors' 7th International Conference Conference Dates: October 22-24, 2004 Conference Location: Hyatt Deerfield Hotel, 1750 Lake Cook Road, Deerfield, IL 60015 Sponsoring Group: ThyCa: Thyroid Cancer Survivors' Association, Inc. Conference Web Page URL: www.thyca.org Topics Covered: Thyroid cancer research advances and care, including testing, treatment, short-term follow-up, |
| Keystone Breast Cancer Conference Conference Dates: October 6, 2004 Conference Location: Harrisburg Hilton Sponsoring Group: PA Breast Cancer Coalition Conference Web Page URL: http://www.pabreastcancer.org/kbcc.html Topics Covered: "Grand Rounds for Medical Professionals: Breast Conservation Treatment for Early Stage Breast Cancer and Ductal Carcinoma In Situ (DCIS)" "The |
| Translational and Therapeutic Advances in Colorectal Cancer Conference Dates: October 28-30, 2004 Conference Location: New York, NY Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: Individualizing Drug Therapy / Pharmacogenomics EGFR-Targeted Therapies in Colorectal Cancer Targeting Angiogenesis in Colorectal Cancer Optimizing Chemotherapy |
| The 4th European Conference: Perspectives in Bladder Cancer Conference Dates: November 12-13, 2004 Conference Location: Seville, Spain Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes |
| Prognosis After Regional Nodal Recurrence in Patients With Stage I-II Breast Cancer Treated With Breast Conservation Therapy Presenter: Eleanor HarrisPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Regional nodal recurrences as first sites of failure are rare in early stage breast cancer treated with breast conservation therapy (BCT). They have been reported as first sites of failure in 1-3% of patients, with prognosis after this |
| Correlates of Distant Metastasis and Death in Prostate Cancer Patients Treated with Radiotherapy Presenter: Pollack, AlanPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Prostate cancer is a slow growing disease that requires a long follow-up to determine data on survival. Due to this phenomenon, many patients die of intercurrent disease unrelated to prostate cancer. Therefore, other endpoints are used, |
| Biochemical Relapse Free Survival After External Beam Radiotherapy for Clinical Stage T1-3 Prostate Cancer in the PSA Era: What Should We Expect Presenter: Kuntia, DeepakPresenter's Affiliation: Cleveland ClinicType of Session: ScientificBackground Past studies in prostate cancer reflecting on Relapse Free Survival (RFS) have done so using the development of symptoms-either local or distant (usually by bone pain). It has differed as to whether this included radiographic evidence of disease |
| Monotherapy for Stage T1/T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Prostate Brachytherapy Presenter: L. PottersPresenter's Affiliation: Department of Radiation Oncology, Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, NY, USAType of Session: ScientificBackground Tumors confined to the prostate, stages T1-2N0 are generally managed by radical surgery or radiation therapy. Controversies exist as to the optimal mode of |
| A Randomized Prospective Trial of Sequential Neutron - Photon vs. Photon-Neutron Irradiation in Organ Confined Prostate Cancer Presenter: J. FormanPresenter's Affiliation: Department of Radiation Oncology, Wayne State University, Detroit, MI, USAType of Session: ScientificBackground Fast neutrons have been examined as a potential modality to improve the results of therapy for organ confined prostate cancer. The biologic properties of neutrons differ from conventional |
| Should We Treat the Regional Nodes in Patients with Skin Cancer of the Head and Neck with Perineural Invasion
Presenter: A. Garcia-SerraPresenter's Affiliation: Department of Radiation Oncology, University of Florida, Gainesville, FL, USAType of Session: ScientificBackground Once the decision to treat a patient with radiation therapy has been made, the next most important isuue is to dermine what area to treat. While increasing the size of the radiation |
| Automated Delineation of Regional Target Volumes for Patients with Head and Neck Cancer Treated Conformally
Presenter: J. BarkerPresenter's Affiliation: Department of Radiation Oncology, University of Washington, Seattle, WA, USAType of Session: ScientificBackground One of main challenges in designing radiation treament fields is accurately identifying anatomic structures on planning radiographs. This issue is becoming even more important when conformal |
| Target Volume Delineation in Intensity-Modulated Radiation Therapy (IMRT) for Head and Neck Cancer and Correlation With Patterns of Failure Presenter: Lee, NancyPresenter's Affiliation: Dept of Radiation Oncology, Univ of California-San Francisco Medical Center, San Francisco, CAType of Session: ScientificBackground IMRT delivers highly focused radiation that closely conforms to the three-dimensional shape of the tumor being treated. Accurate delineation of the diseased tissues is |
| Radiation Therapy With or Without Chemotherapy for Cervical Cancer With Periaortic Lymph Node Metastases Presenter: Saad, AymanPresenter's Affiliation: Wayne State UniversityType of Session: ScientificBackground Several large randomized studies have demonstrated increased local control and overall survival in patients with cervical cancer. However, patients with documented spread to the paraaortic lymph nodes have not been actively investigated. |
| Pelvic Radiation With Concurrent Chemotherapy versus Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer: An Update of RTOG 90-01 Presenter: Patricia EifelPresenter's Affiliation: RTOGType of Session: PlenaryBackground There have been several studies documenting the efficacy of chemoradiation over radiation alone in the treatment of locally advanced cervical cancer. One of these studies, published in the NEJM in 1999, was RTOG 90-01, which randomized patients between |
| Screening Mammography Is Associated with Earlier Stage Disease and Greater Eligibility for Breast Conservation in Women Aged 40 and Older with Breast Cancer Presenter: G.M. FreedmanPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PA, USAType of Session: PlenaryBackground No cancer screening test has been studied more than mammography. Yet, after more than 35 years of trials, many questions remain regarding at what age and at what interval women should be screened. Currently, screening |
| Patterns of Failure for Resected Advanced Head & Neck Cancer Treated by Concurrent Chemotherapy and Radiation Therapy: An Analysis of RTOG 9501/Intergroup Phase III Trial Presenter: Jay CooperPresenter's Affiliation: New York University Medical Center, New York, NYType of Session: PlenaryBackground The most common failure after grossly or microscopically complete surgical resection and post-operative radiation therapy for advanced cancers of the head and neck is local-regional recurrence. This study evaluates |
| Larynx Preservation and Tumor Control in Stage III and IV Laryngeal Cancer: A Three-Arm Randomized Intergroup Trial; RTOG 91?11 Presenter: Moshe MaorPresenter's Affiliation: M. D. Anderson Cancer Center, Houston, TXType of Session: PlenaryBackground Previously, the Veterans Administration evaluated whether irradiation of patients who respond to induction chemotherapy could safely preserve the larynx in patients with stage III and low-volume stage IV glottic and supraglottic |
| Brachytherapy Versus Brachytherapy Plus Beam Radiation for Prostate Cancer: Morbidity Outcomes from Two Prospective Randomized Multicenter Trials
Presenter: M. GhalyPresenter's Affiliation: Department of Radiation Oncology, New York Methodist Hospital, Weill Medical Collage-Cornell UniversityType of Session: ScientificBackground Localized prostate cancer is typically treated with surgery or radiation therapy. Forms of radiation therapy include external beam, brachytherapy(implantation of |
| Eighteen-Year Results in the Treatment of Early-Stage Breast Cancer With Breast Conservation Versus Mastectomy Presenter: Matthew PoggiPresenter's Affiliation: Radiation Oncology Branch, NCI, Bethesda, MDType of Session: ScientificBackground Several randomized clinical trials comparing conservative surgery followed by whole breast irradiation to mastectomy for patients with early stage breast cancer have reported long-term outcomes. These studies include |
| Long-Term Outcome by Risk Factors Using Conformal High Dose Rate Boost for Prostate Cancer Presenter: R. GalalaePresenter's Affiliation: Dept. of Radiation Oncology, Kiel University, GermanyType of Session: ScientificBackground Radiation therapy is widely used in the treatment of prostate cancer. Forms of this treatment include external beam radiation or brachytherapy, or a combination of the two. With brachytherapy, radioactive seeds |
| Pathologic Evidence of Dose-Response and Dose-Volume Relationships for Prostate Cancer Treated with Combined External Beam Radiotherapy and High-Dose-Rate Brachytherapy Presenter: L. KestinPresenter's Affiliation: Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USAType of Session: ScientificBackground There has been a long-running debate as to if prostate biopsies should be obtained following radiation therapy. In this study, investigators performed a detailed pathologic review of |
| Accelerated Partial Breast Irradiation Via Interstitial Brachytherapy as the Sole Radiation Modality for Treatment of Early-Stage Breast Cancer Presenter: Peter Y. ChenPresenter's Affiliation: Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground In several randomized clinical trials BCT including whole breast irradiation has been found to yield equivalent survival rates when compared to mastectomy in patients with early carcinoma |
| The Value of Adding Radiation to Tamoxifen in Post-Menopausal Women with Stage I Breast Cancer: A Decision Analysis Presenter: R.S. PungliaPresenter's Affiliation: Joint Center for RadiationTherapyType of Session: ScientificBackground Large randomized trials have proven that radiation therapy (RT) decreases local recurrence in post-lumpectomy patients with breast cancer. However, the effect on the development of distant metastases and overall survival is less |
| The Hazards of Dose Escalation in Prostate Cancer Radiation Presenter: D.A. KubanPresenter's Affiliation: Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX, USAType of Session: ScientificBackground Numerous previous studies have suggested that there is a dose-response relationship with radiation therapy (RT) used in the treatment of prostate cancer. The current study analyzes the |
| Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 9406 Dose Level IV Presenter: J.M. MichalskiPresenter's Affiliation: Dept. of Radiation Oncology, Washington University Medical School, St. Louis, MO, USAType of Session: ScientificBackground Numerous previous studies have suggested that there is a dose-response relationship with radiation therapy (RT) used in the treatment of prostate cancer. This study is a |
| Phase III Trial of Conformal Radiotherapy Following Neoadjuvant Hormone Treatment in Early Prostate Cancer Presenter: Alan HorwichPresenter's Affiliation: The Royal Marsden Hospital & Institute of Cancer Research, Sutton & London, UKType of Session: ScientificBackground There is evidence that a short course of neoadjuvant hormone therapy (NHT) prior to standard dose radiotherapy (RT) can increase local control in patients with clinically localized |
| Does Short-Term Androgen Deprivation Substitute for Radiation Dose in the Treatment of High Risk Prostate Cancer Presenter: Khanh H. NguyenPresenter's Affiliation: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PAType of Session: ScientificBackground There are several randomized trials that confirm a clinical and/or biochemical benefit with the use of androgen deprivation (AD) as a component of treatment in high risk prostate cancer, |
| Prevalence and Management of Anemia in Patients with Hematologic Malignancies and Solid Tumors: Results from the European Cancer Anemia Survey (ECAS) Presenter: Heinz LudwigPresenter's Affiliation: ECAS Advisory BoardType of Session: PosterBackground Anemia (hgb Large randomized trials show that correction of anemia leads to symptom improvement and improved quality of life (QOL). Unfortunately, the majority of anemic cancer patients receive no treatment for their anemia. (ASH/ASCO guidelines |
| Quality of Life, Blood Transfusions, and Toxicity, in Anemic Patients with Advanced Cancer Receiving Weekly Erythropoietin While on Chemotherapy: Results from a Phase III Randomized Double-Blind Placebo-Controlled Study. Presenter: Jeff A. SloanPresenter's Affiliation: Mayo ClinicType of Session: PosterBackground Anemia is obviously a large problem in the population of patients who are receiving chemotherapy. This anemia is likely amplified in those patients with advanced cancer. Anemia causes fatigue and jointly affects patients' quality of life (QOL). |
| Pulmonary radiological-, physiological-, and clinical side-effects after adjuvant radiotherapy in breast cancer Presenter: P.A. LindPresenter's Affiliation: Karolinska Institute, SwedenType of Session: PosterBackground Adjuvant radiation therapy used in the treatment of breast cancer has been shown to decrease cancer deaths However, toxicity from radiation therapy leads to an increase in deaths from other causes At least some of these increased deaths are |
| Randomized Phase III Study of I.V. Vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone refractory prostate cancer (HRPC) Presenter: R.P AbrettPresenter's Affiliation: Groote Schuur Hospital, Cape Town, South AfricaType of Session: ScientificBackground Vinorelbine has been shown to be active in hormone refractory prostate cancer. Controversy exists regarding the proper palliative management of hormone refractory patients who have failed first line hormonal therapy |
| Two year survival for Concurrent Carboplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Unresectable Head and Neck Cancer. Presenter: D. CarterPresenter's Affiliation: US Oncology, Houston TXType of Session: PosterBackground Several randomized trials and meta-analyses have shown superior local control, disease-free and overall survival for simultaneous chemoradiotherapy compared with radiation alone for patients with locally advanced head and neck cancers. Recent |
| Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. Presenter: A. V. D'AmicoPresenter's Affiliation: Dana-Farber Cancer InstituteType of Session: ScientificBackground Various algorithms using pre-treatment risk groups to predict for PSA failure in prostate cacner patients currently exist, namely through single-institution studies by Roach et al and D'Amico, et al. The three main components of these |
| Paclitaxel (T) following doxorubicin/cyclophosphamide(AC) as adjuvant chemotherapy for node positive breast cancer: Results from NSABP B-28 Presenter: E. P. MamounasPresenter's Affiliation: NSABPType of Session: ScientificBackground This prospective randomized trial intended to determine whether the addition of T to AC chemotherpy provided a benefit in node positive patients with operable breast cancer. Though definitive data regarding the benefit of adjuvant taxanes in node |
| Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy Presenter: M. G. Le ArriagadaPresenter's Affiliation: Institut Gustave-RoussyType of Session: ScientificBackground Premenopausal women with early breast cancer receive a significant reduction in overall mortality from adjuvant ovarian suppression (AOS) following surgery, approximately 24% (+/- 7%). However, in the presence of adjuvant chemotherapy, |
| Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101) Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive breast cancer are a topic of much research. The benefit of chemotherapy in node-positive breast |
| The impact of concurrent versus sequential tamoxifen and radiation therapy in breast cancer patients undergoing breast conservation therapy. Presenter: Vasathi J. ChristnesenPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Hormonal Therapy plays an important role in the adjuvant therapy of breast cancer patients. The optimal sequencing of tamoxifen therapy and radiation (XRT) is not well established. This study was conducted in order |
| Ten-Year outcomes for elderly women treated with breast-conserving surgery and definitive breast irradiation for early stage breast cancer. Presenter: Sandra L. UrtishakPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Breast cancer is a major cause of morbidity and mortality among elderly women, but it is not well studied in this population. Older women are more often under treated by conventional criteria when compared with younger |
| The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Presenter: S.K.L.ChiaPresenter's Affiliation: British Columbia Cancer AgencyType of Session: ScientificBackground Metastatic Breast Cancer is an extremely prevalent diagnosis. Median OS for these patients has historically been 12-24 months. No studies have shown population based data indicating improved survival with newer chemotherapeutic agents |
| Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leukovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV Presenter: S.R. SmalleyPresenter's Affiliation: SWOGType of Session: ScientificBackground 5-FU based chemoradiotherapy is standard post-operative management of T3-4N0 or node positive rectal cancer patients. Controversy regarding the optimal method of 5-FU delivery exists. The Intergroup 864751 trial suggested improved RFS and OS in patients |
| A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced non-nasopharygeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study Presenter: G FountzilasPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground The prognosis of locally advanced head and neck cancer (HNC) is poor. More than 50% of patients with locally advanced HNC will recur locally despite optimal treatment and another 15-20% will develop distant metastatic disease. |
| Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Presenter: D CunninghamPresenter's Affiliation: BOND InvestigatorsType of Session: ScientificBackground Cetuximab is a chimeric anti-EGFR monoclonal antibody that results in the blockade of EGF and TGF-alpha. The downstream results of this blockade results in modulation of reponse to chemotherapy, and effects on cell growth, differentiation, and |
| Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first-line therapy in subjects with metastatic CRC Presenter: H HurwitzPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground Vascular endothelial growth factor (VEGF) is frequently overexpressed in cancers and plays an important role in tumor angiogenesis. Bevacizumab (BV)is a recombinant, humanized monoclonal antibody that has direct action against VEGF. Phase II trials |
| Early Study Results Promising: Oral Medication Active Against Skin Cancer Abramson Cancer Center Research Presented at ASCO: Abstract #2854 FOR IMMEDIATE RELEASE (Saturday, May 31, 2003, Chicago, IL) - Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented early study results showing that a new kind of drug, a Raf kinase inhibitor, is well tolerated and may prove effective in |
| Surgical variables impact bladder cancer outcomes: A cooperative group report Presenter: H. HerrPresenter's Affiliation: Southwestern Oncology Group, IntergroupType of Session: ScientificBackground The use of neoadjuvant MVAC (methotrexate, vinblastine, adriamycin, cisplatin) followed by cystectomy was shown to be superior to cystectomy alone in patients with muscle invasive bladder cancer in the SWOG 87-10 (INT-0080) |
| Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs. radiochemotherapy in patients with locally advanced esophageal cancer) Presenter: F BonnetainPresenter's Affiliation: Federation Francophone de Cancerologie DigestiveType of Session: ScientificBackground FFCD 9102 was a randomized trial comparing chemoradiation + surgery versus chemoRT alone for locally advanced, but resectable esophageal cancer. The results were previously presented and showed no difference in |
| Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer Presenter: L PusztaiPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PlenaryBackground Multiple different chemotherapy regimens are used in the treatment of breast cancer. One common regimen involves neoadjuvant paclitaxel + FAC (5-FU, doxorubicin, and cyclophosphamide) (T/FAC) which offers modest benefit over FAC alone at |
| Surveillance of "high-risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial Presenter: C. K. KuhlPresenter's Affiliation: University of Bonn, GermanyType of Session: PlenaryBackground Hereditary breast cancer is associated with a high lifetime risk of developing breast cancer and a relatively early age of onset. As a result, early and intensive surveillance is typically recommended starting at age 30 years or at least 5 |
| MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC) Presenter: M. KriegePresenter's Affiliation: University Medical Center RotterdamType of Session: PlenaryBackground Women at high genetic or familial risk for breast cancer undergo careful surveillance. The value of screening in these women is unknown. MRI is a newer modality of breast cancer detection with high sensitivity. It may be able to |
| Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 9379397)
Presenter: W. AllumPresenter's Affiliation: Epsum General Hospital; Surrey, UKType of Session: ScientificBackground The combination of Epirubicin, Cisplatin and infusional 5-FU (ECF) has demonstrated increased RR and statistically significant benefit in advanced oesophagogastric cancer This trial was designed to determine if this benefit could be |
| A Phase III Trial comparing Gemcitabine plus Cisplatin vs. Gemcitabine alone in advanced pancreatic cancer Presenter: V. HeinemannPresenter's Affiliation: University of Munich; Munich, GermanyType of Session: ScientificBackground Pancreatic cancer has a very poor prognosis. Most patients are diagnosed in the metastatic stage. Median survival is 3-4 months with best supportive care. Single agent gemcitabine (Gem) has increased this MS to 5-6 |
| Patterns of Recurrence by Sequence of Chemotherapy and Radiotherapy in Early Stage Breast Cancer Presenter: Lori Pierce, M.D.Presenter's Affiliation: University of MichiganType of Session: ScientificBackground The impact of sequencing of chemotherapy and radiation therapy (RT) for breast conservation therapy (BCT) is unclear. A previous large randomized trial of the sequencing of chemotherapy and RT following surgery showed no difference in |
| A Randomized Trial Comparing Two Fractionation Schedules for Patients with Localized Prostate Cancer Presenter: H. LukkaPresenter's Affiliation: McMaster UniversityType of Session: PlenaryBackground Prostate cancer is the most commonly diagnosed cancer in men External beam radiation therapy is a potentially curative treatment for men with localized prostate cancer Most treatments involve a long course of radiation, with up to 8 weeks of |
| Ten-Year Results of Dose Escalation with 3-Dimensional Conformal Radiotherapy for Patients with Clinically Localized Prostate Cancer Presenter: Michael ZelefskyPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground Prostate cancer is the most commonly diagnosed cancer in men External Beam Radiotherapy is a potentially curative treatment for patients with localized disease There has been a trend of dose escalation in prostate cancer |
| Improved Sphincter Preservation of Low Rectal Cancer with High Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial Presenter: Jean Pierre GerardPresenter's Affiliation: Centre Antoine-Lacassagne, Nice, FranceType of Session: ScientificBackground Historically, the management of rectal cancer centered around extensive surgical resection, with local disease control being tantamount and sphincter preservation a low priority. Over the years, with the improvement in |
| Intramural Distal Spread of Rectal Cancer Following Preoperative Radiotherapy: The Results of a Multicentre Randomized Clinical Study Presenter: K. BujkoPresenter's Affiliation: Cancer Centre and Institute of Oncology, Warsaw, PolandType of Session: ScientificBackground Preoperative radiotherapy regimens have generally followed one of two basic schema: 5 fractions of 5 Gy each, followed by immediate surgery, as was employed in the only rectal cancer study to show a survival |
| The Impact of Regional Nodal Radiation In Patients With Early-Stage Breast Cancer with Clinically Negative Nodes Treated with Breast-Conserving Therapy Presenter: T. VuPresenter's Affiliation: CHUQ, Pavillon Hotel-Dieu de QuebecType of Session: ScientificBackground Breast cancer is the most common cancer in women Axillary dissection is often part of breast conservation therapy (BCT) because it can decrease axillary recurrence, it helps with staging and prognosis, it guides medical oncologists in |
| IMRT for Head and Neck Cancer: Updated Clinical Results Moderator: Theodore L. Phillips, MD., University of California, San Francisco Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center, New York Approximately 150 papers have reported on the outcomes of H&N cancer patients treated with IMRT. The primary endpoints for these trials usually are rates of xerostomia and local control. It is |
| Analysis of Local Failure After Breast Conserving Therapy for Locally Advanced Breast Cancer Presenter: Eugenio F. Vines, MDPresenter's Affiliation: Instituto de Radiomedicina, Santiago, ChileType of Session: ScientificBackground Locally advanced breast cancer remains a large problem in developing countries. The standard treatment for LABC remains mastectomy; however, in Chile, patients with LABC who achieve adequate response to |
| International Research Conference on Food, Nutrition and Cancer Conference Dates: July 14-25, 2005 Conference Location: Washington, DC Sponsoring Group: World Cancer Research Fund International/American Institute for Cancer Research Conference Web Page URL: www.wcrf.org/home/2005_conference.lasso Topics Covered: Life Course Approach to Cancer Phytochemicals and Nutritional Interactions |
| Targeted Therapies for the Treatment of Breast Cancer Conference Dates: July 6-9, 2005 Conference Location: Dana Point, California Sponsoring Group: The CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/currentactivities.asp Topics Covered: Statement of Need: Rationally designed target-based therapies beyond those targeting the estrogen |
| 5th Annual Conference for Young Women Affected by Breast Cancer Conference Dates: February 19-20, 2005 Conference Location: Pennsylvania Convention Center, Philadelphia Sponsoring Group: Living Beyond Breast Cancer and the Young Survival Coalition Conference Web Page URL: www.youngsurvivorsconference.org Topics Covered: This program is the only international educational conference focused on the critical |
| Current Concepts in the Management of Colorectal Cancer Conference Dates: Friday, February 25, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Brochure: View the full conference brochure as a PDF. You will need Adobe Acrobat Reader which is available free online. |
| Breast Cancer: When Taking Care Means Taking Charge Conference Dates: March 5, 2005 Conference Location: San Francisco Sponsoring Group: Northern California Cancer Center Conference Web Page URL: www.nccc.org Topics Covered: treatment, research, side effect management, disability and insurance benefits, pain management, reconstructive surgery, intimacy and sexuality, quality of life |
| Practical Issues in Multidisciplinary Management of Breast Cancer: 29th Annual Symposium of the American Society of Breast Disease Conference Dates: April 14 - 16, 2005 Conference Location: Mandalay Bay Resort and Casino, Las Vegas, Nevada Sponsoring Group: American Society of Breast Disease Conference Web Page URL: www.asbd.org Topics Covered: Topics and Interactive Workshops to include: Is Breast MRI Ready for Prime Time? Oncoplasty in Partial Mastectomy |
| Fifth Annual New Strategies in Breast Cancer Conference Conference Dates: April 8-10, 2005 Conference Location: Philadelphia, PASponsoring Group: The Center for Biomedical Continuing Education)Conference Web Page URL: www.thecbce.com/futureprograms.aspTopics Covered: Optimizing Imaging Techniques in High-Risk Patients; Targeted Adjuvant Therapy: Where Do We Go From Here?; Genetic Susceptibility and |
| 7th Annual Changing Concepts in Breast Cancer Conference Dates: Friday, April 8, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania and the University of Pennsylvania School of Medicine Office of CME Conference Brochure: Changing Concepts in Breast Cancer Topics |
| Fostering Wellness in Cancer Survivorship Conference Dates: April 4, 2005 Conference Location: Seton Hall University, South Orange NJ Sponsoring Group: NJ Commission on Cancer Research/ Psychosocial and Nursing Advisory Group Topics Covered: Emerging Issues in Survivorship Research; Effective Surveillance and Monitoring; Psychosocial Adjustment to Survivorhsip; Challenging the notion |
| 9th Annual Cancer Survivors Conference Conference Dates: Saturday, April 30, 2005 Conference Location: Philadelphia, PA Sponsoring Group: American Cancer Society Conference Web Page URL: Conference Brochure Topics Covered: Survivorship; Exercise & Well-being; Spirituality; Integrative Nutrition; Dance/Movement Therapy; Caregivers; |
| Focus on Gynecologic Cancers Conference Dates: Friday, May 6, 2005, 8:30 AM to 4:00 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA 19131 Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Brochure: Focus on Gynecologic Cancers Topics Covered: Workshop Sessions: Restoring Vitality Taking |
| 4th World Conference on Breast Cancer Conference Dates: June 8-12, 2005 Conference Location: Halifax, Nova Scotia, Canada Sponsoring Group: The World Conference on Breast Cancer Foundation Conference Web Page URL: www.wbco.ca Who Should Attend: Survivors, family members, research scientists, clinicians Conference Agenda: Each day of the conference will expand on three key themes |
| Genitourinary Malignancies: Current Perspectives in Bladder, Kidney, and Testis Cancer Conference Dates: Friday, November 4, 2005 Conference Location: The Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Objectives: At the completion of this conference, participants should be able to: Identify risk factors in bladder |
| Emerging Technologies: Changing the Face of Cancer Care Conference Dates: October 28, 2005 Conference Location: NJ Performing Arts Center, Newark, New Jersey Sponsoring Group: Atlantic Health System, New Jersey Commission on Cancer Research Conference Web Page URL: nj.gov/health/ccr/documents/changingfacecancercare.pdf Topics Covered: Advances in understanding the epigenetic and molecular |
| 10th Annual Joint Cancer Conference of the Florida Universities Conference Dates: September 28-October 1, 2006 Conference Location: The Breakers, Palm Beach, FL Sponsoring Group: University of South Florida College of Medicine Conference Web Page URL: www.jcc-fl.org Topics Covered: The Business of Medicine Complementary Therapies Multidisciplinary Approach to Treating Cancer Clinical Trials for the Private |
| 5th International Symposium on Minimal Residual Cancer Conference Dates: September 11-14, 2005 Conference Location: Fairmont Hotel, San Francisco, CA Sponsoring Group: International Symposium on Minimal Residual Cancer Conference Web Page URL: www.ismrc.org Topics Covered: The Detection of Microscopic Disease in Breast Cancer: a Paradigm for Other Solid Tumors ICC- and PCR-based strategies |
| Fourteenth Annual Life After Breast Cancer Patient Conference Conference Dates: September 16, 2005 Conference Location: Hilton, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Objectives: Patient Education Who Should Attend: Breast Cancer Survivors and Their Loved Ones Conference Brochure: Life After Breast Cancer PDF Conference |
| Recent Clinical Advances in Pancreatic Cancer Conference Dates: September 28, 2005, 6:00pm Conference Location: Riva, 700 E. Grand Avenue/Navy Pier, Chicago, IL 60611 Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Who Should Attend: MDs and PAs Conference Agenda: Clinical Overview of Pancreatic Cancer Registration Information: Visit |
| Facing Prostate Cancer with Information & Support Conference Dates: Saturday September 24, 2005 Conference Location: Holiday Inn, Presidential Boulevard, Philadelphia, PA Sponsoring Group: American Cancer Society Conference Web Page URL: www.cancer.org Conference Objectives: Increase understanding of prostate cancer, treatment options, and managing side effects. Meet experts |
| Treatment of Cancer-Related Anemia Faculty Disclosure: Janice Gabrilove, M.D. Amgen - Research Support Ortho Biotech - Research Support, Speakers Bureau Berlex - Speakers Bureau Presenter: Janice Gabrilove, M.D. Affiliation: Mt. Sinai Hospital Cancer-related anemia is a very serious issue that often arises during the management of cancer patients. It has |
| PTK 787/ZK 222584: Clinical results with a novel angiogenesis inhibitor in colorectal cancer Faculty Disclosure: Peter J. O'Dwyer, M.D. Novartis - Research Support AstraZeneca - Consultant, Speakers Bureau Lilly - Consultant BMS - Consultant Bayer - Consultant, Speakers Bureau Sanofi - Consultant Cell Therapeutics - Consultant 3D - Speakers Bureau GSK - Speakers Bureau This presentation by Dr. O'Dwyer |
| Adjuvant Multimodality with Gemcitabine versus 5-Fluorouracil in Pancreatic Cancer: Status of U.S. Intergroup Trial Faculty Disclosure: William F. Regine, M.D. Nothing to Disclose Presenter: William F. Regine, M.D. Affiliation: University of Maryland Even with potentially curative resection, 5 year survival for pancreatic cancer patients is less than 20%. Approximately 25 years ago, the Gastrointestinal Study Group found a small survival advantage |
| Bevacizumab (Avastin) in Colorectal Cancer Faculty Disclosure: Daniel Haller, M.D. Roche - Research Support, Consultant OSI - Research Support Pfizer - Research Support, Consultant This presentation by Dr. Haller discusses the use of bevacizumab in the treatment of colorectal cancer which has not been approved by the FDA. Presenter: Daniel Haller, M.D. Affiliation: University |
| Alimta and Oxaliplatin in Colorectal Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant This presentation by Dr Hochster includes discussion on the use of pemetrexed in the treatment of colorectal cancer which has not been approved by the FDA Presenter: Howard S. Hochster, M.D. Affiliation: New York University Pemetrexed is a |
| Emerging Role of EGF (Epidermal Growth Factor) Receptor-Directed Therapy of Colon Cancer Faculty Disclosure: Howard S. Hochster, M.D. Lilly - Consultant AstraZeneca - Consultant In this presentation by Dr. Hochster there is discussion of cetuximab (C 225) and erlotinib (Tarceva) for the treatment of colorectal cancer which is not FDA approved and gefitinib (Iressa) for the treatment of colorectal cancer which is an off |
| Update on Gynecologic Oncology Group Studies in Ovarian Cancer Faculty Disclosure: Robert F. Ozols, MD This presentation by Dr. Ozols discusses the use of bevacizumab (Avastin), Erbitux (C225), and PS 341 for the treatment of ovarian cancer which is not approved by the FDA. Also discussed is the off label use of gefitinib (Iressa), thalidomide, and gemcitabine. The standard of care for FIGO stage I/II |
| Motexafin Gadolinium (MGd) and Concurrent Chemoradiation in Head and Neck Cancer Faculty Disclosure: David M. Brizel, MD In this presentation Dr. Brizel discusses the use of Motexafin Gadolinium (MGd)in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: David M. Brizel, MD Affiliation: Duke University Medical Center Approximately 60% of those patients diagnosed with head and neck |
| Paclitaxel and Platinum versus Platinum-based Chemotherapy in Relapsed Ovarian Cancer: ICON 4 Presenter: Jonathan A. Ledermann, MD Affiliation: University College, London, UK/ MRC The optimal second-line chemotherapy for platinum-sensitive patients with relapsed ovarian cancer is an issue of ongoing research. Despite advances in therapy over the years, there remain unacceptably high relapse rates in patients following initial |
| Adding Carboplatin to Trastuzumab/Paclitaxel in Her2+ Breast Cancer: An Update Presenter: Nicholas Robert, MD Affiliation: US Oncology Research Network The HER family of oncogenes are prevalent in breast cancers. This has allowed for the development of trastuzumab, a monoclonal antibody against the HER2 oncoprotein. Alone or with other agents, trastuzumab has improved survival of many patients with breast cancer that |
| Duration of Therapy for Ovarian Cancer: How Long is Enough? Presenter: David R. Spriggs, MD Affiliation: MSKCC New York, NY There are little scientific data available on the optimal duration of chemotherapy in the first-line treatment of ovarian cancer. As can be expected, there is even less information available on duration of treatment in recurrent disease, either in platinum-sensitive or |
| Epidermal Growth Factor Receptor Inhibitors in the Treatment of Head and Neck Cancer Faculty Disclosure: Merrill S. Kies, MD In this presentation by Dr. Kies there is discussion of C225 in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: Merrill S. Kies, MD Affiliation: MDACC The treatment of patients with squamous cell cancer of the head and neck (SCCHN) is challenging both for the |
| Cox-2 Hormonal Approaches for the Treatment and Prevention of Breast Cancer Faculty Disclosure: Paul E. Goss, MD, PhD In this presentation by Dr. Goss there is discussion of celecoxib for the treatment and prevention of breast cancer which is not approved by the FDA. Presenter: Paul E. Goss, MD, PhD Affiliation: Princess Margaret Hospital The advent of hormonal and chemotherapeutic agents has been a significant |
| Vaccines for Breast Cancer: Real Challenge or Reality? Faculty Disclosure: Nuhad K. Ibrahim, MD This presentation by Dr. Ibrahim discusses the use of the STn vaccine for the treatment of breast cancer which has not been approved by the FDA. Presenter: Nuhad K. Ibrahim, MD Affiliation: M.D. Anderson Cancer Center Vaccine mediated cancer therapies are theoretically attractive for many reasons: |
| Bevacizumab (Avastin) in Advanced Prostate Cancer Faculty Disclosure: Joel Picus, MDThis presentation by Dr. Picus discusses the use of bevacizumab in the treatment of prostate cancer which has not been approved by the FDA. Presenter: Joel Picus, MD Affiliation: Washington University School of Medicine Hormone refractory prostate cancer has a very aggressive natural history with reported |
| Clinical Updates and New Approaches: Hematologic Malignancies and GI Cancers Program Description and Objectives As our understanding of the underlying molecular abnormalities and pathogenesis of various cancers continues to grow, while simultaneously new chemotherapeutic agents and new biological "targeted agents" continue to proliferate, the ability of the clinical oncologist (i.e., those not focused on research) to |
| Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study Presenter: N. TchenPresenter's Affiliation: Princess Margaret Hospital, Toronto, CAType of Session: ScientificBackground Adjuvant chemotherapy is given to many beast cancer patients; however, it can result in significant toxicity A previous report from this group showed significantly increased fatigue and menopausal symptoms for women receiving |
| Irinotecan plus fluorouracil/leucovorin (IFL) verus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) This presentation discusses an off-label use of irinotecan in the treatment of colon cancer. Presenter: L.B. SaltzPresenter's Affiliation: CALGBType of Session: ScientificBackground Metastatic colorectal cancer is a disease in which the natural history can be markedly altered by the application of effective chemotherapy agents. First-line |
| Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. Presenter: J.-F. BossetPresenter's Affiliation: Besancon University Hospital, Besancon, FranceType of Session: ScientificBackground Preoperative radiation treatment is used frequently in cases of resectable rectal cancer due to the advantages of more precise tumor definition, decreased amount of irradiated normal tissue, pathological downstaging, |
| Long-term use of NSAID reduces the risk of oral cancer Presenter: J. SudboPresenter's Affiliation: Norwegian Radium Hosptial, Oslo, NorwayType of Session: ScientificBackground Oral cavity cancers are often associated with high rates of morbidity and mortality COX-2 may play a role in the development of squamous cell carcinomas (SCCA) of the head and neck Cycloxegenase-2 (COX-2) has been found to |
| Sentinel node staging of resectable colon cancer: Results of the CALGB 80001. Presenter: M. M. BertagnolliPresenter's Affiliation: Brigham and Women's Hospital, Boston, MAType of Session: ScientificBackground The most important predictor of outcome in resected colon cancer is the locoregional nodal status. Currently, there exists a population of conventionally evaluated node negative patients that performs |
| Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer Presenter: M. YoshimotoPresenter's Affiliation: Cancer Institute Hospital, Tokyo, JapanType of Session: ScientificBackground Many breast cancer patients receive chemotherapy as part of their treatment program A common chemotherapeutic agent used in breast cancer is paclitaxel Response to paclitaxel varies greatly from patient to patient |
| Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips The cDNA arrays and Gene Chips discussed in this study have not been approved by the FDA for use in patients. Presenter: Lajos PusztaiPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Gene profiling has increasingly been used in attempts to classify cancer into clinically-relevant subgroups |
| Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911) Presenter: M. BollaPresenter's Affiliation: CHR de Grenoble, Grenoble, FranceType of Session: ScientificBackground A significant number of patients with clinical T1-2N0M0 prostate cancer are treated with radical prostatectmy. However, after pathologic evaluation, some patients are found to have risk factors for local failure. |
| Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer. Presenter: M.R. SmithPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Several small retrospective studies have reported that GnRH agonists increase fracture risk in prostate patients. However, the studies have been limited by small sample size, short follow-up, and a potential recall bias. This |
| The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer Presenter: P.L. NguyenPresenter's Affiliation: Harvard Medical School/ University of PennsylvaniaType of Session: ScientificBackground It has been demonstrated that prolonged delay between cancer diagnosis and the start of radiation therapy (RT) is associated with decreased local control in head and neck cancer. This study sought to evaluate if a |
| SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) Presenter: D.P. PetrylakPresenter's Affiliation: SWOGType of Session: PlenaryBackground The present-day standard of care in the treatment of AIPCA patients consists of the combination of mitoxantrone and prednisone for palliation of disease-related symptoms. There is no remarkable survival benefit with the use of these agents, and thus the ultimate |
| A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer This article discusses non-FDA approved dosing of docetaxel Presenter: M.A. EisenbergerPresenter's Affiliation: TAX-327 InvestigatorsType of Session: PlenaryBackground Therapy for metastatic hormone-refractory prostate cancer (HRPC) has usually consisted of chemotherapy, with studies showing response rates as high as 40-50% The standard |
| HMG CoA reductase inhibitors and the risk of colorectal cancer This article discusses non-FDA approved uses of simvastatin and pravastatin Presenter: J. N. PoynterPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground In vitro data have shown that 3-hydroxy-2-methylglutaryl coenzyme A (HMG CoA) reductase is overexpressed in colorectal cancer (CRC) cell lines and |
| Phase III randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety Presenter: Joseph WeePresenter's Affiliation: National Cancer Center, SingaporeType of Session: ScientificBackground Nasopharyngeal cancer (NPC) is most prevalent in Asia and in these endemic areas, the types of NPC differ from those seen in other parts of the world. In Asia, non-keratinized WHO grade II/III NPC represents >90% |
| Changing patterns of practice in the management of nasopharynx carcinoma (NPC): Analysis of the National Cancer Database (NCDB) Presenter: Langer, CoreyPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground The standard of care in the management of nasopharynx cancer (NPC) has been defined by several randomized phase III trials using concurrent chemoradiation with or without additional adjuvant chemotherapy. Two of these studies (Lin et al |
| Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 Multicentre Trial Presenter: V.G. BudachPresenter's Affiliation: AROType of Session: ScientificBackground The use of combined modality therapy in locally advanced head and neck cancer, specifically concurrent chemoradiation, is accepted by many clinicians as a superior regimen to standard radiation therapy alone. Further gains in locoregional control have |
| Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy Presenter: J. BourhisPresenter's Affiliation: Institut Gustave-Roussy, Villejuif, FranceType of Session: ScientificBackground In 2000, the MACH-NC performed a meta-analysis including all non-metastatic head and neck studies conducted between 1965 and 1993 randomizing patients to locoregional therapy versus locoregional therapy plus |
| Tumor Regression Grading as Prognostic Factor in Patients with Locally Advanced Rectal Cancer Treated with Preoperative Radiochemotherapy Presenter: C. RoedelPresenter's Affiliation: German Rectal Cancer Trial GroupType of Session: ScientificBackground It has been previously reported by the German Rectal Cancer Trial Group that preoperative chemoradiatherapy (CTRT) for rectal cancer improves local control, improves the rate of sphincter function preservation, and may decrease |
| Post-Operative Radiotherapy (P-XRT) After Radical Prostatectomy (Px) Improves Progression-Free Survival (PFS) in pT3N0 Prostate Cancer (PC) (EORTC 22911) Presenter: M BollaPresenter's Affiliation: Radiotherapy, Centre Hospitalier Regional de Grenoble-La Tronche, Grenoble, FranceType of Session: ScientificBackground Radical Prostatectomy is a definitive treatment option for patients with low-risk, clinically staged T1-2N0M0 prostate cancer, where the cancer appears confined to the prostate |
| A Randomized Trial of Tamoxifen With or Without Breast Radiation in Women With Early Breast Cancer 50 Years of Age and Over Presenter: A. FylesPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: PlenaryBackground The search continues for a subset of women with favorable breast cancer characteristics in whom radiation may be avoided. This trial was designed to determine the effects of radiation therapy plus tamoxifen versus |
| Preliminary Results of a Phase II Study of Cyclooxygenase-2 (Cox-2) Inhibition in Rectal Cancer Presenter: B. ChakravarthyPresenter's Affiliation: Vanderbilt UniversityType of Session: ScientificBackground Manipulation of arachidonic acid metabolism via the cyclooxygenase-2 (COX-2) pathway is an active area of oncology research. Studies have established that COX-2 leads to tumor growth via prostaglandin E2 (PGE2) production and |
| Breast Cancer Patients Attitudes Towards Clinical Trials in the Radiation Oncology Clinic Versus Those Searching for Trial Information on the Internet Breast Cancer Patients Attitudes Towards Clinical Trials in the Radiation Oncology Clinic Versus Those Searching for Trial Information on the Internet Presenter: Christopher Dolinsky, MD |
| Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin, and docetaxel in primary breast cancer. Presenter: A. SchneeweissPresenter's Affiliation: German Cancer Research Center, Heidelberg, GermanyType of Session: ScientificBackground - One of the benefits of using preoperative chemotherapy for primary breast cancer is that one can reliably assess the efficacy of the preoperative regimen by |
| High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Presenter: Bruce GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: PlenaryBackground Bevacizumab (BEV) is a recombinant humanized monoclonal antibody which binds VEGF A. Half life is 17-21 days. 40-60% of rectal cancers express VEGF and such expression is associated with recurrence and poorer prognosis. A |
| E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer Presenter: L.J. GoldsteinPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PennsylvaniaType of Session: KeynoteBackground A number of recent studies have shown the benefit of taxane based chemotherapy given in combination with other active agents for high risk breast cancer. A regimen including doxorubicin (A) and docetaxel (T), a |
| Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95) Presenter: T WeigelPresenter's Affiliation: University Hospital Ulm, AROType of Session: ScientificBackground A common treatment for patients diagnosed with prostate cancer is a radical prostatectomy, often with excellent results Disease outside of the prostate (pT3) is often found at surgery, either because this advanced disease was known prior |
| BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer. Presenter: B.J. ThurlimannPresenter's Affiliation: BIG 1-98 Collaborative, Bern, SwitzerlandType of Session: ScientificBackground Letrozole is a drug in a class of medications known as aromatase inhibitors, which almost completely inhibit the synthesis of estrogen. Tamoxifen is an estrogen receptor blocker. |
| Statins to reduce breast cancer risk: A case control study in U.S. female veterans. Presenter: R. KochharPresenter's Affiliation: VA Medical Center, Shreveport, LouisianaType of Session: ScientificBackground Statins (HMG CoA reducatse inhibitors) are a widely studied, effective class of medications used to lower cholesterol in an effort to reduce atherosclerosis and heart disease. In certain animal models, statins have been |
| Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom Presenter: M.W. KattanPresenter's Affiliation: Transatlantic Prostate GroupType of Session: ScientificBackground The natural history of untreated prostate cancer is not well understood This is especially true, as no studies have addressed this in the PSA era. Also, studies lack centralized review of pathology to determine Gleason score, |
| Two Phase III Clinical Studies of Cevimeline for Post-Radiation Xerostomia in Patients with Head and Neck Cancer Presenter: M.S. ChambersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground A majority of patients with head and neck cancers receive treatment with external beam radiotherapy (EBRT). Reduction in salivary flow occurs when the major salivary glands are included with the irradiated volume. Symptomatic |
| Integration of Gefitinib into a Concurrent Chemoradiation Regimen Followed by Gefitinib Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer: A Phase II Trial Presenter: E.E.W. CohenPresenter's Affiliation: University of ChicagoType of Session: ScientificBackground At the University of Chicago, a series of sequential phase II trials have established induction carboplatin and paclitaxel x 2 cycles followed by concurrent chemotherapy and radiation (CTRT) with paclitaxel, 5-FU, and hydroxyurea (HU) (TFHX) |
| Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Presenter: A. deGramontPresenter's Affiliation: Hopital Saint Antoine, Paris, FranceType of Session: ScientificBackground Oxaliplatin is a new chemotherapeutic agent with demonstrated activity in colorectal cancer. This abstract presents an update to previously published results from a large phase III randomized trial (MOSAIC). MOSAIC |
| Preoperative (preop) radiotherapy (RT) +/- 5FU/folinic acid (FA) in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. Presenter: J.P. GerardPresenter's Affiliation: Center Antoine Lacassagne, Nice, FranceType of Session: ScientificBackground Multiple studies have demonstrated the safety and efficacy of preoperative radiation therapy for the treatment of advanced rectal cancer. Data in patients given preoperative radiation therapy alone show unacceptably high |
| Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16-21years of age with Hodgkin's disease (HD): The Children's Cancer Group (CCG) experience Presenter: J. NachmanPresenter's Affiliation: Children's Hospital, Redmond, WAType of Session: ScientificBackground Little data exist regarding treatment outcomes in HD patients aged 16-21 years. The optimal combination of chemotherapy with or without radiation has yet to be defined.Materials and Methods 227 patients age 16-21 with newly |
| Randomized Phase III Trial Comparing Infused Irinotecan/5-flurouracil (5-FU)/Folinic Acid (IF) versus 5-FU/FA (F) in Stage III Colon Cancer Patients (PETACC-3, v307) Presenter: E. Van CutsemPresenter's Affiliation: PETACC-3 investigatorsType of Session: ScientificBackground Use of post-operative chemotherapy in patients with stage III colon cancer is well established. Irinotecan and infusional 5-FU and FA are standard options for first-line therapy in metastatic colorectal cancer. This study examines |
| Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) Presenter: R.T. ChlebowskiPresenter's Affiliation: The WINS InvestigatorsType of Session: PlenaryBackground Laboratory and retrospective research has suggested that dietary fat intake may be related to outcomes in breast cancer patients. The feasibility of interventions that decrease dietary fat intake in women has been demonstrated. Multiple |
| Fifth International Conference on Laryngeal Cancer - Call for Posters maxwords){ alert("Sorry, but you have exceeded the 150 word limit. Please reduce the length of your abstract. Thank you.") return false } } //--> Call for Posters The deadline for receipt of abstracts is Wednesday, February 1, 2006. The Abramson Cancer Center of the University of Pennsylvania and Penn's Department of |
| Fifth International Laryngeal Cancer Conference Date: March 2-4, 2006 Location: Philadelphia, Pennsylvania, USA Conference Brochure: View the full conference brochure . You will need Adobe Acrobat Reader which is available free online. Sponsors: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Who Should Attend: This |
| Sixth Annual New Strategies in Breast Cancer Conference Conference Dates: April 28-29, 2006 Conference Location: Philadelphia, PA Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com Topics Covered: After attending this activity, participants should be able to: Evaluate the results of recent studies on molecular profiling of breast cancer, and consider how the use of such |
| Prostate and Kidney Cancers Symposium Conference Dates: April 29, 2006 Conference Location: Houston, Texas Sponsoring Group: The Methodist Hospital Foundation Conference Web Page URL: www.methodisthealth.com Topics Covered: Prostate and Kidney Cancers: Discussions will focus on the role of chemotherapy, surgery, radiation therapy, nutrition, etc and the management of metastatic |
| The Group Room® Gynecologic Cancer Awareness: Highlights from the Society of Gynecologic Oncologists (SGO) Conference Dates: Sunday, April 23, 2006 Conference Location: Cancer Talk Radio Show Time: 1–3 pm PT • 4–6 pm ET Sponsoring Group: Vital Options International Conference Web Page URL: www.vitaloptions.org 2006 Annual Meeting on Women's Cancer In association with SGO and the Gynecologic Cancer Foundation With host, Selma |
| CancerGuides Conference Dates: October 9-15, 2006 Conference Location: Indian lakes Resort, Bloomingdale, IL Sponsoring Group: Center for Mind-Body Medicine Conference Web Page URL: www.cmbm.org Topics Covered: Alternative and Complementary approaches to cancer care, current research, psychological crises and turning points in cancercare, mind-body |
| 7th Annual Focus on Gynecologic Cancers Conference Dates: Friday, October 6, 2006 8:30 AM - 4:15 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Annual conference that provides the latest treatment and research information on the various types of gynecologic cancer, as |
| 15th Annual Life After Breast Cancer Conference Conference Dates: Friday, September 15, 2006, 8:30 AM - 3:30 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: This day-long conference is an opportunity for women with breast cancer and their loved ones to come together to obtain |
| Yoga Unites for Living Beyond Breast Cancer Conference Dates: Sunday, May 21, 2006, 8:00 a.m.-12:00 p.m. Conference Location: Philadelphia Museum of Art, East Entrance Steps Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org Conference Objectives: An outdoor yoga class and Healthy Living Expo to benefit women affected by breast cancer Who Should Attend: |
| Community Symposium on Prostate Cancer Conference Dates: May 13, 2006 Conference Location: Masonic Temple, One North Broad Street, Philadelphia, PA 19107 Sponsoring Group: University of Penn Center for Population Health and Health Disparities, Center of Excellence for Diversity in Research and Education, Health Promotion Council of Southeastern PA Topics Covered: Dispelling myths |
| Post-ASCO Update on Breast Cancer Conference Dates: Thursday, June 15, 2006 Conference Location: Independence Visitor's Center, 6th & Market Streets, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Who Should Attend: Medical oncologists, radiation oncologists, surgeons, hematology/oncology fellows, oncology nurses, and other |
| AICR/WCRF International Research Conference on Food, Nutrition and Cancer Conference Dates: July 13, 2006 - July 14, 2006 Conference Location: Washington, D.C. Sponsoring Group: American Institute for Cancer Research/World Cancer Research Fund Conference Web Page URL: www.aicr.org/conference Topics Covered: Topics include: Micronutrients, Lifestyle and Cancer Risk; Inflammation and Cancer Prevention; Epigenetics |
| The 8th World Congress on Gastrointestinal Cancer Conference Dates: June 28 - July 1, 2006 Conference Location: Barcelona, Spain Sponsoring Group: World Congress on Gastrointestinal Cancer Conference Web Page URL: http://www.worldgicancer.com/WCGI/ Topics Covered: Select the most appropriate detection, screening and chemoprevention methods for colorectal cancer; Determine the most appropriate |
| Focus on Prostate Cancer Conference Conference Dates: Friday, July 28, 2006 8:30 AM - 4:00 PM Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Penn's Urologic Cancer Program specialists are at the forefront of treating patients with cancer of the prostate. Conference |
| Fifth Biennial Gastrointestinal Cancer Conference: Focus on Upper Gastrointestinal Tumors Conference Dates: Friday, December 8, 2006 Conference Location: The Rittenhouse Hotel, 210 W. Rittenhouse Square, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Endoscopic evaluation for pancreatic cysts Familial pancreatic neoplasms Adjuvant and neoadjuvant |
| Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Presenter: G. P. SwansonPresenter's Affiliation: UT San AntonioType of Session: PlenaryBackground Prostate cancer patients with adverse findings at surgery have an increased risk of local failure. Although radiation in the post-prostatectomy setting has been shown to improve local control, its long-term benefit is unclear. The Southwest Oncology |
| The Prognostic Value of the Epidermal Growth Factor Receptor in Locally Advanced Rectal Cancer (LARC) Patients Treated with Preoperative Chemo-radiation Presenter: J. KimPresenter's Affiliation: Radiation Oncology, Chungnam National University, College of Medicine, Daejon, South KoreaType of Session: ScientificBackground More recently, the use of targeted agents against epidermal growth factor receptors (EGFR) has become more and more integrated into the treatment of colon cancers. The hypothesis |
| Location and Control of Local Disease Predict Overall Survival and Distant Metastases Free Survival in Patients with Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy for Stage I/II Breast Cancer Presenter: Y. ChenPresenter's Affiliation: Radiation Oncology, Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground The best approach to ipsilateral breast tumor recurrence after breast conserving surgery and radiation has not been established. Studies have shown that patients with ipsilateral breast tumor |
| Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Presenter: R. PoetterPresenter's Affiliation: Dept. of Radiotherapy and Radiobiology, Medical University of ViennaType of Session: PlenaryBackground In treating early-stage breast cancers with favorable prognostic features, the question has been raised as to whether oncologists might be overtreating these patients. In other words, is it necessary |
| Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Presenter: P. RomestaingPresenter's Affiliation: CHU Lyon Sud, Lyon, FranceType of Session: PlenaryBackground Based on prior studies on the role of chemo-radiation in the management of patients with locally advanced rectal cancers (LARC), there has been a consistent increase in local control in favor of chemo-radiation. The goal of this study was |
| Patterns of Locoregional Recurrence and Their Predictors in Rectal Cancer Patients Treated with Surgery and Chemoradiation Presenter: T. Yu.Presenter's Affiliation: MD Andersen Cancer CenterType of Session: ScientificBackground The current standard of care for treating locally advanced rectal cancer is combined modality chemotherapy and radiation with surgical resection. Little is known about the location of tumor recurrences following this therapy. |
| Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma. Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after chemotherapy and radiation (around 9 months). GITSG trials from the 1980s showed a benefit to adding |
| ASTRO Patient Summary: Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) This study looked at prostate cancer patients who were found to have "adverse pathologic features" (invasion beyond the prostate or positive surgical margins) after surgical removal of the prostate. There are two |
| ASTRO Patient Summary: Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial This study examined patients with T3 or T4 rectal adenocarcinoma with no metastases. Patients were assigned to receive either preoperative radiation (RT) or preoperative radiation and 4 cycles of chemotherapy with 5-FU |
| ASTRO Patient Summary: Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer This presentation reviewed a recent study involving postmenopausal women with early stage, hormone receptor positive breast cancer (ER+ or PR+). Some have wondered if treating these patients with lumpectomy, radiation and |
| Adaptive Planning and Delivery to Account for Anatomical Changes Induced by Radiation Therapy of Head and Neck Cancer Presenter: M.B. SharpePresenter's Affiliation: Princess Margaret Hospital, Toronto, ONType of Session: PlenaryBackground Radiation-induced changes manifested during treatment can theoretically increase the risk of local failure and alter predicted normal tissue toxicity. For this reason, a framework is necessary to assess and potentially intervene |
| Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Presenter: SE McGuirePresenter's Affiliation: Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Neoadjuvant chemotherapy is the standard for locally advanced breast cancer and for large operable breast cancer. A pathological complete response rate of 15-20% after neoadjuvant |
| Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Presenter: J. R. BellonPresenter's Affiliation: Dana-Farber Cancer InstituteType of Session: ScientificBackground Her-2-Neu is overexpressed in approximately 25% of breast cancer patients and confers a worse prognosis. Adjuvant trastuzumab improves outcome in node-positive breast cancer patients with Her-2-Neu positivity and high risk node-negative |
| Lobular Carcinoma in Situ (LCIS) in Association with Invasive Breast Cancer: Does LCIS Predict for Local Recurrence? Presenter: S. JollyPresenter's Affiliation: Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, Pathology, William Beaumont Hospital, Royal Oak, MIType of Session: ScientificBackground More than 5% of malignant breast cancers have a component of LCIS. The association of LCIS with invasive breast cancer for patients |
| ASTRO Patient Summary: Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Radiation is an Important Component of Therapy for Patients with Stage III Breast Cancer Who Achieve a Pathological Complete Response after Neoadjuvant Chemotherapy Patients who present with locally advanced breast cancer (spread to local lymph nodes or local tissue) or large operable tumors are usually treated with chemotherapy prior to surgical |
| ASTRO Patient Summary: Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer Patients with Her2/neu positive breast cancer are considered to have higher risk disease, but have an additional therapy option in trastuzumab (Herceptin). Doctors would like to administer trastuzumab during the same time period as the radiation therapy, |
| A Phase I-II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128 Presenter: Presenter: D.K.GaffneyPresenter's Affiliation: Radiation Oncology, University of Utah, Salt Lake City, UT, Statistics, RTOG, Philadelphia, PA, Radiation Oncology, Thomas Jefferson Univ., Philadelphia, PA, Obstetrics/Gynecology, Wake Forest Univ.,Type of Session: ScientificBackground Cyclooxygenase 2 (COX-2) is an enzyme induced by |
| Subcutaneous (SbQ) Versus Intravenous (IV) Administration of Amifostine for Head and Neck (HN) Cancer Patients Receiving Radiotherapy (RT): Preliminary Results of the GORTEC 2000-02 Randomized Trial Presenter: E. BardetPresenter's Affiliation: Crlcc, Nantes, FranceType of Session: ScientificBackground There are several advantages offered by SbQ amifostine over IV amifostine including easier administration and a favorable window between drug injection and radiation delivery. This trial tested the hypothesis that SbQ amifostine was associated |
| Hypofractionated Intensity Modulated Radiotherapy (70 Gy at 2.5Gy Per Fraction) for Localized Prostate Cancer: Long-Term Outcome Results Presenter: V.V. ThakkarPresenter's Affiliation: Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OHType of Session: ScientificBackground The principle of α /β has always been instrumental in guiding radiation therapy fractionation and doses. With the prostate having an α /β of 1.5-3, while the |
| ASTRO 2005 Breast Cancer Highlights OncoLink selected breast cancer topics from the Annual Meeting of the American Society for Therapeutic Radiology And Oncology October 16-20, 2005, held in Denver, Colorado. Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Location and Control of Local Disease Predict |
| Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers. Results of the FFCD 9203 randomized trial Presenter: J GerardPresenter's Affiliation: Centre Antoine Lacassagne, Nice, FranceType of Session: ScientificBackground There has been a dramatic shift over the past few years to using preoperative radiation therapy for rectal cancer as opposed to using it in the postoperative setting. Some of the initial studies that showed a benefit to |
| The Role of Chemotherapy and Biologic Therapy in the Treatment of Metastatic Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women in the US, with an estimated annual incidence of almost 150,000 new cases. In terms of cancer-related deaths in the US, it ranks second (after lung cancer), with about 60,000 deaths yearly. Worldwide, the incidence and mortality are 800,000 and 500,000 respectively. |
| Gemcitabine and Erlotinib in Pancreatic Cancer Presenter: Malcolm Moore, MDPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer-related deaths. In 2005, there will be an estimated 35,400 new cases and 35,000 deaths in the United States and Canada. The 5-year survival is dismal, hovering |
| Adjuvant Therapy for Rectal Cancer Presenter: Bruce D. Minsky, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, New YorkType of Session: ScientificBackground Based on data published in the Journal of Clinical Oncology, it has become apparent that 5-year follow-up data are not sufficient for rectal cancer clinical trials. The standard |
| Ixabepilone in Breast Cancer Presenter: Sandra M. Swain, MDPresenter's Affiliation: National Cancer InstituteType of Session: ScientificBackground Microtubules are formed from a protein called tubulin. Microtubules form the skeleton of cells, and have to be broken down for a cell to divide. Certain chemotherapy drugs are actually microtubule-stabilizing |
| Experience with ABI-007 (Abraxane) in Head and Neck Cancers ABI-007 (brand name Abraxane™) is a protein-bound form of the popular chemotherapy drug paclitaxel (brand name Taxol®)). Standard paclitaxel is formulated with ethanol and a substance called Cremophor EL (polyoxyethylated castor oil) in order to improve drug delivery. However, these additives are felt |
| Panitumumab, A Fully-Human IgG2 Antibody Treatment for Colorectal Cancer Overexpression of epidermal growth factor receptor (EGFR) is seen in many human malignancies, including colorectal cancer. The cellular pathways that are triggered by EGFR activation are involved in cell growth and proliferation. Thus, inhibiting EGFR by blocking the binding of ligand to the receptor can inhibit these |
| Role of Ras Inhibitors in the Management of Breast Cancer Presenter: Joseph A. Sparano, MDPresenter's Affiliation: Albert Einstein Cancer Center, Bronx, New YorkType of Session: ScientificBackground G proteins are a superfamily of >100 proteins which are widely distributed in mammalian cells. They regulate a variety of cellular functions, and are classified into 5 families. The names |
| Docetaxel Combination Therapy in Prostate Cancer Presenter: Daniel Petrylak, MDPresenter's Affiliation: Columbia University, New York, New YorkType of Session: ScientificBackground SWOG 9916 compared doctaxel/estramustine to mitoxantrone/prednisone for patients with metastatic, hormone-refractory prostate cancer, and found an improvement in overall survival in the docetaxel arm |
| Pancreatic Cancer: Progress on the Horizon Presented by: Shannon Holloway, MHS , PA -C, New York Presbyterian Weill Cornell Medical Center Pancreatic cancer accounts for 30,500 new cases annually, with a dismal 5-year survival rate of 15% when respectable, down to 1.8% when distant metastases are present. Approximately 80-95% of cases are unresectable at diagnosis, leading to the poor |
| Trastuzumab Adjuvant Therapy in Breast Cancer: Bringing the Promise of Clinical Results to Patients Presented by: Tamsin Mulrooney, PhD(c), MS, ARNP, OCN, Norris Cotton Cancer Center at Dartmouth Hitchcock Medical Center Tammy presented the data, recently discussed at ASCO 2005 and published in the New England Journal of Medicine, that many clinicians called stunning and predicted will transform the way many women with breast cancer are |
| Relative Dose Intensity: Improving Cancer Treatment and Outcomes Presented by: Cheryl Lenhart, RN, BSN, HRM, Western Pennsylvania Cancer Institute, West Penn Allegheny Health System Relative dose intensity is a term that refers to the amount of a particular chemotherapy given over a specific time (i.e. paclitaxel 175mg/m2 every three weeks) in relation to what was ordered (or is considered standard). The |
| Hormonal Therapies in Breast Cancer Maureen Major , MS , RN from Memorial Sloan-Kettering Cancer Center started the morning by updating the group on the latest studies in hormonal therapies for the treatment of early stage breast cancer. There are approximately 215,900 cases of breast cancer annually, with 40,110 deaths. Although lung cancer now accounts for more deaths in women, |
| Moleculoar Targets In Cancer Therapy, Fourth Biennial Meeting Conference Dates: January 25-28, 2007 Conference Location: Sheraton Sand Key Resort, Clearwater Beach, Florida Sponsoring Group: University of South Florida College and the H. Lee Moffitt Cancer Center & Research Institute Conference Web Page URL: http//www.moffitt.usf.edu/continuinged/mt2007 Topics Covered: Mechanism and Therapeutic |
| Breast Highlights: Highlights from the 30th Annual San Antonio Breast Cancer Conference Dates: February 9, 2008 Conference Location: New York, New York Conference Dates: February 16, 2008 Conference Location: Chicago, IL Sponsoring Group: The American School of Oncology Conference Web Page URL: http://www.asoncology.com/Appweb/AsOncologyRegistration/frmPmMeetingWebList.asp Topics Covered: Breast Highlights: |
| Focus on Gastrointestinal Cancers Conference Conference Dates: Friday, March 14, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Topics Covered: Covers the range of gastrointestinal cancers including: colon, rectum, pancreas, liver and bile duct, as well as esophageal and stomach. |
| Navigating the Health Care System for Prostate Cancer Care Conference Dates: March 31, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA 19131 Sponsoring Group: University of Pennsylvania Center for Population Health and Health Disparities Topics Covered: A panel of guests including a Urologist, Radiation Oncologist, Internist and Social Worker will answer questions about |
| Fourth Biennial Prostate Cancer Conference: Focus on Current Aspects in Diagnosis and Treatment Conference Dates: Friday, November 2, 2007 Conference Location: Rittenhouse Hotel, 210 West Rittenhouse Square, Philadelphia, PA Sponsoring Group: Univeristy of Pennsylvania School of Medicine/Office of Continuing Medical Education Topics Covered: Robotic surgery, genetics, prevention, PET scanning, radiation therapy, proton therapy, |
| 1st International Betty Ford Breast Cancer Treatment and Survivorship Symposium Conference Dates: April 05, 2007 - April 07, 2007 Conference Location: Vail, Colorado Sponsoring Group: Postgraduate Institute for Medicine, Medical Education Strategies & Communications, Shaw Regional Cancer Center Conference Web Page URL: www.mesc-edu.com/BreastCancer Topics Covered: Some topics include information on drug treatment |
| Seventh Annual New Strategies in Breast Cancer Conference Conference Dates: April 13-14, 2007 Conference Location: The Rittenhouse Hotel, Philadelphia, PA Sponsoring Group: The Center for Biomedical Continuing Education Conference Web Page URL: www.thecbce.com Conference Objectives: Please see website for further details Who Should Attend: This activity is intended for medical oncologists, |
| Focus on Head and Neck Cancers Conference Dates: April 13, 2007 Conference Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Web Page URL: www.penncancer.com/events.cfm Topics Covered: An Educational Conference for Those Affected by Head and Neck Cancer Conference Agenda: See |
| Kidney & Prostate Cancer Symposium Conference Dates: April 28, 2007 Conference Location: The Methodist Hospital, Houston, Texas Sponsoring Group: The Methodist Hospital (TMH) Topics Covered: Renowned physician-scientists from TMH, UT and Baylor College of Medicine will cover a wealth of info on Kidney and Prostate Cancers and their treatment options. Conference Objectives: |
| 1st Annual International Medical Assembly at the United Nations: Meeting the Global Challenge of Cancer Conference Dates: April 3-5, 2007 Conference Location: United Nations Headquarters, New York, New York Sponsoring Group: United Nations Conference Web Page URL: www.medicalassemblyun.org Topics Covered: In this conference, we will: Explore ways and means for abating the spread of cancer worldwide Examine the challenges that |
| Second Annual Biological Basis of Breast Cancer Conference Conference Dates: June 30 - July 1, 2007 Conference Location: The Fairmont Miramar Hotel, Santa Monica, CA Sponsoring Group: The Center for Biomedical Continuing Education (CBCE) Conference Web Page URL: www.thecbce.com Who Should Attend: This activity is intended for medical oncologists, advanced practitioners, pharmacists, physician |
| 1st Annual Total Cancer Care Summit: The Future of Personalized Medicine Conference Dates: October 24, 2007 Conference Location: October 28, 2007 Sponsoring Group: H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida College of Medicine Conference Web Page URL: www.moffitt.org/continuinged/tcc Topics Covered: Session topics include: Introduction to Personalized Medicine, Linking |
| 16th Annual Life After Breast Cancer Conference Conference Dates: Friday, October 12, 2007 Conference Location: Hilton Hotel, 4200 City Line Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Conference Website: 16th Annual Life After Breast Cancer Conference Topics Covered: Save the Date flier Who Should Attend: The Sixteenth |
| Great Debates in Breast Cancer Conference Dates: October 26-27 Conference Location: New York, New York USA Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at www.imedex.com or call |
| Current Role of Hormonal Therapies for Breast Cancer Conference Dates: Wed. October 17, 2007, 7-8pm(CT) Conference Location: Teleconference Sponsoring Group: Y-ME National Breast Cancer Organization Conference Web Page URL: www.y-me.org/sharering Conference Objectives: Discuss role of hormonal therapies, risks and benefits, and new developments Who Should Attend: People wth breast cancer |
| Conference for Women Living With Advanced Breast Cancer: Enhancing Your Health and Quality of Life Conference Dates: Saturday, July 14, 2007 Conference Location: Philadelphia Marriott West, West Conshohocken, Pennsylvania Sponsoring Group: Living Beyond Breast Cancer Conference Web Page URL: www.lbbc.org/news-detail.asp?news_id=1387 Topics Covered: Medical Treatments and Research Developments; Understanding Symptom and Side-Effect |
| Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 Presenter: C. Pepe Presenter's Affiliation: Princess Margaret Hospital, Toronto, Canada Type of Session: Scientific Background There is a high incidence of lung cancer in the elderly. The elderly are under-represented in clinical trials. There is a significant survival benefit with adjuvant chemotherapy after resection of early |
| A Phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Presenter: Roy S. HerbstPresenter's Affiliation: M. D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Death receptors, such as TNF-alpha receptor, Fas, and TRAIL-R (TNF-alpha Related Apoptosis Inducing Ligand Receptor)-1 and –2, can stimulate the extrinsic apoptotic pathway in tumor cells when activated by |
| Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy Presenter: A.J. Stephenson Presenter's Affiliation: Cleveland Clinic, Cleveland, OH Type of Session: Keynote Background Following radical prostatectomy, 25% of patients experience a rising PSA. Risk factors for metastatic disease include a rapid PSA doubling time, high grade Gleason, and a short disease-free interval. High risk |
| Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. Presenter: P. PaschkaPresenter's Affiliation: Ohio State University, Columbus, OHType of Session: PlenaryBackground Core binding factor acute myeloid leukemia (CBF AML) is a specific subtype of leukemia. CBF AML has 2 of the most prevalent cytogenetic subtypes of primary AML, t(8;21) and inv(16) These genomic aberrations disrupt |
| Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Presenter: Calais GPresenter's Affiliation: Centre Henry S. Kaplan, Tours, FranceType of Session: ScientificBackground Induction chemotherapy followed by radiation treatment (RT) provides a potential for functional laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancer PF is the standard induction |
| Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. Presenter: Y. KangPresenter's Affiliation: Asan Medical Center, Seoul, KoreaType of Session: ScientificBackground Capecitabine is an oral fluropyrimidine with proven efficacy and favorable safety in metastatic colorectal cancer. Because it is given orally, patients who receive capecitabine are spared a central line and hospitalization |
| The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study Presenter: D. L. WickerhamPresenter's Affiliation: National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PAType of Session: PlenaryBackground The NSABP-P1 study demonstrated that tamoxifen given to high-risk pre- and post-menopausal women decreased the risk of both invasive and non-invasive breast cancers There |
| Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 Presenter: Tepper JEPresenter's Affiliation: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NCType of Session: ScientificBackground There is disagreement regarding the proper treatment of resectable esophageal carcinoma The purpose of this study was to compare surgical resection alone versus neoadjuvant chemoradiation followed |
| The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. Presenter: R. T. ChlebowskiPresenter's Affiliation: Los Angeles Biomedical Research Institute, Torrance, CAType of Session: PlenaryBackground In 12 of 16 retrospective observational studies, calcium (Ca) and vitamin D (D) have been associated with reduced breast cancer risk, decreased breast density, and decreased arthralgias Question: |
| Patient Summary: The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study The STAR trial included post-menopausal women with a high risk of developing breast cancer (Gail model risk 1.66%). Women were randomized to receive tamoxifen 20mg daily for 5 years or raloxifene 60mg daily for 5 years. Tamoxifen and |
| Patient Summary: The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. This study looked at the question: would calcium and vitamin D supplements decrease risk of breast cancer ? 32,282 women were randomized to receive either 1000 mg calcium carbonate and 400 IU vitamin D or placebo. The women were |
| Patient Summary: Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781 There is some controversy over the best treatment for surgically resectable esophageal cancer , so this study looked to compare surgery alone to chemotherapy followed by surgery (neoadjuvant chemotherapy). Eligible patients had stage I-III disease, |
| Patient Summary: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5FU/cisplatin (FP) as first line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. This study looked to prove that Xeloda (a newer oral chemotherapy) and cisplatin (XP) are as effective as intravenous therapy with 5-FU and |
| Patient Summary: Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy When a patient has a rising PSA after radical prostatectomy, they are often recommended hormone therapy, but this is not without side effects. These investigators wondered if they could predict which patients will respond to salvage radiation |
| Patient Summary: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01 Chemotherapy followed by radiation treatment (RT) provides a potential for laryngeal preservation in patients with locally |
| A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer Presenter: Marc Peeters Presenter's Affiliation: Ghent University Hospital, Ghent, Belgium Type of Session: Clinical Plenary Background Epidermal growth factor receptor (EGFR) signaling contributes to tumor growth, and overexpression of EGFR is associated with worse prognosis in metastatic colorectal cancer. Cetuximab (Erbitux) is a |
| Intra-arterial vs. Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial Presenter: C. R. N. Rasch, M.D., Ph.D.Presenter's Affiliation: NetherlandsType of Session: PlenaryBackground The addition of concurrent cisplatin-based chemotherapy to definitive radiotherapy for locally advanced squamous cell carcinoma of the head and neck (HNSCC) improves local control and survival. Cisplatin has significant systemic |
| The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" Presenter: Paul McGale, PhDPresenter's Affiliation: Clinical Trial Service Unit, United KingdomType of Session: PlenaryBackground Randomized trials have shown that post-mastectomy radiation therapy ( PMRT ) confers both a local control and survival benefit in certain patient populations. It is generally accepted that patients with 4 or |
| Long-Term Results of a Randomized Trial of Tamoxifen With or Without Radiation in Women Over 50 Years of Age With T1/2 N0 Breast Cancer Presenter: A. FylesPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Multiple studies have attempted to define a population of women with early stage breast cancer in whom the inclusion of radiation as a part of breast conservation treatment is not necessary This report represents long-term results |
| Long-term Toxicity Outcomes After High-Dose Conformal Radiotherapy for Clinically Localized Prostate Cancer Presenter: A. ShippyPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground Higher doses of radiotherapy have been shown in prospective randomized trials to correlate with improved clinical outcomes in prostate cancer patients Toxicity has also been found to increase with increasing dose, |
| Long-term Neck Control Rates After Complete Response to Chemoradiation in Patients with Advanced Head and Neck Cancer Presenter: R. RenganPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground The indications for planned neck dissection in patients with advanced head and neck cancer who achieve a complete response to chemoradiation are unclear This study sought to evaluate outcomes in advanced head and neck |
| The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" The 2006 Worldwide Overview of the Effects of Local Treatments for Early Breast Cancer On Long-term Outcome? "Meta-analysis of the Randomized Trials of Radiotherapy After Mastectomy With Axillary Clearance" It is well understood that radiation therapy after mastectomy ( PMRT ) improves survival and decreases recurrence rates in women |
| 10 Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer Presenter: G. HanksPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Multiple large randomized trials have demonstrated a clinical benefit with the addition of androgen deprivation to external beam radiotherapy for treatment of locally advanced prostate cancer This report represents long-term |
| Patterns of Failure Following the Brachytherapy Management of Prostate Cancer Patterns of Failure Following the Brachytherapy Management of Prostate Cancer There are relatively few studies with long-term outcomes for men who have been treated with radioactive seed implant (brachytherapy) for prostate cancer. It is important to understand treatment failures after brachytherapy in order to decide which patients should be |
| Cardiac Morbidity and Mortality After Breast Conservation Treatment in Early-stage Breast Cancer Patients With Pre-existing Cardiac Disease Presenter: R. GuttPresenter's Affiliation: University of MarylandType of Session: ScientificBackground Patients with left-sided breast cancer have been shown to have an increase in the subsequent development of coronary artery disease (CAD) and myocardial infarction (MI), but no increase in mortality versus patients with right-sided breast |
| Cetuximab in Combination With Capecitabine, Oxaliplatin, and Concomitant Radiotherapy (Cet-Capox-RT) as Preoperative Therapy for Rectal Cancer Cetuximab in Combination With Capecitabine, Oxaliplatin, and Concomitant Radiotherapy (Cet-Capox-RT) as Preoperative Therapy for Rectal Cancer Cetuximab is a monoclonal antibody to the EGF-receptor and has been shown to improve outcomes in metastatic colorectal cancer and in combination with radiation therapy for head and neck cancers. Previous |
| The Breast Cancer Epigenome Presenter: M. Esteller Affiliation: Spanish National Cancer Centre (CNIO), Madrid, Spain Background Epigenetics is the study of information related to DNA that does not depend on the DNA sequence itself. Examples include methylation of DNA itself, modification of histones, and micro-RNA expression. In general, the progression of normal |
| Combined Clinical Trial Results Of A HER2/Neu (E75) Vaccine For Prevention Of Recurrence In High-Risk Breast Cancer Patients Presenter: G. E. Peoples Affiliation: Walter Reed Army Medical Center, Washington, DC Background Immunotherapy to treat cancer has been a popular idea for decades. Interferon therapy is FDA-approved and has been used in a variety of settings, such as in renal cell cancer. Cancer vaccines can potentially harness specific immune responses, |
| A Sharp Decrease In Breast Cancer Incidence In The United States In 2003 Presenter: P. M. Ravdin Affiliation: M.D. Anderson Cancer Center, Houston, TX Background The incidence of breast cancer over time may reflect a differences in etiologic factors and screening practices. For example, after the wide-spread institution of mammography, there was bump in the incidence of breast cancer The incidence of |
| Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer Presenter: W. Gradishar Affiliation: Robert H. Lurie Comprehensive Cancer Center of Northwestern University Background Recent trial results have shown that adjuvant first-line aromatase inhibitors give superior disease free survival compared to tamoxifen in hormone receptor-positive breast cancer When these women recur, it is unclear |
| Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up Presenter: K.S. Hughes Affiliation: Massachusetts General Hospital, Boston, MA Background After lumpectomy for early breast cancer, adjuvant breast irradiation reduces local recurrence by about two-thirds. The EBCTCG overview has shown a survival benefit from adjuvant radiation, noting that for every 4 local recurrences that are |
| Axillary lymph node nanometastases are prognostic factors for metastatic relapse in breast cancer patients Presenter: S. Alberti Affiliation: University of Chieti, Chieti, Italy Background There is a wide range of outcomes after diagnosis and treatment for early stage breast cancer. The unexplained heterogeneity of outcomes may be a result of inaccurately under staged axillary lymph node metastases Routine pathologic analysis of axillary |
| OncoLink Professor On-Call: Lawrence Solin, MD provides exclusive expert review and insights from the recent San Antonio Breast Cancer Symposia for OncoLink The 29th Annual San Antonio Breast Cancer Symposium was held from Thursday, December 14 through Sunday, December 17, 2006. A wide range of topics was discussed. This symposium is widely considered to be one of the major breast cancer conferences in the world. As such, much of the scientific information presented at this symposium is quickly |
| Incidence of Human Papillomavirus (HPV)-Related Head and Neck Cancers in the U.S. from 1998-2003: Pre-HPV Vaccine Licensure Presenter: M. SaraiyaPresenter's Affiliation: Centers for Disease ControlType of Session: ScientificBackground The majority of head and neck cancers are related to alcohol and tobacco use (75%). However, human papillomavirus (HPV) has been shown to be related to between 15-25% of head and neck cancers worldwide. In certain head and neck |
| Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) Scientific Session: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) The combination of C225 and radiation has been proven superior to radiation alone for the treatment of |
| The cognitive effects of modafinil in breast cancer survivors: A randomized clinical trial Presenter: Kohli, S.Presenter's Affiliation: University of Rochester, Rochester, NYType of Session: ScientificBackground As the number of cancer survivors continues to increase, after-effects of cancer and its treatments have become increasingly important. Cognitive changes and impairment after cancer treatment, often referred to as |
| A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA. Presenter: Soori, G.S.Presenter's Affiliation: Mayo Clinic College of Medicine, Rochester, MN.Type of Session: ScientificBackground Fatigue is an extremely important issue for cancer patients, recently having been reported to occur in 58% of patients undergoing cancer treatment, as compared to pain, encountered by 22%, and nausea and |
| Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer Presenter: M. O. MeyersPresenter's Affiliation: Duke University Medical CenterType of Session: ScientificBackground It is well known that lymph node metastasis is associated with a worse outcome in rectal cancer. It has generally been accepted that 12 lymph nodes are needed for proper nodal staging. However, only 37% of patients in the SEER |
| Phase III Trial of Ixabepilone plus Capecitabine Compared to Capecitabine Alone in Patients with Metastatic Breast Cancer (MBC) Previously Treated or Resistant to an Anthracycline and Resistant to Taxanes. Presenter: L.T. VahdatPresenter's Affiliation: Weill Cornell Medical CollegeType of Session: ScientificBackground Currently, the standard of care for the systemic treatment of breast cancer involves treatment with anthracyclines and taxanes. The use of the anthracyclines and taxanes is increasing and more patients are developing resistance to |
| Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: Results of the randomised MRC ASTEC and NCIC CTG EN.5 trial Presenter: J. OrtonPresenter's Affiliation: Medical Research Council Clinical Trials Unit, London, UKType of Session: ScientificBackground Endometrial cancer is the most common gynecologic cancer among women in North America and affects over 40,000 women per year. 75% of endometrial cancer cases present with disease confined to the |
| A randomized phase III study on adjuvant treatment with radiation (RT) +/- chemotherapy (CT) in early stage high risk endometrial cancer (NSGO-EC-9501/EORTC 55991) Presenter: T. HogbergPresenter's Affiliation: Nordic Society of Gynecologic Oncology, Odense, DenmarkType of Session: ScientificBackground Endometrial cancer is the most common gynecologic cancer among women in North America, affecting over 40,000 women per year. 75% of endometrial cancer cases present with disease confined to the |
| Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer Presenter: Perez, E.A.Presenter's Affiliation: Mayo Clinic, Jacksonville, FL.Type of Session: ScientificBackground Up to 25% of women diagnosed with early-stage breast cancers have tumors which demonstrate overexpression of human epidermal growth factor receptor 2 (HER-2). Trastuzumab (Herceptin) is a monoclonal antibody directed against the |
| Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years Presenter: Aimery De GramontPresenter's Affiliation: Hopital St. Antoine, Paris, FranceType of Session: ScientificBackground Oxaliplatin is a chemotherapeutic agent with demonstrated activity in colorectal cancer. This abstract presents a 6 year update to previously published results from a large phase III randomized trial (MOSAIC). |
| Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases Presenter: Bernard NordlingerPresenter's Affiliation: Hospital Ambroise Pare, Boulogne Cedex, FranceType of Session: PlenaryBackground Liver metastases are observed in 40 to 50% of patients with newly diagnosed colorectal cancer worldwide. When resected, 5 year survival is close to 35%, but disease relapse is common. The benefit |
| Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 Scientific Session: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 The optimal duration of hormone therapy for locally advanced prostate cancer remains controversial. Since the EORTC |
| Secondary Cancers After Radiotherapy: An Increasing or Decreasing Concern? Presenter: Eric J. Hall Presenter's Affiliation: Columbia University Type of Session: Scientific Background Approximately 10% of patients presenting to US cancer centers have secondary malignancies. This may be due to an increase genetic susceptibility to cancer or continued life style habits which put patients at increased risk for |
| Chemotherapy Foundation Symposium XXVI Innovative Cancer Therapy for Tomorrow Conference Dates: November 4 - November 8, 2008 Conference Location: Marriott Marquis Hotel, New York City Sponsoring Group: Mount Sinai School Of Medicine Conference Web Page URL: www.chemotherapyfoundationsymposium.org Topics Covered: Pediatric Oncology, Hematologic malignancies, GI Cancers, Gynecological cancers, Head and neck cancers, |
| Eighth Annual New Strategies in Breast Cancer Conference Dates: April 4-5, 2008 Conference Location: Philadelphia, Pennsylvania Sponsoring Group: CBCE™ (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Please visit www.thecbce.com for the topics covered during this program, or send an e-mail to info@theCBCE.com. Conference |
| Highlights: Highlights from the 30th Annual San Antonio Breast Cancer Symposium Conference Dates: January 19, 2008 Conference Location: New York, New York Conference Dates: January 26, 2008 Conference Location: Santa Monica Sponsoring Group: The American School of Oncology Conference Web Page URL: http://www.asoncology.com/Appweb/AsOncologyRegistration/frmPmMeetingWebList.asp Topics Covered: Breast Highlights: |
| 12th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Held in Conjunction With the Ninth Annual Medical Oncology Fellows Forum Conference Dates: September 19-21, 2008 Conference Location: Hilton Head, SC Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/multi_disease/12th_fall_oncology_1102037/index.php Topics Covered: The 12th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Held in |
| 14th Annual Perspectives in Breast Cancer Conference Dates: September 26-27, 2008 Conference Location: New York, New York Sponsoring Group: Imedex Conference Web Page URL: http://www.imedex.com/appweb/announcements/a042-01.asp Topics Covered: Surgery/Radiotherapy, Translational Research, Early and locally advanced disease, Advanced/metastatic disease, Adjuvant therapy Conference |
| 10th World Congress on Gastrointestinal Cancer Conference Dates: June 25-28, 2008 Conference Location: Barcelona, Spain Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com Who Should Attend: oncologists, other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) Registration Information: Please register at www.imedex.com or call |
| Workshop on Inflammation in Cancer Development Conference Dates: October 30, 2008 Conference Location: Westin Horton Plaza- San Diego, CA Sponsoring Group: International Society for Biological Therapy of Cancer Conference Web Page URL: http://www.isbtc.org/meetings/am08/workshop08/ Conference Objectives: This small group, interactive workshop will assemble thought-leaders in the field to |
| Primer on Tumor Immunology and Biological Therapy of Cancer Conference Dates: October 30, 2008 Conference Location: Westin Horton Plaza- San Diego, CA Sponsoring Group: International Society for Biological Therapy of Cancer Conference Web Page URL: http://www.isbtc.org/meetings/am08/primer08/ Topics Covered: Adoptive T Cell Therapy Anti-Angiogenic Therapies Antibody Therapy of |
| Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008 Conference Dates: October 3-5, 2008 Conference Location: New York, NY Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/breast_cancer/adjuvant_1008_1102027/index.php Topics Covered: The Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008 3-day congress is dedicated to |
| Seventh International Colorectal Cancer Congress Conference Dates: October 16-18, 2008 Conference Location: Aventura, FL Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/gastrointestinal/7th_ccc/index.php Topics Covered: The Seventh International Colorectal Cancer Congress is dedicated to an in-depth discussion of the best care |
| Seventh International Congress on Targeted Therapies in Cancer Conference Dates: August 22-24, 2008 Conference Location: Washington, DC Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/other_solid_tumors/7th_targeted_therapies_2032/index.php Topics Covered: The Seventh International Congress on Targeted Therapies in Cancer has been designed to |
| Seventh International Congress on the Future of Breast Cancer Conference Dates: July 23-26, 2008 Conference Location: Koloa, HI Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/breast_cancer/7th_bcc/index.php Topics Covered: The Seventh International Congress on the Future of Breast Cancer is an international educational and scientific meeting |
| Fourth Annual Multidisciplinary Symposium on Head and Neck Cancer Conference Dates: December 6, 2008 Conference Location: Philadelphia, PA Sponsoring Group: Physicians' Education Resource Conference Web Page URL: http://www.cancerconferences.com/thoracic/4th_headneck_1208_1102042/index.php Topics Covered: The purpose of the Fourth Annual Multidisciplinary Symposium on Head and Neck Cancer is to provide an |
| Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients with Complete Response to Definitive Chemoradiotherapy? Scientific Session: Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients wtih Complete Response to Definitive Chemoradiotherapy? Patients with locally advanced squamous cell cancer of the head and neck are typically treated with a combination of chemotherapy and radiation therapy. This therapy can achieve a |
| Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Scientific Session: Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer There is no consensus on standard therapy for locally advanced pancreatic |
| Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Scientific Session: Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Although no large, randomized trials have directly compared outcomes between the two leading treatment options for patients with low-risk prostate cancer, historical |
| Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Scientific Session: Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Improved radiation techniques (IMRT and 3D conformal radiation therapy) have allowed for higher doses of radiation to be given in the treatment of prostate cancer. This study updated a previous report which showed |
| Can Adjuvant Neck Dissection be Deferred in Locally Advanced Head and Neck Cancer Patients wtih Complete Response to Definitive Chemoradiotherapy? Presenter: S. YovinoPresenter's Affiliation: University of Maryland Medical System, Baltimore, MDType of Session: ScientificBackground With recent advances in radiotherapy techniques and their use with concurrent chemotherapy, patients with locally advanced squamous cell carcinoma of the head and neck who are felt to be at risk for |
| Breast Magnetic Resonance Imaging in the Management of Early Breast Cancer: Implications for Partial Breast Irradiation Presenter: R.D. TendulkarPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground For patients with early stage breast cancer, breast conserving treatment (BCT), consisting of lumpectomy followed by breast irradiation is currently a standard of care. Current radiotherapy techniques involve delivery of |
| Comparison of Health Related Quality of Life (HRQOL) in Men Treated With Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer Presenter: Varagur M. Venkatesan, MDPresenter's Affiliation: London Regional Cancer Program, London Health Sciences CentreType of Session: ScientificBackground Although no large, randomized trials have directly compared outcomes between the two leading treatment modalities for patients with low-risk prostate cancer, historical comparisons |
| Breast Cancer After Supradiaphragmatic Irradiation for Hodgkin's Disease; Risk Analysis and Possible Surveillance Strategies Presenter: M. A. Alm El-Dina, MDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Radiation therapy imparts an antitumor effect through the formation of free radiations. Radiation can also have effects on normal tissues. It can also induce cancer in long-term cancer survivors, |
| Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer Presenter: C.H. Crane substituting for F. MornexPresenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon Pierre Benite, FranceType of Session: ScientificBackground Pancreatic cancer is the fourth most common malignancy in the United States, and the annual incidence rate is almost identical to the mortality rate. In 2007, over 37,000 |
| Chest Wall Radiation Alone for Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated by Mastectomy Presenter: Shannon M. MacDonald, MDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Numerous studies have demonstrated that the administration of adjuvant comprehensive postmastectomy radiation, which includes radiation to the chest wall and supraclavicular region, reduces locoregional recurrences |
| A Phase II Study of a Paclitaxel Based Chemoradiation Regimen With Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246 Presenter: Stephen Swisher, MDPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Prior studies (RTOG 8501) have demonstrated that chemoradiation is more effective than radiation alone in the treatment of esophageal cancer. However, in this study the majority of patients had squamous cell carcinoma and |
| Statin Use and Clinical Outcomes after High-Dose Radiotherapy for Prostate Cancer Presenter: M. ZelefskyPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NYType of Session: ScientificBackground Clinical and laboratory work has suggested that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins, may have anti-cancer activity. These drugs have been demonstrated |
| Update of the Results of the Dutch Multicenter Dose Escalation Trial of Radiotherapy for Localized Prostate Cancer Presenter: Abrahim Al-Mamgani, MDPresenter's Affiliation: Erasmus Medical Center, Rotterdam, The NetherlandsType of Session: ScientificBackground With the increased use of three-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiation therapy (IMRT), radiation oncologists have been able to treat patients with prostate |
| Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONCEPT trial Presenter: A. Grothey Presenter's Affiliation: Mayo Clinic Type of Session: Scientific Background Oxaliplatin is widely used as a 1st line treatment for metastatic colorectal cancer (mCRC). The addition of Bevacizumab has also been shown to improve efficacy, and these 2 agents are often used in combination. Although oxaliplatin is relatively |
| Long-term outcomes among survivors of childhood central nervous system tumors: A report from the childhood cancer survivor study Presenter: G. T. ArmstrongPresenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TNType of Session: ScientificBackground Over 270,000 childhood cancer survivors reside in the United States, and this number is expected to grow as survival rates after childhood cancer continue to increase. Currently, one in 640 adults |
| BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy BRCA1 mRNA expression in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy Improved overall survival has been demonstrated with the use of cisplatin-based chemotherapy given prior to radical cystectomy in patients with locally advanced bladder cancer, as compared to radical cystectomy alone (Lancet, 2003). |
| Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7 Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04C7 The addition of oxaliplatin to the arsenal of therapies for GI cancers has had a profound effect on survival, but not without additional side |
| Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib Researchers believe that having multiple copies of a cromosome (i.e. 3 or more, a condition known as polysomy), specifically of chromosome 17, may result in higher |
| Initial Safety Report of NSABP C-08, a Randomized Phase III Study of Modified 5-Flurouracil (5-FU/leucovorin (LCV) and oxalliplatin (OX) (mFOLFOX6) with or without Bevacizumab (bev) in the Adjuvant Treatment of Patients with Stage II/III Colon Cancer Presenter: Allegra, C.J.Presenter's Affiliation: University of FloridaType of Session: ScientificBackground There is a rationale for combining antiangiogenic agents, such as bevacizumab, with cytotoxic chemotherapy, such as mFOLFOX6, in the treatment of solid tumors. The tumor vasculature is thought to be disorganized and leaky, |
| A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has clinical implications for hormonal therapies. 55% of metastatic breast cancer patients are |
| Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial Presenter: R.A. NoutPresenter's Affiliation: Leiden University Medical Center, Leiden, NetherlandsType of Session: ScientificBackground Endometrial carcinoma represents the most common gynecologic malignancy in the United States, and the second most common cause of gynecologic cancer death. Tumor grade (1 -3), histology, and depth of |
| Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG Presenter: M. GnantPresenter's Affiliation: Medical University of ViennaType of Session: ScientificBackground In hormone receptor-positive breast cancers, growth of the tumor is stimulated by estrogens. Decreasing the production of estrogens therefore leads to suppression of recurrence, and drugs such as tamoxifen and aromatase |
| KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience Presenter: Van Cutsem E. Presenter's Affiliation: University Hospital Gasthuisberg, Leuven, Belgium Type of Session: Plenary Background Cetuximab is a chimeric antibody which blocks epidermal growth factor (EGF) signaling by binding to the EGF receptor (EGFR). The EGFR has several downstream targets, including the PI3K/Akt pathway and |
| Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO Bevacizumab is a monoclonal antibody that targets VEGF, which allows it to inhibit angiogenesis (growth of blood |
| KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience Cetuximab is a targeted therapy agent that blocks epidermal growth factor receptor (EGFR) and that is used in the treatment of colon cancers. EGFR has several |
| Cancer-related fatigue interferes with activities of daily living among 753 patiens receiving chemotherapy: A URCC CCOP study Presenter: K.M. MustianPresenter's Affiliation: University of Rochester Cacner Center, Rochester, NYType of Session: ScientificBackground Cancer-related fatigue (CRF) is common in cancer patients, and may be under-diagnosed, under-recognized, and under-treated (Savard, 2001). Cancer-related fatigue is in all likelihood multifactorial, |
| A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study Presenter: G. R. MorrowPresenter's Affiliation: U. of Rochester Medical Center, Rochester, NYType of Session: ScientificBackground Cancer-related fatigue (CRF) is one of the most common side effects of cancer and its treatment, and has been shown to affect nearly 70-100% of cancer patients in previous studies. It usually comes |
| ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Presenter: Picozzi R.A.Presenter's Affiliation: Virginia Mason Medical Center, Seattle WashingtonType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented (Jemal, CA Cancer J Clin, 2007). |
| CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) Presenter: Neumann J.P.Presenter's Affiliation: Charite School of Medicine, Berlin, GermanyType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States, and in 2007, over 37,000 cases were diagnosed, and over 33,000 deaths documented . Surgery is the only curative |
| Electronic self-report assessment for cancer (ESRA-C): Results of a randomized clinical trial Presenter: D.L. BerryPresenter's Affiliation: University of Washington, Seattle, WAType of Session: ScientificBackground As the healthcare milieu continuously evolves, healthcare providers are faced with the difficulties of shrinking resources, which may ultimately impact upon the amount of time spent with patients during individual clinic |
| ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Surgery is considered the only curative therapy for pancreatic cancer. However, 50-80% of patients will develop recurrence after surgery. For this reason, patients also receive adjuvant (meaning |
| Cancer-related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study Cancer-related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study Cancer-related fatigue is unfortunately a very common problem with few to no effective solutions. This study looked to evaluate rates of fatigue and how they interfere with activities of daily living (ADLs) (such as |
| CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) This study has previously reported (Oettle H., et al. JAMA 2007) that the use of post-operative gemcitabine in patients with pancreatic cancer |
| Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Depression and insomnia are two common issues in people with cancer. Studies have found that approximately 30% of people with cancer report insomnia and they are 2.5 times as likely to have insomnia compared with the general population. This |
| A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study Cancer-related fatigue (CRF) is one of the most common side effects of cancer and its treatment, and has been shown to affect nearly 70-100% of cancer patients in previous studies. This |
| A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 Prior studies of gemcitabine with radiation therapy in pancreatic cancer have concluded that the drug adds toxicity, with little, if any benefit. But, gemcitabine if known |
| Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer “Chemobrain” or “chemofog” was originally described by the female breast cancer population, and refers to symptoms of decreased cognitive acuity described by patients. Often, these symptoms include |
| Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% of patients who present with resectable disease experience 5-year survivals of only 10-25%. |
| The Impact of Short Course Pre-Operative Radiotherapy on Patients’ Quality of Life: Data from the MRC CR07/ NCIC CO16 Randomised Clinical Trial in Patients with Rectal Cancer Presenter: D. Sebag-Montefiore, MDPresenter's Affiliation: Medical Research Council Clinical Trial Unit, CR07 Trial Management GroupType of Session: PlenaryBackground The current standard of care for treatment rectal cancer involves surgery; however, there is a high incidence of local recurrence seen after surgery due to failure to remove all |
| A Randomized Trial Comparing Antiandrogens with or without Radiotherapy in the Treatment of Locally Advanced Prostate Cancer: Survival and QOL Outcome Presenter: Anders WidmarkPresenter's Affiliation: Umeå University, SwedenType of Session: ScientificBackground Hormonal therapy has become a standard addition to definitive radiation therapy for higher risk and locally advanced prostate cancer. Luteinizing hormone-releasing hormone (LHRH) antagonist administration, a form of medical |
| Long-term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation Following Breast Conserving Surgery in Women with Node-Negative Breast Cancer Presenter: T.J. WhelanPresenter's Affiliation: Juravinski Cancer Centre and McMaster University, Hamilton, ON, CanadaType of Session: PlenaryBackground Large, well-designed trials have demonstrated that lumpectomy followed by whole breast radiotherapy is equivalent to mastectomy as treatment for early-stage breast cancer (Fisher B, NEJM, |
| Results of the Phase III ENRICH (RT-016) Study of Efaproxiral Administered Concurrently with Whole Brain Radiation Therapy (WBRT) in Women with Brain Metastases from Breast Cancer Presenter: J. H. SuhPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground Brain metastasis is a common and deadly complication of many cancers, including lung, breast, renal cell, melanoma, and others. 170,000 individuals are diagnosed with new brain metastases annually in the United States. |
| The Incidence of Stroke in Patients with Head and Neck Cancer with or without Radiotherapy Presenter: D.J. HuangPresenter's Affiliation: Mount Sinai School of Medicine, New York, NYType of Session: ScientificBackground Radiotherapy is an essential component of treatment for many cancers of the head and neck, and may be delivered in combination with surgery and/ or chemotherapy. As the number of cancer survivors living in the |
| CaP Calculator: An Online Decision Support Tool to Improve Evidence-based Doctor-Patient Communication for Clinically Localized Prostate Cancer Presenter: M.S. KatzPresenter's Affiliation: Saints Medical Center, Lowell, MAType of Session: ScientificBackground Prostate cancer is the most commonly diagnosed cancer in men living in the United States, and most patients have localized disease at the time of diagnosis. At the time of prostate cancer diagnosis, patients are faced with |
| Stereotactic Body Radiosurgery for 121 Cases of Spinal Metastases Treated at M.D. Anderson Cancer Center Presenter: E. L. ChangPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: ScientificBackground · Spinal metastases commonly develop in patients with cancer, and can often cause extreme back pain, weakness, autonomic dysfunction, and difficulty with |
| Final Report of a Canadian Phase III Trial of 3 vs. 8 months Neoadjuvant Androgen Deprivation Prior to 66 Gray External Beam Radiotherapy for Clinically Localized Prostate Cancer. Presenter: J. M. Crook, MDPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Data from prior RTOG and EORTC trials indicate that the combination of hormonal therapy to radiation treatment for prostate cancer may improve survival in certain subsets of patients. However, |
| Long-term Quality of Life after Chemoradiation for Anal Cancer Presenter: Prajnan DasPresenter's Affiliation: UT MD Anderson Cancer Center, Houston, TXType of Session: ScientificBackground There are an estimated 4700 cases/year of anal cancer in the US. Definitive radiation therapy with concurrent chemotherapy represents the standard of care for squamous cell carcinoma of the anus. RTOG 9811 |
| A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312 Presenter: Anthony ZietmanPresenter's Affiliation: Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground Prospective randomized studies have shown dose escalation to be effective in prostate cancer A previous study of dose escalation to 79.2 Gy utilized conformal photon therapy to 50.4 with a proton boost to the |
| Acupuncture for the Treatment of Vasomotor Symptoms in Breast Cancer Patients Receiving Hormone Suppression Treatment Presenter: E. M. Walker, MDPresenter's Affiliation: Henry Ford Health System Department of Radiation Oncology, Detroit, MIType of Session: ScientificBackground Anti-estrogen hormonal therapy given as treatment for breast cancer can induce early menopause, and often causes patients to experience debilitating vasomotor symptoms, mainly hot |
| Radiation Therapy for High Risk Prostate Cancer: Do Patients 70 Years or Older Benefit from Combined Androgen Deprivation Therapy? Presenter: J. S. Silverman, MDPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PAType of Session: ScientificBackground It has been well established from previous research that long-term (2 to 3 years) of androgen deprivation therapy (ADT) significantly improves survival in men with high-risk prostate cancer. ADT is now widely |
| Psychological Distress in Long-term Survivors of Adult-onset Cancer: Results from a National Survey Presenter: K. E. HoffmanPresenter's Affiliation: Harvard Radiation Oncology Program, Harvard Medical School, Boston, MAType of Session: ScientificBackground The number of cancer survivors has increased steadily over the past four decades, and an estimated 12 million cancer survivors are living in the United States currently (MMWR, 2004). |
| Preliminary Results of Proton Radiotherapy for Esophageal Cancer Presenter: Suwen LiuPresenter's Affiliation: Wanjie Proton Therapy Center, Zibo, ChinaType of Session: ScientificBackground China has the highest incidence of esophageal cancer in the world with a rate of 479 per 100,000 people. Radiation therapy plays an important role in the treatment of this disease. However, standard radiation therapy is |
| Separating the Rectum from the Prostate during Proton Beam Radiotherapy of Prostate Cancer Patients Reduces Rectal Side Effects Presenter: K. NilssonPresenter's Affiliation: Uppsala University, SwedenType of Session: ScientificBackground Radiation therapy is one of the mainstays of treatment for localized prostate cancer. Common side effects of this treatment include acute and late rectal toxicity. Many investigators and clinicians have attempted to reduce |
| Pelvic Proton Radiotherapy for High-Risk Prostate Cancer Presenter: Bhishamjit S. Chera, M.D. Presenter's Affiliation: University of Florida Department of Radiation Oncology, Gainesville, FL Type of Session: Scientific Background Treatment options for prostate cancer in the current era are largely based on risk assessment and stratification. Patients with clinical stage T3 – T4 disease, |
| Comparison of Proton and Photon Radiation Treatment Plans for the Adjuvant Treatment of Pancreatic Cancer Including Comprehensive Nodal Radiation Presenter: Mark Ingram Presenter's Affiliation: University of Pennsylvania Type of Session: Poster Background Pancreatic cancer is the fourth leading cause of death and most patients present with unresectable disease. The five year survival is poor even in patients who can be resected (5 year survival ~10%) and is even worse in patients who |
| Effectiveness of Rectal Balloon as an Internal Immobilization Device for Proton Therapy of Prostate Cancer Presenter: Andrew Lee, M.D., M.P.H.Presenter's Affiliation: Division of Radiation Oncology, The University of Texas M.D. Anderson Cancer CenterType of Session: ScientificBackground Radiotherapy for prostate cancer depends largely on the technical ability to deliver adequate dose to the prostate without severe bladder and rectal |
| Head and Neck Cancer and Proton Therapy Presenter: William Mendenhall, MD Presenter's Affiliation: University of Florida Type of Session: Reporting There are several potential advantages to proton treatment compared with IMRT in the treatment of patients with head and neck cancers. The major advantage is likely to be a decrease in the late side effects associated with radiation |
| Beyond Treatment: Challenges & Solutions for Cancer Survivors...Employment Law Conference Dates: January 15, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Topics include: who is covered by the ADA, reasonable accommodation, the scope and limits of protections under the ADA, who |
| Mitosis and Cancer Symposium Conference Dates: February 26 - 27 , 2009 Conference Location: Amsterdam, The Netherlands Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/mitosiscancer Topics Covered: - Cellular responses to checkpoint activation in G2 and mitosis - Targeting mitotic pathways in cancer therapy - The mitotic checkpoint and cancer Conference |
| Beyond Treatment: Challenges & Solutions for Cancer Survivors...Social Security Disability Conference Dates: February 19, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Eligibility for SSD and SSI, available benefits, applying for benefits and the appeals process. Conference Objectives: |
| 9th Annual Conference for Young Women Affected by Breast Cancer Conference Dates: February 27-March 1, 2009 Conference Location: Hilton Anatole, Dallas, TX Sponsoring Group: Living Beyond Breast Cancer & Young Survival Coalition Conference Web Page URL: www.youngsurvivorsconference.org Topics Covered: Understand how various treatments can impact fertility — and what options can help you maintain |
| Beyond Treatment: Challenges & Solutions for Cancer Survivors...Finding Work Conference Dates: March 19, 2009 Conference Location: teleconference Sponsoring Group: Legal Clinic for the Disabled, St. Mary's Medical Center, American Cancer Society, Leukemia & Lymphoma Society Topics Covered: Information to help unemployed or under employed cancer survivors find work. Available resources, how to avoid problems, advice |
| Eighth Annual Recent Advances and New Directions in Cancer Conference Dates: March 27-29, 2009 Conference Location: The InterContinental, San Francisco, CA Sponsoring Group: CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com/ccc2009 Topics Covered: The rapidity of recent advances in the use of targeted agents, molecular biomarkers, and expression profiling in |
| Ninth Annual New Strategies in Breast Cancer Conference Conference Dates: April 3-4, 2009 Conference Location: Philadelphia, PA Sponsoring Group: The CBCE (The Center for Biomedical Continuing Education) Conference Web Page URL: http://www.thecbce.com/nsbc2009 Topics Covered: In this 2-day intensive review, clinical experts will discuss recent progress in the detection, prevention, diagnosis, |
| Immune Tolerance in Cancer and Autoimmune Disease Conference Dates: May 06 - 09, 2009 Conference Location: Antigua Sponsoring Group: Abcam, Inc. Conference Web Page URL: www.abcam.com/go.cfm?p=3321 Conference Objectives: Immune Tolerance in Cancer and Autoimmune Disease: how to break it, and how to (re-)make it. Conference Agenda: Immune Tolerance in Cancer and Autoimmune Disease: how to |
| Apoptosis and Cancer: The Bcl-2 family of proteins Conference Dates: June 25-26, 2009 Conference Location: Dartmouth College, New Hampshire Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/go.cfm?p=2733&Cl=2282 Topics Covered: The Bcl-2 family of proteins (Bcl-2-like proteins, Bax/Bak, BH3-only proteins): -Regulation and role in apoptosis and tumorigenesis |
| Great Debates and Updates in Breast Cancer Conference Dates: June 19-20, 2009 Conference Location: San Francisco, CA Sponsoring Group: Imedex, LLC Conference Web Page URL: www.imedex.com/appweb/announcements/A048-01.asp Topics Covered: Chemoprevention of breast cancer Selecting techniques for breast cancer surgery Confusion and controversies in radiation therapy |
| 2009 Update on Breast Cancer: Coverage of the American Society of Clinical Oncology's Annual Meeting Conference Dates: Thursday, June 11, 2009 Conference Location: The Hub Cira Center, 2929 Arch Street, Mezzanine Level, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine/ CME Conference Web Page URL: www.oncolink.org/conference/asco Topics Covered: Adjuvant chemotherapy, adjuvant hormonal therapy, surgery, |
| Cancer Transitions: Moving Beyond Treatment Conference Dates:Thursdays, October 1, 8, 15, 22, 29 And November 5, 2009 Conference Location: The Suzanne Morgan Center at Ridgeland, Chamounix Drive, West Fairmount Park, Philadelphia, Pennsylvania 19131 Sponsoring Group: The Wellness Community of Philadelphia Conference Web Page URL: twcp.org Topics Covered: This is a six-week |
| Cancer in Africa - The New Reality Conference Dates: November 11-14, 2009 Conference Location: Dar Es Salaam, Tanzania Sponsoring Group: AORTIC (African Organisation for Research and Training in Cancer) Conference Web Page URL: www.aortic2009.org Topics Covered: The AORTIC 2009 conference will have a strong focus on cancer control. The main themes will be cancer treatment, |
| Breast Cancer Support for Lesbians and Bisexual Women and their Families Conference Dates: November 1, 2009 (8am-5:30pm) Conference Location: Gilda's Club, Warminster, PA Sponsoring Group: Gilda's Club Delaware Valley Conference Web Page URL: http://www.gildasclubdelval.org/events.htm Topics Covered: Breast cancer support networking Self-Advocacy Nutrition Survivorship Issues Intimacy and cancer and much more! |
| Cetuximab-based neoadjuvant chemoradiation and surgical resection in patients with locally advanced esophageal and gastric cancer Presenter: H.J. Wanebo, Brown University Oncology Group, Providence, Rhode Island Background Although surgical treatments remain a mainstay of definitive treatments for esophageal and gastric cancers, several groups have demonstrated benefit to multimodality treatments (Krasna, 2006). Although up-front surgical procedures are often performed |
| Final safety findings from a randomized phase III trial of preoperative FU-based chemoradiation +/- weekly oxaliplatin as neoadjuvant therapy for patients with locally advanced rectal cancer: the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial Presenter: C. Aschele on behalf of STAR Network Investigators Background Beginning in the mid-1990s, with the publication of results from the German CAO/ARO/AIO 94 trial, a paradigm shift from treatment of locally advanced rectal cancer with up-front surgery to administration of preoperative chemoradiotherapy took place. This change was based |
| Use of endoscopic ultrasonography in screening patients at high-risk for pancreatic cancer Presenter: J. Poley, University Medical Center, Rotterdam, Netherlands Background Screening of the general population for certain malignancies, including breast cancer, prostate cancer, colon cancer, and cervix cancer has become standard of care within the United States and in many countries abroad. The feasibility and cost-effectiveness of |
| European Multidisciplinary Colorectal Cancer Congress Conference Dates: March 28-30, 2010 Conference Location: Nice, France Sponsoring Group: ESMO, ESSO, ESTRO, ESP, ESGAR Conference Web Page URL: www.colorectal2010.org Topics Covered: All aspects of diagostic & treatment of colorectal cancer Conference Objectives: offer a real multidisciplanary approach for the treatment of colorectal |
| Practical Advice and Tools to Balance Cancer and Employment Conference Dates: March 4, 2010 Conference Location: Teleconference Sponsoring Group: Cancer and Careers Conference Web Page URL: www.cancerandcareers.org/healthcare_professionals/ Who Should Attend: Oncology nurses, social workers, patient navigators, etc. Registration Information: |
| Chemotherapy Foundation Symposium, Innovative Cancer Therapy for Tomorrow Conference Dates: November 9-13, 2010 Conference Location: Marriott Marquis, NYC Sponsoring Group: Mount Sinai School of Medicine and The Chemotherapy Foundation Conference Web Page URL: chemotherapyfoundationsymposium.org Topics Covered: New agents, clinical trials, targeted therapies, biotherapies, hematology, breast, GI, |
| The 2010 AICR Annual Research Conference on Food, Nutrition, Physical Activity and Cancer Conference Dates: October 21-22, 2010 Conference Location: Capital Hilton, Washington, DC Sponsoring Group: American institute for Cancer Research Conference Web Page URL: www.aicr.org/conference Topics Covered: Cancer, Nutrition, Food, Physical Activity Conference Objectives: Research Conference on Food, Nutrition, Physical |
| The Role of Multi-gene Predictors in Early Breast Cancer Conference Dates: May 1, 2010 Conference Location: WTTW-CH 11 Studios, Chicago, IL Sponsoring Group: ONECONSORTIUM Oncology Education Conference Web Page URL: http://www.oneconsortium.org/registration Conference Objectives: Evaluate the results of recent studies on molecular profiling of breast cancer and apply the knowledge |
| Ninth International Congress on the Future of Breast Cancer Conference Dates: July 22-25, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/520 Conference Objectives: An international educational and scientific meeting that focuses on the |
| Ninth International Congress on Targeted Therapies in Cancer Conference Dates: August 20-22, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/529 Topics Covered: At the conclusion of this congress, you should be able to: Discuss |
| Cancer Metabolism: Pathways to the Future Conference Dates: September 19-21, 2010 Conference Location: Edinburgh Sponsoring Group: Eyal Gottlieb and Karen Vousden (The Beatson Institute for Cancer Research, UK) Conference Web Page URL: www.abcam.com/index.html?pageconfig=resource&rid=12304 Topics Covered: - All the major aspects of metabolic transformation in cancer - Potential |
| 4th Annual Perspectives in Genitourinary Oncology: A Case-Based Approach to Enhance Patient Management of Prostate, Renal and Bladder Cancers Conference Dates: September 24-25, 2010 Conference Location: Chicago, Illinois Sponsoring Group: Imedex Conference Web Page URL: www.imedex.com/AppWeb/announcements/a179-01.asp Topics Covered: Concurrent break-out discussions for oncologists and urologists on the management of prostate, bladder, and renal cancers Role of adjuvant |
| 14th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine Conference Dates: September 24-26, 2010 Conference Location: United States Sponsoring Group: Physicians’ Education Resource in conjunction with Duke Oncology Network Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/545 Topics Covered: Topics to be included: |
| Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy Conference Dates: October 8-10, 2010 Conference Location: Sheraton New York Hotel Towers Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/530 Topics Covered: The Ninth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that |
| Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer Conference Dates: October 1, 2010 - October 1, 2010 Conference Location: 201 Waterfront St., National Harbor, MD 20745 Sponsoring Group: Physicians' Education Resource Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/590 Topics Covered: Evaluate the utility of gene profiling |
| The Future of Cancer Research: Accelerating Scientific Innovation Dates: October 26, 2010 Location: Chemical Heritage Foundation, Philadelphia, PA Sponsoring Group: President's Cancer Panel Web Page URL: pcp.cancer.gov Topics Covered: Future of Cancer Research Subject of Public Forum in Philadelphia, PA Second of Four Meetings in National Series The President's Cancer Panel will conduct an open forum |
| Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy Presenter: S. DawoodPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground The Early Breast Cancer Trialists’ Collaborative Group Overview (Lancet 2005), a meta-analysis of 78 randomized trials, including 42,000 women, showed that radiation therapy (RT) after breast-conserving surgery |
| RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) Presenter: N. J. RobertPresenter's Affiliation: US Oncology GroupType of Session: ScientificBackground Bevacizumab (B) is a humanized monoclonal antibody which inhibits VEGF, a known central mediator of angiogenesis. Two previous large phase III trials, E2100 and AVARO, have demonstrated that B in combination with weekly paclitaxel or |
| National survey of physicians practice patterns: Fertility preservation and cancer patients Title: National survey of physicians practice patterns: Fertility preservation and cancer patientsReviewer: Arpi Thukral, MD Presenter: G. QuinnAffiliation: Moffitt Cancer Center The treatment of cancer often poses a threat to fertility for young patients of child-bearing age. Approximately 450,000 cancer survivors in the U.S. are of |
| Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Title: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Reviewer: Arpi Thukral, MD Presenter: Joyce O'Shaughnessy, MD Affiliation: US Oncology Group PARP is an |
| A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Title: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Reviewer: Geoffrey Geiger MD Presenter: G. J. Rustin, M. E. van der Burg Affiliation: On behalf of the MRC and EORTC collaborators Ovarian |
| First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005) Title: First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005) Reviewer: Christine E. Hill-Kayser, MD Presenter: Christopher Nutting on behalf of the PARSPORT Trial Management Group, Cancer Research UK Radiation therapy is a |
| Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study Title: Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study Reviewer: Christine Hill-Kayser, MD Presenter: Pascal Jean-Pierre, PhD, MPH Affiliation: University of Rochester Medical Center Many cancer survivors report difficulty with neurocognitive functioning, often called |
| Proton Radiation Therapy for Patients with Prostate Cancer Presenter: C. RossiPresenter's Affiliation: Loma Linda, USAType of Session: ScientificBackground The most effective treatment for clinically localized prostate cancer remains controversial, as no randomized trials comparing radiation therapy to surgical resection have been performed. Options for the treatment of clinically localized |
| Proton treatment of prostate cancer in the presence of unilateral hip replacement Presenter: M. Fitzek, K. Shahnazi, J. Simmons, A. ThorntonPresenter's Affiliation: Midwest Proton Radiotherapy Institute, Bloomington, IN, USAType of Session: ScientificBackground Options for the treatment of clinically localized prostate cancer include radical prostatectomy and radiation therapy, and the latter can be delivered via |
| Multi-Institutional Phase II Study of Proton Beam Therapy for Organ Confined Prostate Cancer in Japan, Focusing on the Incidence of Late Rectal Toxicities Presenter: Dr. K. NiheiPresenter's Affiliation: Shizuoka Cancer Center, Shizuoka, JapanType of Session: ScientificBackground At present, IMRT is the predominant modality used to treat prostate cancer using radiation Dose escalation has been shown to provide higher rates of biochemical free survival in numerous studies (Zietman et al., |
| Carbon Ion Therapy for Patients with Pancreas Cancer Presenter: Dr. S. YamadaPresenter's Affiliation: Chiba University, Chiba JapanType of Session: ScientificBackground The treatment of pancreatic cancer remains a therapeutic challenge. The majority of patients are unresectable at the time of diagnosis and even in those patients who are resectable, trimodality therapy still has poor outcomes |
| Randomized Phase III Trial of Radical Radiotherapy with Concurrent Carbogen and Nicotinamide in Locally-advanced Bladder Cancer Presenter: P. HoskinPresenter's Affiliation: Mount Vernon Cancer Centre, Northwood, United KingdomType of Session: ScientificBackground Although radical cystectomy is generally considered to be the standard treatment for patients with muscle-invasive bladder cancer, radiation therapy has been shown to allow for high rates of |
| First Report of Real-time Tumor Tracking in the Treatment of Pancreatic Cancer using the Calypso System Presenter: James M. Metz, MDPresenter's Affiliation: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PAType of Session: ScientificBackground In the United States, surgery followed by combined modality therapy with chemotherapy and radiation therapy remains the standard of care for the approximately 10-20% of patients |
| Changes in Left Ventricular Function after Radiation Therapy and Trastuzumab: Analysis of North Central Cancer Treatment Group Phase III Trial N9831 Presenter: M. HalyardPresenter's Affiliation: Mayo Clinic, Scottsdale, AZType of Session: ScientificBackground Radiotherapy for breast cancer has recently been associated with increased risk of coronary artery disease in patients receiving radiotherapy to the left breast or chest wall (Harris EE, JCO, 2006). Since |
| Cardiac Complications and Mortality in Men with Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormonal Therapy Presenter: A. NandaPresenter's Affiliation: Harvard Radiation Oncology Program, Boston, MAType of Session: ScientificBackground Multiple studies have demonstrated benefit in biochemical and disease-free survival in men with intermediate and high-risk prostate cancer receiving androgen ablation therapy in combination with |
| The Four-Year Beam Delivery Experience at the M.D. Anderson Cancer Center Proton Therapy Center Houston Presenter: Dr. Kazumichi Suzuki Presenter's Affiliation: The University of Texas M. D. Anderson Cancer Center, Proton Therapy Center Houston, Houston, TX Background The M.D. Anderson Cancer Center began delivering proton radiotherapy in May, 2006, and, since that time, > 1800 patients have been treated at their center. The |
| Systematic Review and Meta-Analysis of Best Available Photon, Proton, and Carbon-Ion Radiotherapy in Various Head and Neck Cancers Presenter: Dr. Janneke Grutters for Dr. Bram Ramaekers Presenter's Affiliation: Maastricht Radiation Oncology (MAASTRO), Maastricht, The Netherlands Background Cancers of the head and neck represent a heterogeneous group of malignancies. Although these cancers can and do metastasize to distant sites, local control has been demonstrated |
| Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study Presenter: M. T. Milano, Department of Radiation Oncology, University of Rochester, Rochester, NY Background Second malignant neoplasms are the leading cause of death among long-term survivors of Hodgkin lymphoma (HL) (Hoppe et al. Ann Oncol, 1997). Breast cancer (BC) is the most common solid tumor diagnosed among female HL survivors. |
| Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer Background In locally advanced prostate cancer, the combination of radiation therapy (RT) and androgen deprivation therapy (ADT) has been demonstrated to provide superior outcomes when compared to RT or ADT alone (Bolla, Lancet, 2002). Indications and methodology for delivery of ADT remain uncertain and at times controversial. Outstanding |
| Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients Presenter: S. H. Giordano, University of Texas M. D. Anderson Cancer Center, Houston, TX Background Diabetes and obesity are very prevalent in the US population and the incidence of these disorders continues to rise. The National Institute of Health estimated that in 2007, 7.8% of Americans had either diagnosed or undiagnosed |
| Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer Presenter: K. S. Hughes, CALBG, ECOG, RTOG, Massachusetts General Hospital, Boston, MA Background The Early Breast Cancer Trialists’ Collaborative Group Overview (Lancet, 2005), showed that radiation therapy (RT) after breast-conserving surgery (BCS) produced significant absolute improvements in 5-year LR (17-19% benefit) and 15-year breast |
| Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC) Presenter: J. Y. Lai, PhD; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada Background Cervical cancer is a major cause of cancer morbidity and mortality worldwide, with an estimated 11,270 new cases in the United States in 2009. Gardasil is a vaccine that has been developed to immunize patients against |
| Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study Presenter: A. M. Termuhlen, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, OH Background Wilms tumor (WT) is the most common pediatric abdominal tumor. The development of more effective therapy for WT has translated into marked improvements in overall survival since the 1960's, and currently |
| Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial Presenter: G. Pfeiler, MD, Medical University of Vienna Background In hormone receptor positive breast cancers, drugs such as Tamoxifen and aromatase inhibitors decrease the production of estrogens, and have been shown to lead to suppression of tumor recurrence. Tamoxifen is an orally active selective estrogen |
| Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003 Authors: M. L. Gillison, The Ohio State University, Columbus, OH Background There is a growing body of evidence that Human Papillomavirus (HPV) infection plays an important role in the pathogenesis of a subset of head and neck squamous cell carcinomas (SCC). HPV related tumors are characterized by the presence of HPV DNA within the |
| Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care It will come of no surprise to patients and their families that religious and spiritual concerns are important to the majority (76-88%) of patients facing a life-threatening illness. Support of a patient’s religious or spiritual (R/S) needs by the medical team (nurses, physicians and chaplains) is associated with less aggressive care at the end of |
| Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors Most any person going through cancer diagnosis and treatment will tell you their sleep has been affected. Poor sleep, in turn, leads to worse quality of life (QOL) and difficulty carrying out life’s daily activities. While medications can help a person sleep, many patients are hesitant to take yet another pill and practitioners worry about sleep |
| Immunochemotherapy: Correcting Immune Escape in Cancer Conference Dates: March 10-11, 2011 Conference Location: Philadelphia, USA Sponsoring Group: Abcam Conference Web Page URL: www.abcam.com/philadelphia Topics Covered: Immunological effects of chemotherapy. Inflammatory tumor microenvironment and immune suppression. Intrinsic and extrinsic barriers to cancer. Therapeutic strategies. Conference |
| AICR/AADE Webinar: ‘The Diabetes-Cancer Connection: From Research to Practice Dates: March 20, 2012 Time: 1:00 pm ET Location: Washington, DC Sponsoring Group: American Institute for Cancer Research Web Page URL: http://www.aicr.org/health-professionals/ Topics Covered: Diabetes, Cancer, Nutrition, Diet Objectives: Join leading experts in a lively overview of the research, dietary recommendations for each disease, and |
| Apoptosis and Cancer Dates: June 14-15, 2012 Location: Cambridge, UK Web Page URL: http://www.abcam.com/cambridgecancer Topics Covered: BCL2 Family P53 Family Death Receptors and Inflammation IAP's Who Should Attend: All researchers/scientists from academia and industry Agenda: A failure of cells to undergo apoptosis is a common feature of many |
| JAK Inhibition in Cancer: Exploring a Novel Pathway Dates: Saturday, June 2, 2012 Location: Chicago, IL Web Page URL: www.peerviewpress.com/JAK Objectives: Please see website for further information. Who Should Attend: This activity has been designed to meet the educational needs of oncologists and hematologist-oncologists engaged in the management of patients with cancer.. Fees: Please see |
| Breast Cancer Coordinated Care - BC3 Dates: July 19-21, 2012 Location: JW Marriott Washington, DC Sponsoring Group: Georgetown University Hospital Web Page URL: www.bc3conference.com Topics Covered: Breast Conservation Therapy Oncoplastic Surgery Surgical Challenges in the Management of Breast Cancer Post-Mastectomy Radiation Therapy Coordinating Reconstruction with Post-Mastectomy |
| 2012 World Cancer Congress Dates: August 27-30, 2012 Location: Montréal, Canada Sponsoring Group: Union for International Cancer Control (UICC) Web Page: www.worldcancercongress.org Topics Covered: Track 1 Prevention and early detection Session topics include: Digital media in cancer prevention and tobacco control Countering the tobacco industry Education and |
| Sydney Cancer Conference 2012 Dates: September 27-28, 2012 Location: Sydney, Australia Sponsoring Group: University of Sydney Web Page URL: sydney.edu.au/cancer-research/SCC2012/ Topics Covered: The Sydney Cancer Conference 2012 theme is From Discovery to Implementation covering basic cancer research, biomedical cancer research, Clinical and public health research, and |
| Practical Advice & Tools to Balance Cancer & Employment Dates: September 13, 2012, 3PM ET Location: Teleconference/Webinar Sponsoring Group: Cancer and Careers Web Page URL: www.cancerandcareers.org/en/community/events/healthcare-professionals Information: Take a Break and Earn a CEU! Don't miss the Fall 2012 sessions of Cancer and Careers' FREE educational series for healthcare professionals at |
| The AICR Annual Research Conference 2012 on Food, Nutrition, Physical Activity Cancer Dates: November 1-2, 2012 Location: Capital Hilton Hotel, Washington, DC Conference URL: www.aicr.org/conference |
| Brain Metastases from Breast Cancer: Recursive Partitioning Analysis of Prognostic Factors Including Molecular Subtypes and Treatment Authors: R. Le Scodan, C. Massard, L. Jouanneau, F. Coussy, M. Gutierrez, Y. Kirova, A. Labib, E. Mouret-Fourme Institution: Institut Curie, Hopital Rene Huguenin, Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Site Ulm, Paris, France Background Approximately 20-40% of all cancer patients will develop |
| QRRO 2007 Practice Survey Documents Dramatic Technical Changes in How Radiotherapy for Operable Breast Cancer is Delivered Authors: J.R. White1, N. Khalid2, M.L. Tao3, L.J. Pierce4, A. DeRobertis5, C. Crozier2, J.B. Owen2 and J.F. Wilson1 Institution: 1Medical College of Wisconsin, Milwaukee, WI 2American College of Radiology, Philadelphia, PA 3Epic Care, Orinda, CA 4University of Michigan Medical School, Ann Arbor, MI 5Massachusetts General |
| Intergroup Randomized Phase 3 Study of Androgen Deprivation Therapy (ADT) + Radiation Therapy (RT) in Locally Advanced Prostate Cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633) Authors: M.D. Mason, P.R. Warde, M.R. Sydes, M.K. Gospodarowicz, G.P. Swanson, P. Kirkbride, E. Kostashuk, J. Hetherington, K. Ding, W. Parulekar Affiliations: Cardiff University. Cardiff, UK. Princess Margaret Hospital and University of Toronto. Toronto, ON. Clinical Trials Unit, Medical Research Council. London, UK. University of Texas Health |
| 10-year results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer Authors: M. Bolla1, H. Van Poppel2, B. Tombal3, K. Vekemans4, L. Da Pozzo5, T. M. De Reijke6, A. Verbaeys7, J. F. Bosset8, R. Van Velthoven9, L. Collette10 Institution: 1 CHU de Grenoble - A Michallon, Grenoble, France 2 Leuven University Hospital - UZ Gasthuisberg, Leuven, Belgium 3 Cliniques Universitaires Saint Luc, Brussels, |
| Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Level Authors: W.U. Shipley, D. Hunt, H. Lukka, P. Major, N.M. Heney, D. Grignon, M. Patel, J. Bahary, C. Lawton, H. Sandler. Affiliations: Massachusetts General Hospital. Boston MA. RTOG Statistical Center. Philadelphia, PA. Mcmaster University Juravinski Cancer Center. Hamilton, ON Indiana University. Indianapolis, IN. University of |
| Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004) Authors: N. James1, S. Hussain1, E. Hall2, P. Jenkins3, J. Tremlett4, C. Rawlings5, M. Crundwell6, R. Waters2, R. A. Huddart2 Institution: 1 University of Birmingham, Birmingham, United Kingdom 2 Institute of Cancer Research, Sutton, United Kingdom 3 Cheltenham General Hospital, Cheltenham, United Kingdom 4 Brighton and Susgender |
| Outcome of Radiotherapy Alone in HPV Associated Oropharyngeal Cancer Authors: B. O'Sullivan, S. Huang, B. Perez-Ordonez, F. Liu, C. Massey, I. Weinreb, E. Chen, B. Cummings, J. Kim, J. Waldron Affiliations: Princess Margaret Hospital / University of Toronto, Toronto, ON, Canada Background There is a growing body of evidence that Human Papillomavirus (HPV) infection plays an important role in the pathogenesis |
| Triple-Negative Breast Cancer is Associated with Higher Risk of Local Recurrence after 3D-Conformal External Beam Accelerated Partial Breast Irradiation (3D-APBI) Authors: I. M. Pashtan, M. Ancukiewicz, J. Y.Wo, A. E. Hirsch, B. L. Smith, S. N. Powell, A. Recht, A. G. Taghian. Affiliations: Harvard Radiation Oncology Program, Boston, MA. Massachusetts General Hospital, Boston, MA. Boston Medical Center, Boston, MA. Memorial Sloan-Kettering Cancer Center, New York, NY. Beth Israel Deaconess Medical Center, |
| Pelvic Fracture after Radiation Therapy for Localized Prostate Cancer: A Population Based Study Authors: D. M. Housman, C. J. Savage, M. J. Zelefsky, E. B. Elkin Institution: Memorial Sloan-Kettering Cancer Center, New York, NY Background Prostate cancer is the most common malignancy in men; most are diagnosed over age 65, when age-related bone density is already decreasing and pelvic fracture is a source of morbidity and mortality. |
| The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Authors: C. E. Fasola, K. D. Godette, M. W. McDonald, R. M. O'Regan, A. B. Zelnak, J. C. Landry, M. A. Torres. Affiliations: Emory University School of Medicine, Atlanta, GA. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Department of Radiation Oncology, Indiana University School of Medicine, |
| Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer Authors: A. H. Klopp1, J. Moughan2, L. Portelance3, B. E. Miller4, M. R. Salehpour1, D. D'Souza5, L. Souhami3, W. Small6, R. Gaur7, A. Jhingran1 Institution: 1 M.D. Anderson Cancer Center, Houston, TX 2 RTOG Statistical Center, Philadelphia, PA 3 McGill University Health Centre, Montreal, QC, Canada 4 Wake Forest University |
| Patterns of Radiotherapy Practice for Patients Treated for Intact Cervical Cancer in 2005-2007: A QRRO Study Authors: P. J. Eifel1, N. Khalid2, B. Erickson3, C. Crozier2, J. Owen2, J. F. Wilson3 Institution 1 M.D. Anderson Cancer Center, Houston, TX 2 ACR Clinical Research Center, Philadelphia, PA 3 Medical College of Wisconsin, Milwaukee, WI Background Cervical cancer represents a worldwide problem, and is the third most common |
| Focus on Head Neck Cancers Conference Dates: April 8, 2011, 8am - 3pm Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Web Page URL: http://www.penncancer.org/events.cfm?type=1=view%3Devent%26eventid%3D9264606 Topics Covered: The incidence of head and neck cancers and the impact of this disease on men and women, of all ages, have made head and neck cancers a priority |
| 2011 Update in Breast Cancer: Coverage of the ASCO Annual Meeting Dates: Tuesday, June 28, 2011 Location: The Hub Cira Center, 2929 Arch Street, Mezzanine Level, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Web Page URL: www.penncancer.org/eventdetail.cfm?id=310 Topics Covered: This symposium is designed to present cutting-edge data from the 2011 American Society of Clinical Oncology Annual |
| Family Matters: What Every Family Needs to Know About Colon Cancer Dates: June 23-25 Location: Denver, Co Sponsoring Group: Colon Cancer Alliance Web Page URL: http://support.ccalliance.org/site/Calendar?id=100216=Detail Topics Covered: Hear from national experts on: - genetic risks - designing a treatment plan - advanced disease treatment options - tips for living with colon cancer Objectives: Educate |
| Understanding Pancreatic Cancer: A Free Educational Lecture Dates: October 15, 2011 Location: Cancer Support Community of Philadelphia, The Suzanne Morgan Center at Ridgeland, 4100 Chamounix Dr., Phila. PA 19131 Sponsoring Group: Pancreatic Cancer Action Network and the Cancer Support Community of Philadelphia Web Page URL: http://www.pancan.org Topics Covered: Diet and nutrition issues, |
| The AICR Annual Research Conference 2011 on Food, Nutrition, Physical Activity Cancer Dates: November 3-4, 2011 Location: Capital Hilton Hotel, Washington, DC Sponsoring Group: American Institute for Cancer Research Web Page: www.aicr.org/conference Who Should Attend: Health Professionals, Public Continuing Education: No |
| Cancer and Careers Educational Series for Healthcare Professionals Date: November 17, 2011, 3PM ET Location: Teleconference Sponsoring Group: Cancerandcareers.org Web Page URL: http://www.cancerandcareers.org/en/community/events/healthcare-professionals Topics Covered: Do your patients ask for guidance on working through treatment? Do you wish you had better answers? Learn how to advise your patients at |
| Protons, photons and brachytherapy as the boost in locally advance prostate cancer Presenter/Author: I.N. Kanchelli Presenter's Affiliation: Russian Scientific Center for Roentgen-Radiology, Moscow, Russia Background Locally advanced prostate cancer is a serious health problem, and recurrence after treatment with conventional radiation therapy can leave patients and providers with few curative options. Previous |
| Hypofractionated proton beam scanning radiotherapy for prostate cancer Presenter: Herbst M, Wilms M, Dohr D, Hillbrand M. Presenter's Affiliation: Renecker Proton Therapy Center, Munich, Germany Background Prostate cancer is the most common non-skin cancer found in men, with approximately 200,000 cases occurring per year in the United States. The optimal radiation dose fractionation schedule for localized |
| Capecitabine versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial Presenter: Ralf Hofheinz, MD Presenter's Institution: Day Treatment Centre at the Interdisciplinary Tumour Centre Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany Background 5-FU based chemoradiation prior to total mesorectal excision (TME) followed by additional 5-FU chemotherapy is the standard of care for locally advanced |
| Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and Oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial Presenter: Claus Roedel, MD Presenter's Institution: German Rectal Cancer Study Group; University of Frankfurt, Frankfurt, Germany Background The first German Rectal Cancer Study (CAO/ARO/AIO-04) established pre-operative chemoradiotherapy with infusional 5-FU given during the first and fifth weeks of RT (50.4 Gy), followed by TME and an |
| Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) Presenter: V. Guarneri Presenter's Institution: Modena University Hospital, Modena, Italy Background The treatment of patients with breast cancer continues to evolve, with cytotoxic chemotherapy, endocrine therapy, and molecular targeted therapies as the backbone of systemic therapy. As we continue to better our understanding of the |
| NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer Presenter: Timothy Whelan, MD Presenter's Institution: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada Background/Introduction The majority of women with early stage breast cancer are managed with breast conserving surgery (BCS) and surgical staging of the axilla, followed by adjuvant systemic therapy as |
| Effect of yoga on QOL, cortisol rhythm, and HRV for women with breast cancer undergoing radiotherapy Presenter: L. Cohen Presenter's Institution: University of Texas MD Anderson Cancer Center Background Yoga is an ancient practice that originated in India; this "old" practice has a new following, as complementary medicine utilization has increased in recent years within the general population and among cancer patients. Yoga is both a |
| Impact of out-of-pocket expenses on cancer care Presenter: Yousof Zafar Presenter Affiliation: Duke University Medical Center Background The cost of cancer treatment is high and growing rapidly. Although national media attention and public policy has focused on the cumulative costs of care at the macroeconomic level, the burden on individual patients is great, even among patients |
| Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? Presenter: S. Domchek Presenter’s Institution: U. of Pennsylvania School of Medicine Background Research has shown that women who carry the BRCA mutations benefit from risk-reduction procedures to reduce their risk of developing breast and ovarian cancers. The best risk-reduction strategy appears to be surgical removal of the |
| The impact of socioeconomic status on cancer care and survival Presenter: Sandra L. Wong Presenter's Affiliation: University of Michigan Background Race, less education, low income, unemployment, and lack of health insurance have all been found to be predictors for receipt of suboptimal health care. A growing body of literature has confirmed that disparities exist with regard to access to cancer |
| Cancer diagnosis as a risk factor for personal bankruptcy Presenter: Scott Ramsey Presenter’s Affiliation: Fred Hutchinson Cancer Research Center, University of Washington Background The National Institute of Health (NIH) estimates that cancer care costs in 2010 totaled $264 billion. This represents < 10% of our overall healthcare spending of $2.5 trillion per year. Although cancer costs do |
| Preliminary Analysis of 3DCRT vs IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Toxicity Report Presenter: Jeff Michalski , MD Presenter's Affiliation: Washington University Medical Center, St. Louis, MO Trial was funded by the NCI and run by RTOG. Background Numerous dosimetric and several single institution retrospective studies have evaluated the role of IMRT in the treatment of prostate cancer as a mechanism of dose escalation |
| Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer Presenter: Alan Pollack, MD Presenter's Affiliation: Fox Chase Cancer Center/ University of Miami Background Dose escalation has been shown in a number of prospective randomized trials to improved biochemical recurrence free survival for prostate cancer. It has also been suggested that the ?/? ratio for prostate cancer is low at 1.5 |
| Meta-analysis of the Impact of Androgen Deprivation Therapy on Cardiovascular Death in Patients with Prostate Cancer Presenter: Paul Nguyen, MD Presenter's Affiliation: Dana Farber/ Brigham and Women's Cancer Center Background Although ADT has been shown in prospective, randomized trials to improve prostate cancer mortality in high risk localized, prostate cancer, various retrospective data have suggested that androgen deprivation therapy (ADT) has |
| Prospective Randomized Trial Comparing External Beam Radiotherapy versus Watchful Waiting in Early Prostate Cancer (T1b-T2, pN0, Grade 1-2, M0) Presenting Author: A. Widmark Affiliation: Department of Radiation Sciences, Oncology, Umeå University, Umeo, Sweden Background In the mid-eighties, watchful waiting was an acceptable standard of care but radical prostatectomy and definitive radiotherapy became increasingly used. Watchful waiting is an attractive option for patients |
| Accord12/0405-prodige 2 Phase III Trial Neoadjuvant Treatment In Rectal Cancer. Results After 3 Years Of Follow-up Presenting Author: J. Gerard Affiliation: Centre Antoine-Lacassagne, Nice 06189 Cedex 2, France Background The current standard of care for locally advanced rectal cancer is preoperative chemoradiation followed by surgical resection via total mesorectal excision. The EORTC 22921 (Bosset NEJM 2006) and FFCD 9203 (Gerard JCO 2006) |
| Long Term Outcomes Comparing Three-Dimensional Conformal Radiation Therapy to Intensity Modulated Radiation Therapy with Concurrent Chemotherapy for the Treatment of Esophageal Cancer: The MD Anderson Experience Presenter: BA Myles Presenter Affiliation: MD Anderson Cancer Center, Houston, TX Background 3D-CRT with concurrent chemotherapy (pre-operative or definitive) is the standard of care for treating patients with esophageal cancer. However, with 3D-CRT, there is concern for toxicity to adjacent structures, mainly lung and heart. Keeping this |
| Comparison Of Intensity Modulated Proton Therapy (IMPT) To Passively Scattered Proton Therapy (PSPT) In The Treatment of Prostate Cancer Presenting Author: S. Choi Presenter's Affiliation: M.D. Anderson Cancer Center, Houston, TX Background Prostate cancer can be definitively treated with radiotherapy. Higher doses of radiotherapy have been shown to improve biochemical progression-free survival (bPFS) (Zeitman et al. JAMA 2005, Kuban et al. IJROBP 2011). Proton |
| Music Relaxation Video and Pain Control: A Randomized Controlled Trial for Women Receiving Intracavitary Brachytherapy for Gynecological Cancer Presenting Author: G.C. Chi Institution: Texas Christian University, Fort Worth, Texas Background Intracavitary brachytherapy is used along with external beam radiotherapy for the treatment of gynecologic malignancies including cervical and endometrial cancer. The placement of a vaginal cylinder, which is performed on up to 5 separate |
| Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose escalation Era? Presenter: K.O. Castle Presenter Affiliation: MD Anderson Cancer Center, Houston, TX Background Studies have shown androgen deprivation therapy (ADT) to increase over all survival (OS) in intermediate and high risk prostate cancer patients (D'amico, JAMA 2004). However, most of the prospective data supporting use of ADT comes from studies |
| Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08 Presenter: Jason Efstathiou Presenter's Affiliation: Massachusetts General Hospital, Boston, MA Background Androgen deprivation therapy (ADT) has been shown to increase risk for metabolic syndrome, cardiovascular disease (CVD) up to 16% and diabetes (DM) up to 40% (Keating JCO 2006). It is unclear what is the impact of CVD related |
| Long-term Morbidity of Intensity Modulated vs Conformal Radiation Therapy (RT) for Prostate Cancer: A SEER-Medicare Analysis Presenter: N. Sheets Presenter's Affiliation: University of North Carolina, Chapel Hill, NC Background There is a rapid uptake of intensity modulated radiation therapy (IMRT) for treatment of prostate cancer because of potential reduction of dose to normal tissue and hence reduction in morbidity related to treatment. Although there is |
| Comparative Long-term Morbidity of Intensity Modulated vs Conformal Radiation Therapy (RT) for Prostate Cancer: A SEER-Medicare Analysis Presenter: N. Sheets Presenter's Affiliation: University of North Carolina, Chapel Hill, NC Background There is a rapid uptake of intensity modulated radiation therapy (IMRT) for treatment of prostate cancer because of potential reduction of dose to normal tissue and hence reduction in morbidity related to treatment. Although there |
| Proton Therapy of Cancers of the Nasal Cavity and Paranasal Sinuses Presenter: Robert Malyapa Presenter's Institution: University of Florida Proton Center Background Nasal cavity and paranasal sinuses cancers are rare tumors and compose 3-4% of all head and neck cancers. Approximately 2000 people are diagnosed each year in the United States. The typical age range at the time of diagnosis is |
| Oncologists' and primary care providers' awareness of late effects of cancer treatment: Implications for survivorship care Presenter: Larissa Nekhlyudov, MD, MPH Presenter's Affiliation: Harvard Medical School and Harvard Vanguard Medical Associates, Boston, MA Background Cancer survivorship is on the rise with an estimated 12 million cancer survivors living in the United States today. Unfortunately, all cancer treatments cause side effects, and many |
| Racial disparities in breast cancer survival Presenter: Jeffrey H. Silber Affiliation: The University of Pennsylvania Background Since the 1970s, breast cancer mortality rates in the U.S. have been higher among African-American women than among Caucasian women. The factors contributing to this disparity are multi-factorial and not well understood. Reducing racial disparities |
| Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study Presenter: Sven Mahner Affiliation: University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany Background The incidence of vulvar cancer is rising, with an increasing number of patients being diagnosed at younger ages. While the majority of patients with vulvar cancer can be cured by surgery alone, women |
| Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma Presenter: Torgrim Tandstad, MD PhD Presenter's Affiliation: St. Olav's Hospital, Trondheim, Norway Background Contralateral tumor (CLT) occurs in 3.5-5% of men diagnosed with non-seminomatous testicular cancer. ITGCNU (intratubular germ cell neoplasia of the unclassified type) is a precursor lesion to the development of germ cell |
| Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial Presenter: Thierry Conroy, MD Presenter's Affiliation: Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France Background Definitive chemoradiotherapy (CRT) is currently the standard of care in patients with unresectable, locally advanced esophageal cancer (EC). Historically, studies have used chemotherapy with cisplatin/5FU with local |
| Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41 Presenter: Andre Robidoux Affiliation: National Surgical Adjuvant Breast and Bowel Project and Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada Background Trastuzumab (Herceptin) is a monoclonal antibody directed against HER-2, or the Human Epidermal Growth Factor Receptor 2. Over-expression of HER-2 has been shown |
| 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer Presenter: Renata Duchnowska Affiliation: Polish Brain Metastasis Consortium Background Brain metastases (BM) from breast cancer constitute an important part of therapeutic failures and are associated with severe morbidity and mortality. The risk of BM is particularly high in HER2 positive, advanced breast cancer patients. A |
| Efficacy of the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines in reducing risk of congestive heart failure (CHF) in childhood cancer survivors (CCS) Presenter: F. Lennie Wong, PhD Presenter's Affiliation: City of Hope, Duarte, CA Background Thoracic radiation and chemotherapy increase the risk of cardiovascular disease in survivors of childhood cancer. Previous studies have suggested that cardiovascular death is responsible for more than 25% of the excess risk of death in survivors of |
| Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane Presenter: Kimberly L. Blackwell, MD Presenter's Affiliation: Duke University Medical Center, Durham, NC Background Breast cancer is the most common malignancy affecting women in the United States and Europe. The treatment of breast cancer has evolved enormously in the past few decades. The current standard of care for systemic |
| Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of SWOG 9346 (INT-0162), an international phase III trial Presenter: Maha Hussain Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Background Continuous androgen deprivation is the standard of care for patients with metastatic hormone sensitive prostate cancer. Despite high initial response rates, hormone resistance occurs in the vast majority of hormone |
| Estrogen plus progestin (E+P) and breast cancer incidence and mortality Presenter: Rowan T. Chlebowski Presenter's Affiliation: Women's Health Initiative, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA Background The Women's Health Initiative (WHI) was a major research program launched in 1991 to address the most common causes of death, disability and poor quality of |
| BMI, long-term changes in BMI, and risk of cancer mortality in a large cohort study Presenter: Niloofar Taghizadeh Presenter's Affiliation: Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands Background Many studies have found an association between body mass index (BMI) and the risk of development of cancer. The proposed mechanisms include hormonal systems involving |
| Cluster-randomized trial of early palliative care for patients with metastatic cancer Presenter: Camilla Zimmermann Affiliation: Princess Margaret Hospital, University Health Network, Toronto, ON, Canada Background Patients with metastatic cancer have compromised quality of life (QOL), which tends to worsen towards the end of life. Several recent studies have demonstrated an improvement of quality of life with |
| Cancer and Metabolism 2013 Dates: June 24-25, 2013 Location: Amsterdam, Netherlands Web Page URL: http://www.abcam.com/cancermetabolism2013 Topics Covered: Introduction to metabolic pathways and metabolism -Metabolic alterations and adaptations of cancer cells Identifying and exploiting metabolic vulnerabilities of cancer -Metabolic signaling Advanced technologies |
| Cardiac Toxicity is Not Increased 25 Years After Treatment of Early Stage Breast Carcinoma With Mastectomy or Breast Conservation Therapy From the National Cancer Institute Randomized Trial Abstract # 87 Presenting Author: Charles B. Simone, II, MD Presenting Author's Affiliation: Hospital of the University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA Background The current options for the treatment of early-stage breast cancer are modified radical mastectomy or breast-conserving surgery plus |
| Radiation Modality is a Strong Predictor for Postoperative Pulmonary and GI Complications after Trimodality Therapy for Esophageal Cancer Abstract # 100 Presenter: J. Wang, MD Presenter's Affiliation: The University of Texas, MD Anderson Cancer Center Background Esophageal cancer is the sixth leading cause of death from cancer worldwide. Operable patients are typically treated with neoadjuvant chemoradiation followed by surgical resection The authors note that about 50% |
| Patient Reported Quality of Life in Prostate Cancer Patients Treated with 3D conformal, Intensity Modulated or Proton Beam Radiation Therapy Abstract # 30 Presentation Date: October 28, 2012 Presenter: Phillip Gray, MD Presenter's Affiliation: Harvard Radiation Oncology Program Background Limited data exist comparing contemporary technologies in the treatment of prostate cancer Analysis of SEER Medicare data reveals that in the previous decade the use of IMRT, compared |
| Second Cancer Risk 40 Years After Hodgkin Lymphoma Treatment Presenter: Berthe Aleman, MD, PhD Affiliation: The Netherlands Cancer Institute Background Large studies have identified increased risk of breast and other cancers in survivors of Hodgkin lymphoma, partially due to late toxicity of chemotherapy and radiation. Over the last several years, the treatment of Hodgkin lymphoma has evolved |
| Risk of Fatal Cerebrovascular Accidents After External Beam Radiotherapy for Early Stage Glottic Larynx Cancer Abstract Number: 150 Presenting Author: Justin E. Bekelman, MD (on behalf of Samuel Swisher-McClure, MD) Affiliation: Hospital of the University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA Background Early-stage glottic cancer can be managed by external beam radiotherapy directed at the glottis, or by surgery |
| Early Patterns of Failure in a Prospective Trial of Concomittant Docetaxel and Proton Therapy for High-risk Prostate Cancer Abstract Number: 226 Presenter: Nancy Mendenhall, MD Presenter's Affiliation: The University of Florida Proton Therapy Institute, Jacksonville, FL Background Patients with high-risk prostate cancer are at increased risk of distant metastases and death related to prostate cancer progression. These patients are typically treated more |
| Does Patient Life Expectancy (LE) Affect Receipt of Routine Cancer Screening in the United States? A Population-Based Study Abstract Number: 226 Presenting Author: Trevor Royce, MS4 Affiliation: University of North Carolina at Chapel Hill, Chapel Hill, NC Background Routine cancer screening methods exist for a variety of malignancies including prostate cancer, breast cancer, colorectal cancer, and cervical cancer. Screening, however, has unproven benefit for |
| Repeat CT Simulation during Whole Breast Irradiation Can Influence the Selection of Treatment Modality for Breast Cancer Tumor Bed Boost Abstract Number: 271 Presenting Author: N. Novalchuk, MD Affiliation: Boston Medical Center, Harvard Medical School, Boston, MA Background In the United States, radiation boost to the tumor bed is routinely delivered as part of treatment for early-stage breast cancer. The EORTC boost study (Bartelink H, J Clin Oncol. 2007 |
| Results of a Prospective Randomized Double-blind Placebo Controlled Trial Evaluating the Use Prophylactic Sildenafil Citrate During Radiation Therapy in the Treatment of Prostate Cancer Presenting Author: Michael J. Zelefsky, MD Presenting Author Affiliation: Sloan-Kettering Cancer Center, New York, NY Purpose/Objective(s) Penile rehabilitation has emerged as an important entity after prostate cancer therapy addressing the potential benefit of preservation of corpus cavernosal |
| Celebration of Hope Dates: Friday, October 5, 2012 Location: Hilton Philadelphia City Avenue Sponsoring Group: Cancer Support Community of Philadelphia Web Page URL: www.cancersupport-phila.org/CelebrationofHope2012.htm Topics Covered: Fitness and Cancer, Competing with Cancer, Eating Well with Cancer, NIA exercise Objectives: Provide inspiration, education and |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
